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Background: Neurovascular coupling (NVC) is essential to brain health and the breakdown 
of NVC is proposed to be a key pathological factor in the development of Alzheimer’s disease 
(AD), vascular dementia (VaD) and other cerebrovascular diseases. Importantly; as we age, 
the presence of two or more comorbidities is common and this often leads to clinical 
complications. Whilst preclinical models of human disease are numerous and have supported 
basic and translational neuroscience immensely over the past few decades, models of 
comorbidity are few and often neglected when it is important to study comorbidity to reflect 
clinical presentations in patients. This project will focus on examining neurovascular function 
in 3 different preclinical models of AD, atherosclerosis (ATH) and comorbid AD & ATH (MIX).  
Aims & Objectives: I) To investigate neurovascular function at an early-AD timepoint (6m) in 
the J20-hAPP model of AD (J20-AD); when amyloid-beta deposits begin to form, using a 
chronic surgery recovered animal protocol. Neurovascular function will be assessed by 2D-
optical imaging spectroscopy (2D-OIS) to measure cortical haemodynamics, in addition to 
using multichannel microelectrodes to obtain neural multi-unit activity (MUA). II) To investigate 
neurovascular function in a novel experimental model of ATH using the rAAV8-mPCSK9-
D377Y + Western Diet model (PCSK9-ATH). III) To create a mixed comorbid model of AD and 
ATH (J20-PCSK9-MIX) and to investigate neurovascular function in this novel model. IV) To 
assess neuropathology and neuroinflammation from brain tissue in the 3 disease models.  
Results: Firstly, at an early stage, J20-AD mice exhibit enhanced evoked-haemodynamic 
responses associated with neural hyperexcitability. They also display a unique time-
dependent elevation of baseline blood volume under normobaric hyperoxia. Secondly, 
PCSK9-ATH display reduced evoked-responses and show signs of neurovascular dysfunction 
associated with increased IL1β & TNFα-neuroinflammation. Thirdly, J20-PCSK9-MIX 
comorbid mice have a trebling of Aβ plaques in the hippocampus, although, without any further 
worsening of neurovascular function in the cortex compared to J20-AD mice, although all 3 
disease models show a trend towards the reduced washout of HbR, which indicates metabolic 
inefficiency and inadequate oxygen delivery to neurons. Finally, electrode insertion into the 
brain (causing mild brain injury) leads to cortical spreading depression (CSD) to occur in all 
mice, with the most severe CSD occurring in J20-AD and PCSK9-ATH mice, and this may be 
related to levels of IL1β neuroinflammation, though this needs to be confirmed.  
Conclusions: These results provide novel insights in all 3 disease models which have 
important translational implications by highlighting distinct therapeutic targets and strategies. 
The results also show the importance of neurovascular function in dementia and targeting 
impairments to neurovascular function early on may be key to slowing down the onset and 




I, Osman Shabir, confirm that the thesis is my own work. I am aware of the University’s 
Guidance on the Use of Unfair Means (www.sheffield.ac.uk/ssid/unfair-means). This work has 
not been previously been presented for an award at this, or any other, University.   
 
This thesis is in a publication format and comprises of the following published papers: 
1. Chapter 1a (A Review) – Shabir et al, 2018. Neurovascular dysfunction in vascular 
dementia, Alzheimer’s and atherosclerosis. BMC Neuroscience 19(1):62. In addition 
to Shabir et al, 2018, there is further commentary in chapter 1 that is not published.  
• Chapter 1b (A Review) – Shabir et al, 2020. Preclinical Models of Disease and 
Multimorbidity with Focus upon Cardiovascular Disease and Dementia. Mechanisms 
of Ageing and Development 192:111361 as part of special issue on multimorbidity. 
Only my section of models of cardiovascular disease and cerebrovascular disease has 
been included in this thesis. The other sections were not relevant to the thesis and 
have been omitted. 
2. Chapter 3 – Shabir et al, 2020. Enhanced Cerebral Blood Volume Under Normobaric 
Hyperoxia in the J20-hAPP Mouse Model of Alzheimer’s Disease. Scientific Reports 
10(1):7518. 
 
In addition, the following experimental chapters include papers in submission, and/or currently 
on bioRxiv (biorxiv.org) the preprint server: 
• Chapter 5 – Shabir et al, 2020. Assessment of Neurovascular Coupling & Cortical 
Spreading Depression in Mixed Models of Atherosclerosis & Alzheimer’s Disease 
(submitted to journal at time of submission) – preprint on bioRxiv (2020.08.13.249987). 
 
At the start of each chapter, a full acknowledgment and reference of the publication and its 
format is given, in addition to any full permissions, my contribution, as well as that of my co-
authors and collaborators is stated. All chapters are formatted according the submitted 
journals guidelines and the format may vary between chapters. Some of the chapters contain 








I am hugely thankful to Dr Jason Berwick for his constant excitement & enthusiasm about the 
data and the project, his blunt & honest manner, his sense of humour and his friendship. Jason 
not only has helped me massively with the data analysis, but also being heavily involved with 
the experiments themselves given that we had a limited number of animals and resources. 
Maybe I will learn MATLAB, at some point, but a huge thanks for all the help. Also, a very 
special thank you to Prof Sheila Francis who has been one of the most supportive mentors 
and her constant guidance and thorough feedback has been hugely important in improving 
my writing and presentations skills as well as becoming a better scientist all round. I’m also 
hugely thankful to Sheila for believing in my abilities and applying for a project grant to the 
BHF to continue our work with me as the named post-doc that I am very excited to begin. I 
couldn’t have asked for 2 better supervisors than Jason & Sheila, who have both given me 
freedom during my PhD to do my own experiments & to support me in fellowship applications.  
 
The PhD would not have been the same without the Neurovascular Lab members, namely Dr 
Clare Howarth, Llywelyn Lee & Beth Eyre. Firstly, I want to thank Llywelyn for his friendship 
right from the start, him training me on the surgeries and imaging experiments, and for being 
an incredibly supportive friend throughout the PhD. Secondly, I want to thank Clare for all the 
help she has given me throughout the 3 years, especially with data analysis, proofreading 
scripts and applications, helping with experiments as well as all the chats we’ve had in our 
office! Finally, I want to thank Beth for her continuous optimistic outlook on life; which has 
actually rubbed off on me now, and for her rather crude sarcasm – which is lovely. 
 
I would like to thank Monica (Ale) Rebollar for her help in brain dissections. I would also like 
to thank all of the lovely BSU staff, in particular Michelle & Barry Bird (great couple!), Beka 
Armstrong & Rachel Sandy for all their help with the animals, and all the lovely chats we’ve 
had over the last 3 years. I also want to thank all my friends and colleagues across SITraN, 
Psychology, IICD and BMS for their support, laughter and good times along the way (including 
the ‘enemies’ I may have made!). I fear that if I start listing names, I may accidentally miss off 
some, so to all of you – thank you! (Oh, and a special shout out to Toby, Jordon and Lorna!).  
 
Finally, a huge thanks to my family; especially my mum, my dad and my brother who have 
supported me immensely during my PhD (and before), even though they don’t quite 
understand a) what I actually do & b) what I am going to do with my PhD – neither do I! It was 
their encouragement from childhood that has led to me where I am to today. Also, a huge 
shout out to the COVID-19 pandemic for really putting a fantastic end to the PhD (not)! But 
also, hugely thankful to the University for granting me a 2 month fully paid extension.  
IV 
 
Table of Contents 
 
Abstract ................................................................................................................................... I 
Declaration ............................................................................................................................. II 
Acknowledgments ................................................................................................................ III 
Table of Contents ................................................................................................................ IV 
List of Figures ...................................................................................................................... IX 
List of Tables ......................................................................................................................... X 
List of Abbreviations ........................................................................................................... XI 
Chapter 1 – Introduction ....................................................................................................... 1 
1.1 – Paper Title and Authors .............................................................................................. 2 
1.2 – Abstract ....................................................................................................................... 3 
1.3 – Introduction ................................................................................................................. 3 
1.4 – Neurovascular Coupling .............................................................................................. 3 
1.4.1 – The Neurovascular Unit and the Blood Brain Barrier ........................................... 3 
1.4.2 – Neurophysiology of Neurovascular Coupling ....................................................... 6 
1.5 – Neuroimaging Techniques to Study Neurovascular Coupling ..................................... 8 
1.5.1 – fMRI ...................................................................................................................... 9 
1.5.2 – 2-Photon Microscopy and Calcium Imaging ....................................................... 10 
1.6 – Neurovascular Dysfunction in Neurological Disorders .............................................. 11 
1.6.1 – Dementia (Alzheimer’s Disease) ........................................................................ 11 
1.6.2 – Stroke ................................................................................................................. 15 
1.6.3 – Physiological Ageing .......................................................................................... 16 
1.7 – Atherosclerosis .......................................................................................................... 16 
1.8 – Atherosclerosis and Neurovascular Dysfunction ....................................................... 20 
1.8.1 – LDLR, ApoE & PCSK9 ....................................................................................... 26 
1.9 – Conclusions and Future Directions ........................................................................... 29 
1.10 – Paper Title and Authors ........................................................................................... 37 
1.11 – Abstract ................................................................................................................... 37 
1.12 – Introduction ............................................................................................................. 37 
V 
 
1.13 – Cardiovascular Diseases ........................................................................................ 38 
1.14 – Cerebrovascular Disease (CbVD) ........................................................................... 42 
1.15 – Comorbid CVD/CbVD Models ................................................................................. 48 
1.16 – Conclusions and Future Directions ......................................................................... 55 
1.18 – 2D-Optical Imaging Spectroscopy Background .......................................................... 60 
1.19 – Work Leading to my PhD Project ................................................................................ 63 
1.20 – Hypothesis .................................................................................................................. 64 
1.21 – Aims ............................................................................................................................ 64 
Chapter 2 – Materials & Methods ....................................................................................... 65 
2.1 – Materials .................................................................................................................... 66 
2.1.1 – Commercial Kits & Reagents .............................................................................. 66 
2.1.2 – Diets ................................................................................................................... 66 
2.1.3 – Viruses ................................................................................................................ 66 
2.1.4 – Antibodies & Immunohistochemistry Conditions ................................................ 67 
2.1.5 – RNA Extraction ................................................................................................... 67 
2.1.6 – PCR and Primers ................................................................................................ 67 
2.1.7 – Laboratory Equipment ........................................................................................ 68 
2.1.8 – Software ............................................................................................................. 68 
2.1.9 – Statement of Ethics ............................................................................................ 69 
2.1.10 – Animals ............................................................................................................. 69 
2.2 – In Vivo Neuroimaging ................................................................................................ 70 
2.2.1 – Experimental Overview ....................................................................................... 70 
2.2.2 – Thinned Cranial Window Surgery ....................................................................... 72 
2.2.3 – 2D-Optical Imaging Spectroscopy (2D-OIS) ....................................................... 73 
2.2.4 – Neural Multichannel Electrode Electrophysiology .............................................. 74 
2.3 – Cellular Studies ......................................................................................................... 75 
2.3.1 – Tissue Harvest & Perfusion ................................................................................ 75 
2.3.2 – Immunohistochemistry (IHC) .............................................................................. 75 
2.3.3 – Imaging and Analysis ......................................................................................... 75 
VI 
 
2.4 – Genetic Studies ......................................................................................................... 76 
2.4.1 – RNA Extraction ................................................................................................... 76 
2.4.2 – cDNA Synthesis .................................................................................................. 76 
2.4.3 – Real-Time Quantitative Polymerase Chain Reaction (qRT-PCR) ...................... 76 
2.5 – Analysis and Statistics .............................................................................................. 77 
Chapter 3 – Neurovascular Function in Young J20-hAPP Mouse Model of Alzheimer’s 
Disease ................................................................................................................................. 78 
3.1 – Paper Title and Authors ............................................................................................ 79 
3.2 – Abstract ..................................................................................................................... 80 
3.3 – Introduction ............................................................................................................... 80 
3.4 – Results ...................................................................................................................... 81 
3.4.1 – Enhanced Blood Volume (HbT) Responses in J20-hAPP Mice ......................... 81 
3.4.2 – Neural Activity is Substantially Higher in J20-hAPP Mice .................................. 85 
3.4.3 – Baseline Blood Volume is Substantially Higher in J20-hAPP Mice under 
Hyperoxia ....................................................................................................................... 87 
3.4.4 – Amyloid-Plaques Begin to Form in the Hippocampus of 6m J20-hAPP Mice .... 89 
3.5 – Discussion ................................................................................................................. 90 
3.6 – Materials & Methods ................................................................................................. 93 
3.6.1 – Animals ............................................................................................................... 93 
3.6.2 – Chronic Thinned Cranial Window Preparation ................................................... 94 
3.6.3 – 2D-Optical Imaging Spectroscopy (2D-OIS) ....................................................... 94 
3.6.4 – Stimulation Paradigm & Experimental Overview ................................................ 95 
3.6.5 – Neural Electrophysiology .................................................................................... 95 
3.6.6 – Region Analysis .................................................................................................. 95 
3.6.7 – Statistical Analysis .............................................................................................. 96 
3.6.8 – Immunohistochemistry ........................................................................................ 96 
3.7 – Acknowledgments ..................................................................................................... 96 
3.8 – Competing Interests .................................................................................................. 96 
3.9 – Funding ..................................................................................................................... 96 
3.10 – References .............................................................................................................. 97 
VII 
 
3.11 – Supplemental Data ................................................................................................ 100 
Chapter 4 – Neurovascular Function in Experimental Models of Atherosclerosis 
(PCSK9), Alzheimer’s Disease (J20-hAPP) and a Novel Mixed Comorbid Model (J20-
PCSK9) ................................................................................................................................ 102 
4.1 – Paper Title and Authors .......................................................................................... 103 
4.2 – Abstract ................................................................................................................... 104 
4.3 – Significance Statement ........................................................................................... 104 
4.4 – Key Words ............................................................................................................... 104 
4.5 – Author Contributions ............................................................................................... 105 
4.6 – Introduction ............................................................................................................. 105 
4.7 – Results .................................................................................................................... 106 
4.7.1 – 2D-Optical Imaging Spectroscopy (2D-OIS) Measures Brain Cortical 
Haemodynamics Through a Thinned Cranial Window ................................................. 106 
4.7.2 – Chronic Haemodynamic Responses in the Brain are Reduced in PCSK9-ATH 
Mice. ............................................................................................................................. 109 
4.7.3 – CSD is Worse in Diseased Animals and Impacts Haemodynamic Recovery to 
Baseline ........................................................................................................................ 111 
4.7.4 – Stimulus-Evoked Neural Activity is Not Significantly Altered in Any Disease 
Groups Compared to WT Mice ..................................................................................... 114 
4.7.5 – Increased Number of Hippocampal Aβ Plaques in J20-PCSK9-MIX Mice. 
Increased Neuroinflammation in J20-AD and PCSK9-ATH Mice ................................. 116 
4.8 – Discussion ............................................................................................................... 118 
4.9 – Materials & Methods ............................................................................................... 123 
4.9.1 – Animals ............................................................................................................. 123 
4.9.2 – Thinned Cranial Window Surgery ..................................................................... 123 
4.9.3 – 2D-Optical Imaging Spectroscopy (2D-OIS) ..................................................... 123 
4.9.4 – Neural Electrophysiology .................................................................................. 124 
4.9.5 – Region Analysis ................................................................................................ 124 
4.9.6 – Statistical Analysis ............................................................................................ 125 
4.9.7 – Immunohistochemistry ...................................................................................... 125 
4.9.8 – qRT-PCR .......................................................................................................... 126 
VIII 
 
4.10 – Acknowledgments ................................................................................................. 126 
4.11 – Conflicts of Interest. .............................................................................................. 126 
4.12 – References: ........................................................................................................... 126 
4.13 – Supplemental Information: .................................................................................... 130 
Chapter 5 – Conclusions & Future Directions ................................................................ 133 
5.1 – Overview ................................................................................................................. 134 
5.2 – Enhanced Evoked-HbT Is Associated with Neural Hyperexcitability in 6m J20-AD 
Mice. Under Hyperoxia, J20-AD Mice Exhibit Enhanced Baseline HbT and Saturation. . 135 
5.3 – Impaired Neurovascular Function in PCSK9-ATH Mice Characterised by 
Consistently Reduced Evoked-HbT and Potential Neurovascular Breakdown. ............... 139 
5.4 – Increased Aβ plaques in J20-PCSK9-MIX Mice Without Further Impairments to 
Neurovascular Coupling. .................................................................................................. 142 
5.5 – CSD Is More Severe in Diseased Mice and Relates to Levels of Neuroinflammation.
 ......................................................................................................................................... 144 
5.6 – Cellular & Molecular Mechanisms Underpinning the Observed Phenotypes – 
Potential Therapeutic Implications by Targeting Neuroinflammation? ............................. 145 
5.7 – Conclusion .............................................................................................................. 149 
5.7 – Future Directions ..................................................................................................... 150 
References ......................................................................................................................... 152 
Appendix ............................................................................................................................ 156 











List of Figures  
Figure 1.1 - The Neurovascular Unit and the BBB at a capillary. ............................................ 5 
Figure 1.2 - Neurophysiology of Neurovascular Coupling Overview. ...................................... 7 
Figure 1.3 - Overview of Aβ processing. ................................................................................ 13 
Figure 1.4 - Overview of the Pathogenesis of Atherosclerosis .............................................. 18 
Figure 1.5 - Vascular Lesions in Small Vessel Disease. ....................................................... 22 
Figure 1.6 - Summary of Vascular Pathologies in CVD, Stroke & Dementia ......................... 24 
Figure 1.7 - PCSK9 Mechanisms. ......................................................................................... 28 
Figure 1.8 - CVD, CbVD and Dementia Overlap. .................................................................. 54 
Figure 2.1 – Mouse Models Used. ......................................................................................... 69 
Figure 2.2 - Experimental Plan/Paradigms. ........................................................................... 71 
Figure 2.3 – Thinned Cranial Window Surgery. ..................................................................... 72 
Figure 2.4 – 2D-OIS Imaging Setup. Adapted from (Lee et al., 2020); Figure authored by me.
 ............................................................................................................................................... 73 
Figure 2.5 – 2D-OIS Wavelength and Absorption Co-Efficient for HbO & HbR. .................... 73 
Figure 3.1 - Representative 2D-OIS haemodynamic data from an AD mouse to a 2s-
mechanical whisker stimulation. ............................................................................................ 82 
Figure 3.2 – Mean stimulation-evoked haemodynamic responses in WT and J20-hAPP mice.
 ............................................................................................................................................... 84 
Figure 3.3 – Multi-Unit Activity (MUA) Data. .......................................................................... 86 
Figure 3.4 – Average gas transitions between hyperoxic and normoxic conditions in WT and 
J20-hAPP mice. ..................................................................................................................... 88 
Figure 3.5 – Representative hippocampal sections. .............................................................. 89 
Figure 3.6(S) – 10% Hypercapnia Responses. ................................................................... 100 
Figure 3.7(S) – Haemodynamic Responses During Acute Imaging Session (with Electrode 
Inserted). .............................................................................................................................. 101 
Figure 4.1 – Experimental Setup and Data Derivation. ....................................................... 108 
Figure 4.2 – Fractional Changes in Chronic Stimulus-Evoked (Peak) Haemodynamic 
Responses. .......................................................................................................................... 110 
Figure 4.3 – Cortical Spreading Depression (CSD) in WT, diseased and comorbid animals.
 ............................................................................................................................................. 112 
X 
 
Figure 4.4 – Evoked Neural Multi-Unit Activity (MUA) Responses. ..................................... 115 
Figure 4.5 – Neuropathology and Neuroinflammation. ........................................................ 117 
Figure 4.6(S) – Fractional Changes in Acute Stimulus-Evoked Haemodynamic Responses.
 ............................................................................................................................................. 130 
Figure 4.7(S) – Concatenated data showing stability and robustness of the mouse imaging 
preparation. .......................................................................................................................... 131 
Figure 4.8(S) – Chronic & Acute Hypercapnia. .................................................................... 132 
Figure 5.1 – Schematic Summary of Hyperoxia as a Potential Preventative Treatment for 
AD. ....................................................................................................................................... 138 
Figure 5.2 – Proposed Neurovascular Dysfunction Mechanism in Atherosclerosis. ........... 141 
Figure S1 – Oil Red O Staining of Atherosclerotic Aorta. .................................................... 156 
Figure S2 – 2s-Stimulation for WT, WT + HFD and AAV-PCSK9 Mice. .............................. 157 
Figure S3 – Mouse Body Weights. ...................................................................................... 158 
Figure S4 – Bar Graph of Mean HbT for Mouse Groups Across all Stimulations. ............... 159 
Figure S5 – NOS1 and NOS3 qRT-PCR. ............................................................................ 160 
Figure S6 – Qualitative & Quantitative Histological Analysis (Cortical). .............................. 161 
Figure S7 – Aβ Plaques. ...................................................................................................... 162 
Figure S8 – CSD Haemodynamic and MUA Profiles. .......................................................... 163 
Figure S9 – Cerebral Amyloid Angiopathy in 15m J20-AD Mouse. ..................................... 164 
 
List of Tables 
Table 1 – Models of CVD and CbVD ..................................................................................... 46 
Table 2 – Comorbid CVD/CbVD Models ............................................................................... 51 







List of Abbreviations 
2D-OIS 2D-Optical Imaging Spectroscopy 
AAV Adeno-Associated Virus 
Aβ Amyloid Beta 
AD Alzheimer's Disease 
ApoE Apolipoprotein E 
APP Amyloid Precursor Protein 
AQP4 Aquaporin-4 
ATH Atherosclerosis 
BBB Blood Brain Barrier 
BOLD Blood Oxygen Level Dependent 
CAA Cerebral Amyloid Angiopathy 
CBF Cerebral Blood Flow 
CbVD Cerebrovascular Disease 
CSD Cortical Spreading Depression 
CSF Cerebrospinal Fluid 
CVD Cardiovascular Disease 
EMCI (Early) Mild Cognitive Impairment 
EOAD Early-Onset Alzheimer's Disease 
HbO Oxyhaemoglobin 
HbR Deoxyhaemoglobin 
HbT Total Haemoglobin 
IHC Immunohistochemistry 
IL1β Interleukin 1-beta 
LDL Low Density Lipoprotein 
LDLR Low Density Lipoprotein Receptor 
MCA Middle Cerebral Artery 
XII 
 
MUA Multi-Unit Activity 
NOS Nitric Oxide Synthase (e; endothelial, n; neuronal) 
NVC Neurovascular Coupling 
NVU Neurovascular Unit 
PCSK9 Proprotein Convertase Subtilisin/Kexin Type 9 
PDGFRβ Platelet-Derived Growth Factor Receptor Beta 
qRT-PCR Quantitative Reverse-Transcriptase Polymerase Chain Reaction 
ROI Region of Interest 
ROS Reactive Oxygen Species 
SEM Standard Error of Mean 
SVD Small Vessel Disease 
TBI Traumatic Brain Injury 
TNF⍺ Tumour Necrosis Factor-alpha 
VaD Vascular Dementia 














Chapter 1 – Introduction 
 
This chapter contains 2 published review articles:  
Shabir et al, 2018. BMC Neuroscience. 19:62 & Shabir et al, 2020. Mechanisms of 
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1.2 – Abstract  
Efficient blood supply to the brain is of paramount importance to its normal functioning and 
improper blood flow can result in potentially devastating neurological consequences. Cerebral 
blood flow in response to neural activity is intrinsically regulated by a complex interplay 
between various cell types within the brain in a relationship termed neurovascular coupling. 
The breakdown of neurovascular coupling is evident across a wide variety of both neurological 
and psychiatric disorders including Alzheimer’s disease. Atherosclerosis is a chronic 
syndrome affecting the integrity and function of major blood vessels including those that supply 
the brain, and it is therefore hypothesised that atherosclerosis impairs cerebral blood flow and 
neurovascular coupling leading to cerebrovascular dysfunction. This review will discuss the 
mechanisms of neurovascular coupling in health and disease and how atherosclerosis can 
potentially cause cerebrovascular dysfunction that may lead to cognitive decline as well as 
stroke. Understanding the mechanisms of neurovascular coupling in health and disease may 
enable us to develop potential therapies to prevent the breakdown of neurovascular coupling 
in the treatment of vascular brain diseases including vascular dementia, Alzheimer’s disease 
and stroke. 
 
1.3 – Introduction  
The human brain accounts for just 2% of total body weight, yet receives between 15-20% of 
total cardiac output1. It is therefore evident that the brain requires an efficient and adequate 
blood supply to support the metabolic demands it exerts. Unlike the majority of organs and 
tissues, the brain has a tightly regulated blood brain barrier (BBB), which prevents leakage of 
blood into the parenchyma and protects the brain from toxic agents and infection. Neurons, 
therefore, are not in direct association with the blood, but are functionally and structurally 
connected to a network of cell types within a structure called the neurovascular unit (NVU)2. 
The NVU facilitates cerebral blood flow (CBF) changes in response to the metabolic activity 
of neurons in a relationship termed neurovascular coupling3. Neurovascular coupling ensures 
that the brain has a proportionally matched CBF in response to neural activity, however 
dysfunction of neurovascular coupling, either caused by pathology or ageing itself, can cause 
further cerebral pathologies and neurological disorders. This review will focus on the 
neurophysiology of neurovascular coupling, how it is impaired in certain neurological 
conditions, how to study it and will discuss how cardiovascular disease may affect the 
regulation of CBF and neurovascular coupling.  
 
1.4 – Neurovascular Coupling  
1.4.1 – The Neurovascular Unit and the Blood Brain Barrier  
The NVU consists of neurons, astrocytes, microglia, interneurons, pericytes, vascular smooth 
muscle cells (VSMCs) and endothelial cells3. It includes the different cell types involved in the 
4 
 
structural and functional connection between neurons and blood vessels in the brain, including 
cells involved in the formation of the BBB, refer to Figure 1.1. The BBB is formed due to the 
specialised functions of tight-junctions of endothelial cells in cerebral vasculature, astrocytes, 
with some evidence suggesting a crucial role for pericytes4. The BBB is a specialised structure 
in the cerebral vasculature and is not seen in many other organs. It serves to limit the entry of 
pathogens, toxic agents and blood cells into the parenchyma5, protecting the brain from 
infection, whilst allowing controlled transport of nutrients back and forth from the brain. 
However, there are natural pathogens that can penetrate the BBB including group B 
streptococci, which can cause meningitis6. Generic or specialised dysfunction of the NVU is 
associated with an increasing list of pathologies, including stroke, Parkinson’s disease, 
Alzheimer’s disease, multiple sclerosis, amyotrophic lateral sclerosis and vascular dementia2. 













Figure 1.1 - The Neurovascular Unit and the BBB at a capillary.  Cerebral arteries have 
extensive vascular smooth muscle cell (VSMC) coverage regulating vasoconstriction. Capillaries 
on the other hand lack vascular smooth muscle cells and are instead covered by small pericytes 
which maintain the integrity of the BBB, as well as regulate their diameter. Cerebral vessels receive 
inputs from astrocytes by their end-feet to regulate arteriolar diameter, as well as inputs from 



















1.4.2 – Neurophysiology of Neurovascular Coupling 
The NVU facilitates haemodynamic changes (alteration in CBF) in response to neural activity. 
This relationship is termed neurovascular coupling or functional hyperaemia, and is essential 
for normal metabolic functioning of neurons and the brain as a whole3, Figure 1.2. 
Neurovascular coupling is thought to be governed by direct neural and endothelial interactions, 
or through complex neurogliovascular signalling pathways (of which some are highlighted in 
Figure 2). Neural activation causes neurotransmitter release from synaptic terminals (e.g. 
glutamate), which bind to N-methyl-D-aspartate receptors (NMDARs) or metabotropic 
glutamate receptors (mGlutRs) on nNOS-expressing interneurons initiates the synthesis of 
nitric oxide (NO)7. NO can directly cause vasodilation in the endothelium by stimulating cGMP 
in VSMCs. NO also inhibits CYP4A, which is needed to produce 20-HETE; a prominent 
vasoconstrictor8. 
 
Most neurons do not directly innervate the overall vasculature; rather glial intermediaries make 
the majority of neural-mediated inputs (refer to Figure 1.1). With respect to neurogliovascular 
signalling, the most important players are thought to be astrocytes whose terminal processes 
called vascular end-feet, wrap around blood vessels in the brain to contribute to BBB integrity, 
as well as facilitating neurovascular coupling. Calcium, sodium and potassium signalling via 
the astrocytic-endothelial axis within the NVU may promote a slow and prolonged vasodilation 
compared to neural outputs, however this is contested by Lauritzen’s group who suggest that 
astrocytes are involved in the initial vasodilation9. On the other hand, rapidly induced transient 
vasodilation caused by neural NO10, ensures that CBF change is sufficient to match the 
demands of metabolic expenditure. Furthermore, it has been shown that a transient loss of 
oxygen and glucose (as in ischaemia) causes excitotoxicity in neurons leading to delayed 
neuronal death11. At the centre of this excitotoxicity is a delayed mitophagy response (loss of 
mitochondria) from astrocyte end-feet, leading to a toxic increase in intracellular calcium 
[Ca2+]IC and glutamatergic activation11, leading to neuronal death. Although functional 
neurovascular coupling is related to increased neural activity (i.e. stimulation of brain areas), 
the brain at rest also requires an efficient steady supply of blood flow. Astrocytes have been 
shown to influence arteriolar tone by a steady low-level efflux of prostaglandin-E2 (PGE2) as a 
result of basal [Ca2+]IC fluctuations in astrocytic end-feet12. This basal tonic influence of 
arteriolar diameter is independent from stimulus-evoked neural activity-dependent 
haemodynamic changes, without affecting stimulus-evoked functional hyperaemia. It is 
therefore assumed that astrocyte dysfunction is key to the breakdown of neurovascular 




Figure 1.2 - Neurophysiology of Neurovascular Coupling Overview. Neural activity is 
metabolically expensive demanding a high consumption of glucose and oxygen (from arterial 
blood). Simultaneously, CO2 and other by products are also produced, which need to be removed 
by diffusion into venous blood in order to prevent hypercapnia and acidosis. In order to achieve 
this, neurons regulate blood flow via neurovascular coupling. Vasoactive agents such as NO 
directly cause vasodilation of arterial smooth muscle cells. Significant neurogliovascular signalling 
involving glutamate and calcium signalling causes vasodilation via channels on VSMCs e.g. BKCa, 
TRPV4, to stimulate cGMP13. There are indeed multiple and complex signalling pathways 
(including ATP and VIP signalling) also involved in neurovascular coupling. In addition to 
vasodilator signals, vasoconstrictive signals are also produced, namely 20-HETE, however this is 
thought to be pathological and as a result of ageing14. Pericytes regulate capillary diameter by 













In addition to astrocytes, interneurons also play a role in neurovascular coupling. Interneurons 
in the cortex come in distinct varieties: VIP/ChAT, NOS/NPY, SOM7 as well as paravalbumin-
GABAergic interneurons15. Depending on the input these interneurons receive, they have 
different outputs with respect to vasoconstriction or vasodilation. For example, acetylcholine 
(ACh) binding to muscarinic receptors on NOS-interneurons causes the release of NO to 
facilitate vasodilation on nearby micro vessels, however a serotonergic (5-HT) input on the 
same interneurons can cause the release of NPY, which can facilitate vasoconstriction7. The 
role of interneurons in neurovascular coupling is still poorly understood and elucidating the 
mechanistic pathways involved is still to be fully investigated.  
    
As arterioles turn into capillaries in the parenchyma, cerebral vessels no longer have a 
coverage of VSMCs and instead have a scattered covering of specialised contractile cells 
called pericytes16. Pericytes are an important component of the BBB and maintain its integrity 
by regulating adherens junction proteins on endothelial cells17. The exact function and role of 
pericytes in the adult CNS is highly controversial. For example, Hall and colleagues published 
that pericytes are critically involved in the regulation of CBF18 which was also supported by 
Kisler et al19. However, Hill et al20 found that arteriolar smooth muscle cells; and not pericytes, 
regulate regional blood flow. Furthermore, recent evidence has suggested that there may be 
several types of pericytes with differing roles such as pre-capillary pericytes with smooth 
muscle actin (SMA), and capillary pericytes without SMA expression21–24. Some evidence 
suggests that astrocytes may regulate pericyte tone and therefore vascular tone24. Although 
pericytes may be involved in capillary alterations, it is true that the arteries and arterioles, 
which are covered with VSMCs, need to be regulated to bring about a substantial change to 
CBF. It is evident from contradictions in the literature that regulation of CBF is not a simple 
mechanism (or as illustrated in Figure 1.2); rather it is a complex interplay between various 
cell types and signalling pathways with many gaps still remaining in our understanding of the 
exact mechanisms behind neurovascular coupling in health and disease. 
 
1.5 – Neuroimaging Techniques to Study Neurovascular Coupling 
In order to study and measure neurovascular coupling as well as structural alterations to the 
NVU in vivo, live neuroimaging techniques are used. Neuroimaging techniques allow (largely) 
non-invasive visualisation of the brain and are typically employed clinically to aid the diagnosis 
of disease, as well as in research to understand brain function physiologically and 
pathologically. Many of the clinical techniques can also be effectively used in pre-clinical 




1.5.1 – fMRI 
Functional magnetic resonance imaging (fMRI) has been the neuroimaging technique of 
choice for studying brain function in humans and to some extent in rodent models25. Briefly, 
fMRI is based on nuclear magnetic resonance related to proton alignment with a magnetic 
field26. The most commonly used detection paradigm is that of blood oxygen level dependent 
(BOLD) contrast. BOLD exploits the magnetic differences between oxyhaemoglobin (HbO) 
and deoxyhaemoglobin (HbR). In a resting state, the relative ratio between HbO:HbR is equal, 
therefore the magnetic field is unaffected27. Upon neural activation and consequent increased 
CBF, the proportion of HbO increases relative to HbR therefore creating an inhomogeneity in 
the magnetic field27, which can be detected by a fMRI scanner. A positive BOLD signal 
generally reflects increased neural activation, whereas a negative BOLD signal may reflect 
decreased neural activity, and therefore blood flow28, although this relationship is not always 
truly reflective of underlying neural activity especially in cases of pathology or specific cell type 
activation. fMRI can be used in both human subjects for psychiatric/psychological studies of 
brain function, clinically in the diagnosis of neurological disease, as well as pre-clinically in 
animal models. fMRI and related BOLD-based imaging techniques make inferences of neural 
activity by measuring corresponding haemodynamic changes and do not measure neural 
activity directly. Neural activity can be recorded by directly measuring action potentials (spiking 
activity), or the summation of electrical activity determined by local field potentials (LFPs). In 
order to measure the electrical activity of neurons in vivo, multichannel microelectrodes are 
implanted in the brain region of interest, or on top of the scalp, producing electrical waveform 
data29. Correlating electrical neural activity to haemodynamic data enables direct association 
of neural events to corresponding haemodynamics in the study of neurovascular coupling, and 
is important to do so as blood flow may or may not be directly related to changes in neural 
activity.  
 
To overcome some of the limitations of individual techniques and to provide a comprehensive 
representation with respect to brain activity, a multimodal approach is typically used in the 
study of neurovascular coupling with the combination of two or more techniques. For example, 
2D-OIS (optical imaging spectroscopy) or BOLD-fMRI can be combined simultaneously with 
a micro-electrode implant for electrophysiology, or surface electroencephalography (EEG) in 
to give both a haemodynamic and neural response28,30. For example, a recent study has 
shown that multiple sclerosis (MS) patients show reductions in gamma power (through 
magnetoencephalography; MEG) as well as a reduction in BOLD (by fMRI) and CBF 
responses to visual stimulation31.  It is important to consider not only a BOLD (blood oxygen 
level dependent)-related haemodynamic response in neuroimaging, but the source of neural 
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activity itself, as blood flow changes often lag with respect to neural activity and may even 
decouple substantially in neurological disorders such as Alzheimer’s disease (AD)19,32.  
 
1.5.2 – 2-Photon Microscopy and Calcium Imaging  
At rest, neurons typically have a low basal [Ca2+] concentration of appropriately 50nM, which 
is kept constant due to the action of several calcium ion channels and pumps such as the 
efflux plasma membrane calcium ATP-ase (PMCA)33. Upon neural activation (propagation of 
an action potential), influx calcium channels such as voltage gated calcium channels (VGCCs) 
and glutamate-mediated NMDA receptors, allow a significant influx of intracellular calcium with 
levels rising to 100-fold higher than baseline34. Therefore, neural activity directly correlates 
with changes to [Ca2+] levels. These indicators can be virally injected into the brain, or 
genetically engineered. Genetically encoded calcium indicators (GECIs) are bioluminescent 
protein complexes with integral fluorophores, which when stimulated emit a resonance signal 
in the form of visible light which can be detected by a camera, allowing quantification of neural 
activity based on the level of luminescence emitted by the fluorophore. Examples of common 
GECIs include Yellow Cameleon 3.60 (YC3.60), which contains an enhanced cyan fluorescent 
protein (ECFP) donor fluorophore, bound to a Venus protein acceptor fluorophore, linked by 
a calcium-binding domain, calmodulin35. More recent GECIs include modifications to the 
GCaMP family, such as GCaMP6, which is a class of single-fluorophore GECI, where calcium 
binding causes a conformational change in the integral fluorophore (EGFP) to increase its own 
intensity36. Specific GECIs and other fluorescent proteins can be used to label specific and 
multiple cell types of the neurovascular unit simultaneously. This can also be achieved by 2D-
OIS by measuring GCaMP-labelled neuronal activity, whilst simultaneously measuring 
haemoglobin reflectance changes, as done in Hillman’s group37 amongst others. 
 
2-photon microscopy is a technique in which a single laser emits two infrared (low-energy) 
photons to a focused region to cause excitation in fluorophores to a higher-energy state38. As 
the fluorophores return to their resting ground state they emit a light signal which is detected 
by a scanner. Calcium labelling of neurons and glial cells allows quantification of neural activity 
by measuring transient changes in spiking activity34. Fluorescent labelling of other cell types, 
including endothelium allows simultaneous blood flow measurements (RBC velocity), and 
therefore neurovascular coupling at the cellular level39. Multi-labelling in live animals 
eliminates the need to attach electrodes to the area of interest, therefore allowing neural and 
haemodynamic measurements to be taken by 2-photon microscopy over long periods of time. 
For example, it has been shown that amyloidosis (visualised by Methoxy-X04) around cerebral 
vasculature (visualised by TRITC-Dextran) disrupts the NVU function by a displacement of 
astrocytic-end-feet (visualised by Rhod-2 AM-loaded astrocytes) by reducing overall CBF 
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(determined by RBC velocity) in an AD mouse model40. Despite robust neural activity being 
present, the slow-down of CBF marks a decoupling of neurovascular coupling in AD.  
 
Most stimulation paradigms in pre-clinical research involves the mechanical stimulation of 
either whiskers or fore/hind-paws to evoke a neural and haemodynamic response in the 
somatosensory cortex to study neurovascular coupling. Optogenetics involves expressing 
light-responding proteins such as channelrhodopsin 2 (ChR2), a blue-light sensitive protein 
which upon stimulation causes labelled cells to become active41. Neurons, as well as 
astrocytes, interneurons or even pericytes can be tagged with ChR2 in the cell-specific 
optogenetic stimulation approach. Adapting the correct filters in the 2D-OIS setup can allow 
the simultaneous optogenetic stimulation by blue light whilst also measuring haemodynamic 
changes as well as GECI-labelled neurons, in a shift to an all-optical approach to studying 
neurovascular coupling in vivo.  
 
1.6 – Neurovascular Dysfunction in Neurological Disorders  
Many neurological conditions including the common neurodegenerative disorders display 
some level of neurovascular dysfunction; which either initiates or contributes to their 
pathogenesis, or is caused as a consequence. The neurovascular dysfunction seen in 
disorders such as Alzheimer’s and stroke can be directly attributed to cardiovascular deficits, 
however in some cases it may also not be directly associated with any underlying 
cardiovascular pathology, rather a functional breakdown of the neurovascular unit and 
signalling pathways.  
 
1.6.1 – Dementia (Alzheimer’s Disease)  
For the first time since medical records began, dementia has become the single-most leading 
cause of death in the UK surpassing heart disease, strokes and major cancers42. With an ever-
ageing population, higher life expectancy and advances in diagnosis techniques, dementia 
currently affects as many as 1 in 6 in the UK42. Of the dementias, AD is the most prevalent 
followed by vascular dementia, whereas the remainder of cases comprise of frontotemporal 
dementia (FTD), dementia with Lewy bodies (DLBs) and early-onset dementia. In most of 
these cases, a mild cognitive impairment stage usually occurs much earlier on before the 
onset of dementia.  
 
AD is an age-related neurodegenerative disorder and the most frequent form of dementia 
worldwide43. The primary pathological hallmarks of AD consist of extracellular β-amyloid (Aβ) 
plaques and intracellular neurofibrillary tangles (NFTs) of hyper-phosphorylated tau44. Familial 
cases of AD arise in an autosomal dominant inheritance pattern due to mutations to either 
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amyloid precursor protein (APP), presenilin 1 (PSEN1) and presenilin 2 (PSEN2)45–47. Familial 
AD is usually relatively early-onset, however only accounts for around 10% of all AD cases 
worldwide48. Although genetic mutations in AD account for a small proportion of all AD cases, 
most of our understanding of AD pathology and mechanisms have come from animal models 
with these genetic mutations, for example the J20 mouse (PDGFB-hAPPSwInd) harbours the 
more common APP mutation called the Swedish K670N/M671L mutation as well as the 
Indiana V717F mutation, which both increase β-secretase activity49,50. The increased 
production of the toxic form of amyloid, Aβ42, as well as Aβ40, coupled with the decreased 
ability to clear aggregates is the primary cause of Aβ-plaque build-up in the pathogenesis of 


















Figure 1.3 - Overview of Aβ processing. APP can be processed via the α-secretase pathways 
(non-amyloidgenic pathway) producing the soluble APPs-α fragment and a small p3 fragment. The 
amyloidgenic pathway utilises β-secretase to produce the soluble APPs-β fragment followed by γ-
secretase producing Aβ40 or lower in a much higher ratio than the production of Aβ42. Mutations 
to PSEN1/2 and APP (such as the Swedish mutation, marked by a red star on APP) often favour 
the production of the more toxic Aβ42 fragment which forms oligomers leading to the formation of 



















The vast majority of AD cases are sporadic (~90%) and are relatively later-onset, and are 
therefore not attributable to inherited genetic mutations to amyloid processing genes. It is 
important to note that even in sporadic AD cases, β-amyloid plaques are still present, and has 
many similarities to familial AD. Amongst the common risk factors already associated with 
cardiovascular disease and dementia such as age, hypertension, hypercholesterolaemia, 
diabetes etc., there are several risk factor gene polymorphisms which greatly enhance the 
likelihood of developing AD. The most common is the APOEε4 allele which is attributed to up 
to approximately 50-60% of all AD cases53 as carrying the allele (found in around 15% of the 
population) increases the risk of developing AD 4-fold, and homozygous inheritance of the 
APOEε4 increases the risk 9-fold53. APOEε4 AD-patients have amyloid-β plaques as well as 
phosphorylated-tau NFTs similar to familial AD52,54. The knowledge gained from the use of 
genetic models of AD therefore also applies to a vast proportion of all AD cases where amyloid 
is present.  
 
There is a growing body of evidence which suggests that neurovascular coupling may be 
impaired in AD23,32,55,56. It is postulated that impaired blood flow responses to neural activity as 
a result of neurovascular disarray may cause a mismatch between neural activity and 
provision of oxygen and glucose to meet sufficiently adequate metabolic demands. 
Consequentially, neural activity is reduced and thus correlates with impaired cerebral function, 
manifested clinically as cognitive decline32. As discussed previously, pericytes are critical in 
the integrity and maintenance of the BBB and therefore the NVU. Recent evidence has shown 
that patients with AD carrying the APOEε4-allele have a BBB breakdown attributed to pericyte 
degeneration in which patients/carriers have up to 50% less pericyte coverage correlating with 
almost 300-400mm/mm3 total capillary length reduction compared to control subjects without 
the APOEε4 allele57. This study is further supported by Kisler et al19 in which they found that 
PDGFRB-/- (pericyte deficient) mice have a reduced cerebral oxygenation level compared to 
controls as well as neurovascular uncoupling leading to neuronal death19. More recent 
evidence has directly implicated pericyte degeneration in extensive white matter pathology 
characterised by hypoxia and loss of myelination, leading to the loss of structural and 
functional connections within the brain which are typically present in some AD cases58. The 
breakdown of the NVU (pericytes amongst other cell types within the NVU) and the BBB is 
evident in Alzheimer’s patients, and may contribute to exacerbated pathology seen in AD, as 
well as initiating neuropathology. This can be further explained in the 2-hit vascular hypothesis 
model of AD proposed by Zlokovic59 (Figure 1.5). The first ‘hit’ refers to vascular dysfunction 
caused by various risk factors including atherosclerosis leading to a breakdown of vascular 
integrity causing reduced CBF which in itself can cause stroke (discussed below), cognitive 
decline and vascular dementia. The second ‘hit’ refers to the increased Aβ levels (by a 
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reduction in clearance) which further exacerbates neuronal dysfunction and adding further 
insult to the pathogenesis of AD59. It is therefore becoming increasingly more apparent that 
AD is not solely a neurodegenerative disorder, rather it is a complex multifactorial disease with 
a large neurovascular element which needs to be investigated further both in disease initiation 
and in potential therapeutic strategies.  
 
1.6.2 – Stroke 
Vascular dementia and other forms of cognitive impairment can be caused directly by having 
a stroke. Strokes can arise as a direct consequence of arterial pathology with profound 
changes to the neurovascular unit and the normal physiology of neurovascular coupling. This 
impaired blood flow to the brain can lead to the death of neural tissue in specific regions where 
blood flow is disrupted to cause a stroke. Depending on the severity of the stroke, symptoms 
can be mild ranging from a transient ischaemic attack to a potentially fatal in a stroke where a 
large are of the brain is affected60. Strokes can fall into two broad categories: ischaemic, where 
occlusion of vessels leads to death of tissue; or haemorrhagic as a result of a ruptured vessel60. 
As a consequence of stroke, cognitive and motor function can become impaired, sometimes 
permanently leading to vascular dementia for example.  
 
Subarachnoid haemorrhages (SAH) as a result of cerebral aneurysm rupture can cause a 
devastating stroke which usually results in death a few days after the initial rupture, if not fatal 
during the initial stroke61. It has been demonstrated that in such haemorrhagic episodes, there 
tends to be an inversion of neurovascular coupling in response to calcium-signalling mediated 
by astrocytes61. Instead of Ca2+-mediated vasodilation, post-stroke, there is a switch in the 
polarity of neurovascular coupling in which Ca2+ actually causes vasoconstriction 
pathologically. This then limits CBF and functional hyperaemia to the brain parenchyma 
resulting in progressive ischaemia after the stroke takes place usually resulting in death of the 
patient a few days after the stroke61. A potential mechanism as to why this may occur may be 
due to the upregulation of astrocytic endothelin-1 (ET-1); a vasoconstrictor, after SAH62. ET-1 
binds to ETB1 receptors on endothelial cells to reduce overall synthesis of endothelial nitric 
oxide synthase (eNOS), and hence NO levels. ET-1 also binds to ETA receptors on the tunica 
media of vessels to upregulate PKC-α, which in turn inhibits the function of K+ channels to 
contribute to vasospasm, and BBB breakdown causing oedema62. These studies highlight the 
importance of astrocytes in neurovascular coupling by alluding to the critical signalling 
pathways between neurons-astrocytes-endothelial cells in facilitating vasodilation, as well as 




1.6.3 – Physiological Ageing 
Ageing is itself the biggest risk factor in the development of many diseases including 
cardiovascular disease, Alzheimer’s and vascular dementia. Normal physiological ageing itself 
results in progressive neurovascular dysfunction, primarily marked by a reduction of overall 
CBF63,64. A key reason why many age-related disorders begin is due to the accumulation of 
reactive-oxygen species (ROS) coupled with impaired ROS-scavenging. Indeed, it has been 
shown that an enhanced production of ROS leads to an overall reduction in NO within the 
vasculature, therefore impacting NO signalling to cause vasoconstriction over time10. This 
arises as a direct result of aged vessels affecting their structure and function.  
 
A recent study by Duncombe and colleagues explored the pathophysiology of neurovascular 
coupling associated with ageing65. They found that aged mice show key differences in the 
NVU compared to younger mice. Firstly, pericyte coverage is markedly reduced in older mice65. 
However, this study did not find any correlative effects of the loss of pericytes with CBF and 
alterations to neurovascular coupling. This is contradicted by another study by Kisler and 
colleagues19, which found that the loss of pericytes directly causes neurovascular uncoupling, 
in addition to reduced oxygen perfusion in the brain23. As alluded to earlier, studying the role 
of pericytes in neurovascular coupling is a challenging task, mainly as there are few specific 
markers for pericytes, as well as limited scope to study blood flow in capillaries in vivo, which 
is acknowledged by Duncombe. Secondly, Duncombe and colleagues found that aged mice 
exhibit astrocyte end-feet abnormalities by the marked reduction in the expression of AQP465, 
which impairs the cell-cell communication between astrocytes and endothelial cells via the 
neurogliovascular signalling pathways (as shown in Figure 2). Ageing, therefore, progressively 
impairs functional hyperaemia by a wide variety of pathophysiological changes associated 
with the NVU, in addition to the loss of key signalling pathways, which may be further worsened 
in AD through excitotoxic calcium signalling due to Aβ plaque pathology66.  
 
1.7 – Atherosclerosis  
One key pathological change associated with ageing is that of atherosclerosis. Atherosclerosis 
is a chronic inflammatory syndrome resulting in the progressive thickening and hardening 
(arteriosclerosis) of major artery walls67. This continual narrowing of the lumen restricts blood 
flow over time, and is causative in millions of deaths worldwide each year with the commonest 
causes of death being stroke, myocardial infarction and dementia68. The aetiology of 
atherosclerosis is complex with a combination of genetic, lifestyle (e.g. dietary), environmental 




Atherosclerosis can take decades to take full effect with patients being largely asymptomatic 
until their mid-50s, although initiation of disease takes place in early adulthood. The initiation 
of atherosclerosis is still not fully understood, although general consensus is that 
atherosclerosis begins with inflammatory changes within the endothelium caused by low-
density lipoproteins (LDLs) being deposited69,70, and internalised by endothelial cells. However, 
what is becoming increasingly clearer is that deposition of LDLs into the arterial walls is not 
sufficient to cause atherogenesis, rather it is the subsequent immune response facilitated by 
monocytes and leukocytes that initiates the syndrome71. LDLs have been shown to deposit 
more readily in atherosclerotic-prone and low blood flow areas of an arterial branch, where 
they undergo oxidation by reactive oxygen species (ROS), stimulating an immune-response72. 
The arterial branches susceptible to LDL deposition and atherosclerosis tend to be near areas 
of major curvatures (e.g. carotid sinus) which have a high shear index compared to laminar 
areas of the same arterial tree, that tend to be more athero-reistant73.  
 
The solidifying step in atherogenesis is when invading monocytes differentiate into 
macrophages in the intima after binding to endothelial receptors such as VCAM1 and P-
Selectin74, Figure 1.4. Once differentiated into macrophages, oxidised-LDLs are subsequently 
engulfed, slowly transforming normal macrophages into ‘foam-cells’ with a large accumulation 
of lipids intracellularly75. Over time, clusters of foam cells form visible ‘fatty-streaks’ inside the 
intima of the endothelium. Simultaneous to fatty-streak formation, endothelial VSMCs also 
begin to proliferate and migrate from the media into the intima and form a ring around the fatty-
streaks further stabilising the forming plaque76. Over time some of the VSMCs begin to calcify 
and harden adjacent to the atheromatous endothelium, forming a solid core in the intima of 
the endothelium, which begins to enlarge and partially occlude the vessel to cause a 
progressive narrowing (stenosis) of the artery77. The atheromatous plaque (atheroma) may in 
itself cause an obstruction of blood flow, or more commonly the atheroma may rupture and 
form a thrombus with platelets, which can be repeated to form a stable cap disrupting blood 
flow over time further exacerbating stenosis, or rupturing within the vessel wall to cause either 
an embolism or haemorrhage. Either of these can contribute to coronary heart disease, 











Figure 1.4 - Overview of the Pathogenesis of Atherosclerosis 
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Figure 1.4 - Overview of the Pathogenesis of Atherosclerosis. Accumulation of LDLs in the 
blood leads to LDLs being transported into the endothelium, where they become oxidised. 
Infiltrating monocytes become activated and differentiate into macrophages and begin to ingest 
oxidised-LDLs to become foam cells. Over time, foam cells conglomerate to form fatty streaks. 
Simultaneously, due to inflammation and stimulant factors, VSMCs begin to proliferate and migrate 
into the intima and form a cap around the fatty streak. Endothelial cells overlying the growing 
plaque become calcified, with reduced elasticity. Over time this cap restricts blood flow due to a 
luminal constriction. If the plaque ruptures, a thrombus forms and obstructs the lumen completely, 
or partially. This can lead to ischaemia downstream leading to an ischaemic attack in the brain, or 





























1.8 – Atherosclerosis and Neurovascular Dysfunction  
Atherosclerosis affects most large to medium sized systemic arteries including those 
supplying the cerebral circulation, namely the internal carotid and vertebral arteries60. 
Progressive plaque build-up and stenosis of cranial arteries can cause strokes as well as 
contribute to the development of dementia either directly or as a consequence of stroke. 
Strokes can either be ischaemic or haemorrhagic in nature, and can both trace their origins to 
underlying vascular pathologies, such as luminal stenosis as a consequence of 
atherosclerosis in the arteries supplying the brain and cranium60. Here, only the relationship 
between cardiovascular disease and cognitive impairment will be discussed.  
 
Atherosclerosis and related cardiovascular diseases and risk factors can cause a wide array 
of simple and complex vascular lesions in the brain. For example, bilateral carotid occlusion 
directly affects the blood supply to the brain, and is commonly associated with stroke and 
vascular dementia79. Some of the key vascular lesions commonly found in patients with 
cardiovascular pathology range from microbleeds, microinfarcts (lacunar multi-infarct or 
strategic) and lipohyalinosis; the deposition of hyaline in the connective tissue walls to disrupt 
the integrity of the vasculature, affecting the smaller vessels within the white matter termed 
cerebral small vessel disease80, refer to Figure 1.5. These lesions arise directly as a 
consequence of arterial stiffness and inflammation caused by atherosclerosis and vascular 
risk factors including hypertension, hypercholesterolaemia, smoking, diet and advanced age81. 
Cerebral small vessel disease is directly associated with the onset of dementia, primarily 
vascular dementia as well as Alzheimer’s-like pathology and other milder forms of cognitive 
impairment as well as stroke. Depending on where in the brain these vascular lesions occur, 
different symptoms may manifest clinically. Pre-symptomatic (subclinical) carotid 
atherosclerosis (determined by increased endothelial swelling, Figure 5.3) is associated with 
early cognitive impairment, in which pathologic mechanisms have been attributed to cerebral 
microvascular dysfunction (as shown in Figure 5) in the frontal and temporal lobes82.  
 
Lipohyalinosis is a brain-specific vessel disease characterised by vascular wall disruption and 
occurs as a result of systemic atherosclerosis, especially due to extensive inflammation 
occurring through the accumulation of ROS, in addition to gliosis involving astrocytes, 
oligodendrocyte precursor cells and microglia which themselves in their reactive state produce 
ROS83. As discussed previously, atherosclerosis is an inflammatory syndrome which initiates 
as a result of an immune response against oxidised-LDLs in the intima. Monocyte infiltration 
into the vessel wall followed by differentiation into macrophages which subsequently engulf 
the oxidised-LDLs forming foam cells is the primary inflammatory trigger71. In addition to 
monocyte infiltration at sites of LDL retention, TH1 (CD4+) lymphocytes are also involved in 
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the inflammatory response74,84. TH1 cells bind to antigen sites on LDL molecules and 
subsequently produce inflammatory mediators including tumour necrosis factor (TNF) and 
interferons e.g. IFNγ74, which all promote the pathogenesis and development of 
atherosclerosis. Cholesterol crystals activate the NOD-like receptor protein 3 (NLRP3), which 
together with caspase-1 and apoptosis-associated speck-like protein containing a caspase 
activation and recruitment domain (CARD) forms an inflammasome85. This stimulates the 
production of the proinflammatory IL-1β chemokine. IL-1β has been shown to be implicated in 
the pathogenesis of atherosclerosis and thrombosis by the downstream stimulation of IL-6 and 
C-reactive protein (CRP)86. Recent evidence has suggested that targeting the inflammatory 
pathways in atherosclerosis irrespective of reducing LDL-C levels, may actually be 
therapeutically beneficial in patients with atherosclerosis, by reducing the frequency and 
strength of major cardiovascular incidents86,87. Clinical trials involving canakinumab, a 
monoclonal antibody against IL-1β, has shown a significant reduction of major cardiovascular 
incidents in patients with atherosclerosis, by reducing the total levels of plasma IL-6 & CRP 

























Figure 1.5 - Vascular Lesions in Small Vessel Disease. Key types of vascular lesions found in 
the brain as a result of small vessel disease (SVD) leading to cognitive impairment (vascular 
dementia) and stroke include microbleeds, microinfarcts; where fatty deposits accumulate to 
restrict luminal diameter, and inflammatory white matter pathology such as lipohyalinosis, where 
hyaline deposits within connective tissue in addition to astrocytic gliosis (scarring) and wall swelling 






Vascular dysfunction caused by atherosclerosis and lifestyle/genetic risk factors can directly 
lead to cerebral vascular damage to cause small vessel disease and a breakdown of the BBB, 
marked by inflammation and hyper-connectivity23. This vascular damage leads to 
neurovascular dysfunction marked by CBF decrease (oligemia), as well as potentially initiating 
Aβ pathology by a reduction in clearance. Figure 1.6 illustrates how AD can develop (including 
the 2-hit vascular model proposed by Zlokovic59) as a result of vascular dysfunction leading to 
amyloid production, in addition to the pathogenesis of vascular dementia at the level of 
neurovascular dysfunction, independent of amyloid pathology. Figure 1.6 also summarises 
the key processes involved in atherogenesis and vascular dysfunction, including inflammation, 






























Figure 1.6 - Summary of Vascular Pathologies in CVD, Stroke & Dementia 
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Figure 1.6 - Summary of Vascular Pathologies in CVD, Stroke & Dementia. Vascular 
dysfunction pathway for stroke, vascular dementia and AD; AD-specific factors in red text 
(incorporating the 2-hit hypothesis for AD – hit 1 being at vessel damage and hit-2 being Aβ 
increase). CVD can directly cause cerebral vessel damage to cause either strokes and/or vascular 
dementia, in addition to initiating AD pathology if certain risk factors are present. Adapted from 

































1.8.1 – LDLR, ApoE & PCSK9  
LDL molecules comprise of an apolipoprotein B-100 protein, in addition to other lipids 
(including up to 1500 cholesterol molecules), triglycerides and structural protein complexes89. 
LDLs bind to the LDL-receptors (LDLRs) in hepatocytes, primarily, via the ApoB segment to 
stimulate endocytosis of the LDLR/LDL complex90. The closely related ApoE protein, which 
also binds to LDLR, is involved in the selective transport of lipoproteins systemically, especially 
in the transport of chylomicron and LDL remnants91. Genetic mutations that cause a loss of 
function to either the LDLR, ApoE or ApoB of an LDL molecule result in the reduced clearance 
of LDL from the plasma, therefore increasing the circulating plasma levels of cholesterol92. 
Whilst mutations to these genes may cause familial hypercholesterolemia from a much earlier 
age, affecting as many people as around 1:500 (heterozygotic)92, non-affected individuals can 
naturally develop hypercholesterolemia and therefore atherosclerosis with elevated LDL levels 
either through dietary intake of trans and saturated fats, being obese, in addition to having 
diabetes, or simply being male92. ApoE-/- and LDLR-/- knockout mice can develop 
hypercholesterolemia and atherosclerosis and disease severity and progression is 
exacerbated by being fed a high-fat diet93,94. ApoE-/- mice also develop BBB leakage which 
worsens over time, and may contribute to a breakdown of neurovascular coupling95,96.  
 
More recently, an rAAV8 D377Y-mPCSK9 (PCSK9DY) mouse model (on a male C57BL/6 
background) has been used to study atherosclerosis97–99, where a single injection of AAV-
mPCSK9DY is sufficient to cause long-term atherosclerosis in mice comparable to LDLR-/- 
strains, without the need to create a transgenic mutant knock-in line97. The proprotein 
convertase subtilisin/kexin type 9 (PCSK9) gene on chromosome 1 (1p32.3) has been shown 
to homeostatically regulate cholesterol levels in the plasma by directly interacting with the 
LDL-receptor (LDLR) and the related APOE-receptor (ApoER2) by causing their internalisation 
and degradation within a cell100,101. Over-time, the degradation of LDLR with respective 
increased plasma cholesterol levels may be causative to atherosclerosis in ordinary 
individuals102. Gain of function mutations to PCSK9 (e.g. D374Y) are associated with patients 
that have genetic hypercholesterolemia, in particular, familial autosomal dominant 
hypercholesterolemia (FADHC)103. In the case of the human PCSK9D374Y mutation, plasma 
concentrations of cholesterol can exceed 500mg/dL, where normal levels would be less than 
200mg/dL and pathological being above 250mg/dL103. Recently it has been shown that there 
is significantly increased PCSK9 within the CSF of Alzheimer’s patients carrying the APOEε4 
allele, with a yet unknown pathway104, further adding support to the notion that 
hypercholesterolaemia is a major risk factor for AD. With the knowledge that PCSK9 is 
involved in elevated cholesterol levels both physiologically and pathologically, monoclonal 
antibodies and selective inhibitors, such as alirocumab (against PCSK9), have been approved 
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by the FDA for the treatment of patients with hypercholesterolemia and atherosclerosis by 
halting the progression of cardiovascular disease105. Figure 1.7 illustrates the physiological 
and pathological mechanisms of PCSK9 in the regulation of plasma cholesterol levels. It has 
been shown that a high-fat diet exacerbates atherogenesis by elevating total cholesterol levels 
in PCSK9DY mice, much like the LDLR-/- strains, however normal rodent chow can also result 
in moderate atherogenesis99. As this is a relatively novel atherosclerosis model, not much is 
known about the effect on the brain or neurovascular coupling. This viral injection method of 
inducing atherosclerosis in any strain of mouse is far cheaper than breeding and maintaining 
inbred colonies, and it is becoming the model of choice due to its rapid induction (including in 
any genetic model), reliable and consistent atherosclerotic profiles as well as cost. Compared 
to the artificially high serum cholesterol levels seen in the ApoE-/- mice, and having the added 
benefit of not maintaining knockout lines, the rAAV-PCSK9DY model is certainly the more 
economical and more effective model in terms of induction of atherosclerosis as well as a 
























Figure 1.7 - PCSK9 Mechanisms. 
Keywords: LDL, low-density lipoprotein; LDL-C, cholesterol; LDLR, low-density lipoprotein receptor; 
PCSK9 proprotein convertase subtilisin/kexin type 9; HC, hypercholesterolemia; g.o.f, gain of 
function; FADHC; familial autosomal dominant hypercholesterolemia 
A (left) – Physiological homeostatic regulation of LDL-C by LDLR 
A (right) – Physiological homeostatic regulation of LDLR by PCSK9 (which may lead to HC) 
B – Genetic mutant (g.o.f) variant of PCSK9 causing FADHC 
























It is important to note that all animal models of human disease can never completely replicate 
human disease in vivo, due to species-specific physiologies; therefore, the models that we do 
have are our best insight into a more complex scenario with respect to human disease, and 
results must be interpreted with some level of caution before generalising both in terms of 
knowledge gained and potential for therapeutics. Although animal models can model human 
disease and provide insights into disease mechanisms effectively, sometimes the same model 
may provide conflicting evidence in the hands of other researchers. Studies have found a link 
between hypercholesterolemia and the onset of vascular dysfunction causing Alzheimer’s (-
like) pathology in patients106, as well as in high-fat diet mouse models107. However, in a study 
by Hohsfield and colleagues108, it was shown that hypercholesterolemia does not increase 
amyloid-deposition and Alzheimer’s like pathology in the same 3xTg-AD mouse model. 
However, unlike in the previous studies, the 3xTg-AD mice in Hohsfield’s study did not survive 
long enough, therefore probably did not gain enough cumulative amyloid/tau deposition to 
manifest as Alzheimer’s-like pathology. They did not consider more regular behavioural 
assays such as Morris maze tests to establish whether their mice displayed any early mild 
cognitive deficits.  
 
1.9 – Conclusions and Future Directions   
Neurovascular coupling is critical to the proper functioning of the brain, ensuring that increased 
neural activity, which itself is incredibly metabolically demanding, is matched with an 
appropriate change to CBF to both nourish the parenchyma with oxygen and glucose as well 
as the quick and efficient removal of carbon dioxide and waste products. In order to achieve 
this, neurons communicate with endothelial cells via the neurogliovascular signalling pathways 
within the NVU. Pathological changes to the NVU and endothelia impairs the signalling 
pathways involved in neurovascular coupling, leading to brain pathologies ranging from subtle 
cognitive deficits to severe AD. Although our knowledge and understanding of the 
mechanisms behind neurovascular coupling in health, ageing and disease has vastly 
improved in recent years, much is still to be investigated, especially with respect to the effect 
of atherosclerosis on cerebral vasculature and neurovascular coupling. Although there are 
many established models of atherosclerosis, the new rAAV-PCSK9DY method has many 
benefits over the conventional knock-out lines of ApoE-/- & LDLR-/-, including the ability to 
induce atherosclerosis in any mouse model including AD-mouse models. In future studies, 
tracking haemodynamic changes over time combined with cellular, genetic and in vivo imaging 
would provide a comprehensive overview and mechanistic insight into how cardiovascular 
disease affects neurovascular coupling and the brain as a whole in mouse models of 
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The manuscript ends here. The following sections are not part of the above paper, but 
form part of the rest of Chapter 1. In these sections, I discuss the use of preclinical models to 
study human disease, namely cardiovascular and cerebrovascular diseases. Furthermore, I 
discuss the need to generate comorbid models that better reflect the human conditions, as 
many diseases of ageing are often present with two or more multimorbidities. To date, there 
are very limited comorbid models (some of which are outlined in the following section), and 
basic and translational scientists need to develop more representative models if therapies 
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1.11 – Abstract 
The use of animal models is fundamental to furthering our understanding of human disease 
mechanisms, as well as identifying potential therapeutic targets. Diseases of ageing often 
involve multiple body systems; however, multi-systemic features are not fully recapitulated in 
the many of the animal models available. Therefore, combining pre-clinical models to better 
reflect the multimorbidities observed at the clinical level is critical. This review will highlight 
some of the key pre-clinical experimental models associated with cardiovascular 
(atherosclerosis, coronary heart disease), cerebrovascular (stroke, vascular dementia), 
metabolic (obesity, type-2 diabetes mellitus) and neurological (amyotrophic lateral sclerosis, 
frontotemporal dementia, Parkinson’s, epilepsy) diseases, and whether these models 
encompass known multimorbidities. In addition to this, we discuss established pre-clinical 
models that combine two or more conditions, within the context of dementia.   
 
1.12 – Introduction 
Studying the mechanisms of human disease is a complex and challenging task. Pre-clinical 
models are necessary in order to fully interrogate and manipulate different pathophysiological 
processes and to understand the mechanisms involved in disease onset and progression. 
Whilst cell models provide invaluable insight at the molecular level, animal models are 
inevitably required to fully recapitulate the complex multisystem involvement of diseases of 
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ageing. Animal models of human disease have led to significant improvements in our 
understanding of human diseases as well as allowing us to trial novel therapies. The focus of 
this review is to describe some of the main pre-clinical models used to study many of the major 
human diseases (cardiovascular, metabolic & neurological) associated with ageing and 
dementia, as well as outlining some of the mixed comorbid models combining two or more 
diseases.  
 
1.13 – Cardiovascular Diseases 
Cardiovascular diseases (CVDs) are a leading cause of mortality worldwide (1), with an 
estimated 30% of all deaths globally being attributed to CVDs. Within the UK, 7.4 million 
people are currently living with CVDs and these numbers are expected to rise due to the 
increasing ageing population. CVDs include a range of linked diseases that affect the heart 
and/or the circulatory system. These include coronary heart disease (CHD), cerebrovascular 
diseases (CbVDs) including stroke, peripheral arterial disease, aortic aneurysms, 
thromboembolic disease, renal artery stenosis, cardiomyopathy, pulmonary heart disease, 
cardiac dysrhythmias, valvular heart disease, inflammatory heart diseases and heart failure. 
Many of these conditions have similar underlying pathologies including the development of 
atherosclerosis as well as common modifiable risk factors including hypertension, obesity, 
hypercholesterolaemia, sedentary lifestyle (inactivity), diabetes mellitus, smoking and 
excessive alcohol consumption (2). Other non-modifiable factors include genetics (family 
history), ethnicity, being male and advanced age. As such, many CVDs are preventable 
through modifying lifestyle risk factors and adopting a healthier and active lifestyle. In this 
section, models of atherosclerosis and cerebrovascular disease will be discussed, whereas 
diabetes mellitus and obesity will be covered in depth later. 
 
Atherosclerosis is the main underlying cause of CVD and affects most people over the age of 
60 to some degree with around 50% of all people over the age of 40 being in good health 
having a risk of developing serious atherosclerosis (3). Atherosclerosis is the chronic and 
progressive thickening and hardening of major arteries by the build-up of atheromatous 
plaques that can lead to luminal narrowing to restrict blood flow over time (4). Atheromatous 
plaques may themselves rupture to form a thrombus disrupting blood flow or to cause an 
embolism or haemorrhage. Atherosclerosis and thromboembolism are the primary causes of 
CHD, myocardial infarction and stroke. Atherosclerosis whilst itself is a disease, often does 
not present with overt symptoms until plaques severely limit flow/rupture or a secondary effect 
of atherosclerosis occurs – such as CHD or stroke. A more detailed discussion of 





Mouse models of human atherosclerosis tend to centre around genetic knockouts of 
commonly implicated genes in atherogenesis, notably LDLR and APOE mouse knockouts (6). 
LDL molecules (commonly referred to as “bad cholesterol”) alongside other lipids, triglycerides 
and cholesterol molecules bind to the LDLR primarily within hepatocytes in the liver leading to 
lipid endocytosis (7). Mouse models that knockout LDLR have a reduced ability to endocytose 
LDL molecules thus serum LDL and cholesterol levels become elevated 
(hypercholesterolemia). The ApoE protein has numerous physiological roles including its 
ability to bind to chylomicron and VLDL molecules and binding to the LDLR leading to lipid 
endocytosis. Compared to LDLR-/- mice, ApoE-/- mice are hyperlipidaemic even on a normal 
rodent diet without the need for a high-fat Western or Paigen diet; which the LDLR-/- mice 
requires for atherogenesis, however, ApoE-/- mice display much higher serum cholesterol 
levels and atherosclerotic lesions with a Western diet (6). As such, the APOE-/- mouse model 
is much more aggressive than the LDLR-/- mouse model on a high-fat diet, although the latter 
displays hyperlipidaemia profiles that closely resemble the spectrum of lipid levels in humans. 
The specific differences between the two strains with respect to atherogenesis are discussed 
in depth elsewhere (6). A third and more recent model of atherosclerosis utilises a single 
injection of rAAV8-mPCSK9-D377Y that is sufficient to cause robust atherosclerosis in mice 
and hamsters within 8-12 weeks when combined with a Western diet comparable to LDLR-/- 
mice (8, 9). PCSK9 typically regulates cholesterol levels homeostatically by interacting with 
LDLR to cause its internalisation and degradation (10). The murine D377Y mutation confers 
a gain of function mutation to PCSK9 leading to its constitutive activation at all times 
permanently reducing LDLR expression, which is analogous to the human D374Y mutation 
found in familial autosomal dominant hypercholesterolaemia (11). As recently discussed in our 
previous review (5), the AAV8-mediated virally injected model of atherosclerosis is far cheaper 
and simpler than maintaining large inbred colonies and breeding genetically modified animals. 
Not only is the induction of atherosclerosis relatively quick, it can also be induced in almost 
any strain of mouse at any age. Table 1 outlines the key features of these models. 
 
Of the three mouse models, the APOE-/- has been used more extensively in the research of 
atherosclerosis and cerebrovascular function than the LDLR-/- or mPCSK9 models. We have 
previously investigated cerebrovascular changes in the APOE-/- mouse (12), where we found 
that interleukin-1 (IL1ß) was a key driver of systemically mediated cerebrovascular 
inflammation. An anti-IL1ß approach can potentially be used to therapeutically intervene in 
atherosclerosis, dementia and stroke (13). Within the brain, lipid deposition coinciding with 
inflammation was found in the lateral ventricle and choroid plexus associated with Cd45+ cells 
as well as significant microglial (Iba1+) activation. Lipid deposition, but not atherosclerotic 
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lesions, was found within the walls of larger ventricle-associated blood vessels and in some 
smaller parenchymal arteries. However, focal pathologies were not present within the 
parenchyma. Using anti-IL1ß antibodies, the number of CD45+ cells were substantially 
reduced as well as reduced microglial activation (12). It is important to note that the most 
severe neuroinflammatory changes and lipid deposition was substantially more pronounced 
in APOE-/- mice fed a Paigen diet (more cholesterol and cholate) than those fed a Western 
diet. Other work using the APOE-/- model has found impaired cerebrovascular autoregulation 
and worsened ischemic perfusion deficits (14). In accordance to our previous findings, Ayata 
et al did not find any evidence of intracranial atherosclerosis despite evidence of scattered 
foam cells in carotid arteries and fatty streaks within the aorta. Blood pressure was found to 
be 10% higher compared to controls, and indeed hypertension is a common comorbidity of 
atherosclerosis/CVD in humans and animal models. Furthermore, reduced vascular reactivity 
by 30% in APOE-/- mice was observed compared to controls as assessed through a 5% 
hypercapnia test. In addition, blunted neurovascular haemodynamic responses to sensory 
whisker stimulations by 64% were also observed despite no cortical activation differences, 
indicative of impaired neurovascular coupling (14). Other studies have shown cognitive and 
behavioural changes associated with ApoE-/- mice including deficient spatial memory 
(assessed by Morris water maze) (15) as well as in the LDLR-/- mouse fed a Western diet (16), 
which also displayed more anxiety. Furthermore, these mouse models have served as good 
bases for trialling therapeutic strategies for atherosclerosis in. For example, simvastatin has 
been shown to reduce atherogenesis and promotes the expression of genes associated with 
cholesterol uptake using ApoE-/- mice fed high-fat diet (17). In addition, simvastatin has also 
been shown to improve cognitive deficits in the Tg2576 mouse model of AD due to its anti-
inflammatory properties (18). The biggest limitation with mouse models of atherosclerosis is 
that mice in general are resistant to atherosclerosis; which may in part be due to the fact that 
LDL-cholesterol can be degraded rapidly from plasma and mice naturally have much higher 
levels of HDL-cholesterol which is athero-protective (19). Even when atherosclerosis is 
induced in mouse models such as genetically knocking out ApoE & LDLR, or by virally 
inducing by rAAV8-mPCSK9-D377Y, the atherosclerosis is often limited to the aorta and aortic 
sinus without too much further progression to coronary, pulmonary and cerebral circulation. 
Both ApoE-/- and LDLR-/- mice have extremely limited or completely absent plaque rupture and 
thrombosis or any coronary arterial occlusion (19), all which are important features of human 
CVD. 
 
Coronary heart disease (CHD), particularly heart failure, is caused by a reduction of blood flow 
to the heart muscle due to a build-up of atherosclerosis in coronary arteries and is common 
affecting around 2.3 million people in the UK. Individuals with CHD have on average a 45% 
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increased risk of developing cognitive impairment or dementia (20). This is associated with a 
reduced cerebral perfusion due to reduced cardiac output. This is very difficult to model and 
ApoE-/- mice fed a Western diet with severe atherosclerosis do not display complete coronary 
arterial occlusion. However, when ApoE-/- or LDLR-/- mice are crossed with mice deficient for 
Na+/H+ exchange regulatory cofactor NHE-RF3 (encoded by PDZK1); a protein which binds 
to a HDL receptor SRB1, or have SRB1 deficiency, these double transgenic mice fed altered 
fatty diets do present with coronary artery occlusion and myocardial infarction (21, 22) (Table 
1). It is thought that the mechanism for this is that unesterified cholesterols accumulate in 
HDL-cholesterol molecules impairing their naturally athero-protective properties alongside 
HDL-cholesterol increase (toxic forms) causing rapid and robust atherogenesis. These mice 
often die young due to spontaneous myocardial infarction. Normal rodent chow mice live the 
longest, followed by Western diet fed mice, and Paigen diet mice living the shortest due to the 
increased fat and cholesterol levels (22). The mice fed Paigen or Western diets display a 
significantly increased expression of VCAM-1, ICAM-1 in coronary arteries accompanied by 
an increased number of monocytes infiltrating the wall. Other models of CHD with human like 
presentation of symptoms include crossing ApoE-/- mice with those deficient for eNOS (ApoE-
/-/eNOS-/-) (23). These mice develop coronary artery atherosclerosis with heart failure and 
myocardial infarction as well as the presence of aortic aneurysms. The problem with deleting 
eNOS is that other isoforms of NOS are upregulated in a compensatory manner. Total NOS 
knockout (NOS tKO) mice suffer from several comorbidities including hypertension, left 
ventricular hypertrophy, dysfunctional vascular pulsing, coronary spasm initiated by mast-cell 
derived histamine release and death (24). Whilst this mouse model is useful for dissecting 
new mechanisms involving the NOS system and its importance in maintaining normal 
cardiovascular function, it is highly artificial as humans tend not to have complete NOS 
deficiency but allows the possibility of NO-donors as potential therapeutic agents for CHD 
given that NOS deficiency is key in many CVDs (25).   
 
Other models of CVD include rabbit models similar to the rodent models in terms of being fed 
a high-fat or cholesterol diet. The advantage of rabbits over rodents is that they are medium 
sized animals that readily present with fibroatheroma lesions, though much like rodents, 
typically do not exhibit any plaque rupture (26). Rabbits when fed a high-fat diet develop robust 
atherosclerotic lesions which in part resemble human lesions with respect to the involvement 
of immune cells and vascular smooth muscle cell proliferation (26) (Table 1). In addition, 
models of plaque rupture have been successfully modelled in rabbits when a high-fat diet was 
combined with vascular injury modelling leading to vulnerable plaque formation that consist of 
lipid rich cores, macrophage accumulation and fibrous caps which resemble vulnerable human 
atherosclerotic lesions (27). 
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1.14 – Cerebrovascular Disease (CbVD) 
Systemic CVD of the type discussed above can lead to impaired blood circulation to the brain 
and/or to vessels within the brain giving rise to a collection of conditions called CbVDs. These 
diseases include both haemorrhagic and ischaemic strokes, cerebral aneurysms and vascular 
dementia. Every 2 seconds, somewhere in the world suffers from a stroke, and there are 
approximately 100,000 strokes in the UK every year (1 every 5 minutes) and approximately 
1.2 million stroke survivors (28) Stroke is the 4th biggest cause of mortality in the UK and the 
2nd biggest cause of mortality across the world causing around 5.78 million deaths in 2016. 1 
out of 4 affected individuals will suffer from another stroke within 5 years. 85% of all strokes 
are ischaemic whereas only 15% are haemorrhagic (29). The primary cause of ischaemic 
strokes are large vessel atherosclerosis, cardioembolism, lacunar infarcts due to small vessel 
disease (SVD) or rupture of an atherosclerotic plaque, though some strokes remain due to 
undetermined aetiologies known as cryptogenic strokes (30). Strokes can either be transient 
(transient ischaemic attacks) or major cerebrovascular incidents (both fatal and non-fatal). 
Often with non-fatal strokes, cognitive impairment can occur that can lead to vascular 
dementia (VaD) – the 2nd most common form of dementia after AD, along with SVD and 
intracranial atherosclerosis; both also causes of stroke (31). Thus, stroke and vascular 
dementia are tightly linked together with 1 in 3 stroke survivors developing VaD within 5 years 
and 75% of all dementia cases in stroke survivors being attributed to VaD (32).  
 
Rodent models of stroke tend to either be mechanical (surgical) in nature or pharmacological 
to predispose animals to clotting, for example. The most common surgical model is that of the 
middle cerebral artery occlusion (MCAO) model in which a filament is inserted into the internal 
carotid artery and pushed until the MCA is blocked that can either be permanent, or temporary 
to allow reperfusion (33) (Table 1). This model mimics thromboembolic infarcts seen in 
patients where the majority of infarcts occur within the MCA. The major issue, however, with 
this model is that it results in complete occlusion of the MCA whereas ischaemic strokes in 
patients tend not to be completely occluding and spontaneous reperfusion tends to occur in 
most patients due to the resolution of the thrombus within 48hrs (33). Nonetheless, this model 
has provided valuable insights into specific elements of ischaemic stroke including blood-
brain-barrier injury, neuroinflammation and reactivity, and cell death – common features of 
human stroke. Other MCAO techniques include the permanent electrocoagulation of the distal 
portion of the MCA (dMCA) which leads to consistent infarct volumes of up to around 12% of 
the cerebral hemisphere affecting somatosensory and motor cortices, which resembles 
closely a significant proportion of human strokes in terms of area affected (34). Embolic stroke 
models can be modelled by either spontaneously formed or thrombin-induced material. 
Thrombin can be injected directly into the MCA to mimic vessel occlusion, or by introducing 
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an embolic material through the extracranial internal carotid artery or external carotid artery to 
cause occlusion of potentially multiple vessels (35-38) (Table 1). The major advantage of this 
approach of the complete MCAO model is that there is spontaneous and unpredictable partial 
or complete occlusion followed by resolution and reperfusion that mimics human embolic 
stroke more closely. The model is also highly variable, much like clinical strokes and the 
disease-course can present very differently in different animals. Although there has been 
steady development over the years with rodent models, none of the drugs so far studied in 
these models has translated to a successful stroke treatment (39).  
 
Many non-human primate models, unlike rodents, have more complicated and evolved brain 
structures that resemble human brains better, for example the macaque monkey and baboons. 
However, many non-human primates including marmosets still have a lissecephalic brain thus 
in terms of gyri and sulci are not more evolved than rats, for example, despite overall having 
a more complex organisation of the cortex. Thus, the use of a non-human primate in stroke 
research for example would be more suitable using a gyrencephalic brain of a baboon or 
macaque. Endovascular ischaemic stroke has been modelled in rhesus macaques by inflating 
a balloon attached to a micro-catheter to occlude the MCA for 3hrs; similar to the MCAO rodent 
model, and by injection of an autologous clot into the MCA for 3hrs (40) (Table 1). In line with 
rodent studies, perfusion deficits and worse prognoses (including hemiparesis and death) was 
attributed to the full occlusion model compared to the clotting model which displayed better 
outcomes for some but not all of the monkeys. This variability was due to the positioning of 
the clot along the MCA where M1 occlusion would be more fatal rather than via M2 segments, 
allowing M1 reperfusion. The bifurcation (or trifurcation) of MCA branches of such an extent 
can only be modelled using higher order organisms. Indeed, promising therapeutic trials from 
rodent studies have been replicated in monkeys (such as PSD-95 inhibitor) (41). Thus, a more 
natural pre-clinical pipeline would be to assess promising rodent therapies in gyrencepahilc 
non-human primates before human trials. However, compared to rodent studies, the ethical 
and legal framework involved in non-human primate research is much more complex and often 
holds a public stigma associated with it, despite the increasing need to replicate rodent studies 
in non-human primates due the immense failures of most translational therapies for stroke 
from rodents.  
 
After non-fatal stroke, VaD can occur in around 75% of all stroke survivors. This second most 
common form of dementia after Alzheimer’s is estimated to affect 150,000 people in the UK 
and causing around 15,000 deaths each year (42). Individuals with CHD and diabetes are at 
a particularly high risk of developing VaD (42) therefore with respect to models of VaD and 
vascular cognitive impairment dementia (VCID), there is a need to effectively recapitulate 
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hypoxia and inflammation that is associated with deep white matter lesions. In order to do this, 
similar to the stroke models discussed, bilateral occlusion of the carotid arteries (rather than 
cerebral arteries) is typically performed (BCAO) to cause generalised hypoperfusion and 
hypoxia-induced white matter damage (43, 44) (Table 1). The original study from 1994 
explored neuropathological changes associated with the BCAO rat model and found 
significant glial (GFAP+) activation associated with increased MHCI/II expression on microglia, 
and infiltration of CD4+ and CD8+ immune cells were found within the white matter (43). This 
results in severe, but temporary oligemia, which gradually returns to baseline within a few 
weeks with a compensatory enlargement of the basilar artery. Behavioural tests on BCAO 
mice have shown prolonged responses and learning times as well as increased error rates 
during Morris water maze tests indicative of learning and memory deficits in these mice (44). 
This occurred alongside a significant reduction in CA1 hippocampal neuronal number/ 
disorganisation, BBB disruption associated with vasogenic oedema, loss of oligodendrocytes 
and reductions in myelination density (45). Bilateral carotid arterial partial stenosis (BCAS) 
methods are preferred in mice as opposed to permanent BCAO (which leads to death in mice) 
using small coils that lead to hypoperfusion but allow some slow reperfusion (46) (Table 1). 
These mice also display working memory deficits assessed by radial maze tests associated 
with hippocampal atrophy with widespread evidence of apoptosis (46, 47). This gradual 
stenosis model compared to a sudden acute oligemia is more reflective of human carotid 
stenosis implicated in VaD/VCID onset and maybe a better preclinical model as only white 
matter lesions are reported rather than extensive grey matter damage. Several treatment 
strategies have emerged using this model including the use of cyclosporin A which has been 
shown to suppress glial activation and BBB breakdown through inhibition of the MMP-9 
pathway in pericytes thus preventing neurodegeneration (48).  
 
Although VaD is linked to stroke, the actual term ‘dementia’ refers to a group of diseases 
characterised by progressive cognitive decline. Currently, there are no effective treatments to 
prevent, cure or slow down the disease progression of these diseases. Symptoms include, but 
are not limited to, behavioural changes, memory loss, difficulties in communicating and 
impaired executive function interfering with daily activities of affected individuals (49). 
Dementia is a leading cause of mortality worldwide with over 50 million people affected 
globally (50). This is set to triple to approximately 152 million by 2050, with nearly 10 million 
new cases every year (50). Within the UK, there are currently over 537,000 people with a 
dementia diagnosis, and this figure is projected to increase to 1 million by 2025 (51). In order 
of prevalence, common types of dementia include Alzheimer’s disease (AD), followed by 
vascular dementia (VaD, described above), frontotemporal dementia (FTD), and dementia 
with Lewy bodies (DLB). Up to 20% of all dementia patients often present with more than one 
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of these diseases leading to a mixed dementia diagnosis (52). Relevant to this review, the 
most common mixed dementia is AD with VaD or other cerebrovascular disease (CbVD). 
Since these diseases are associated with age, the prevalence of cardiovascular diseases 
(CVD) and CbVD increases, which is also the case for dementia. The main pathological 
hallmarks of AD include amyloid-beta (Aβ) plaques and neurofibrillary tangles of 
hyperphosphorylated-tau; however, many AD patients also display significant hallmarks of 
CbVD including white matter lesions (52, 53). Many other diseases of ageing often coexist 
with other diseases with common overlapping risk factors. For example, dementia is 
associated with CVD, hypercholesterolaemia/hyperlipidaemia, obesity, diabetes mellitus, 
hypertension and CbVD (53).  
 
The presence of Aβ plaques and neurofibrillary tangles characterises neuropathological 
changes in AD (54), and is followed by microglial and astrocytic activation, release of pro-
inflammatory mediators and neuronal death, leading to brain atrophy. Familial and sporadic 
AD cases are observed. Sporadic AD (sAD) is not typically associated with any specific 
genetic mutations, whilst familial AD (fAD) is typically inherited in an autosomal dominant 
pattern (55). Mutations associated with familial AD include mutations in the APP gene, which 
are associated with increased Aβ production (56-58). Other causative mutations include 
PSEN1 and PSEN2, which can result in abnormal production of Aβ (59-62). Animal models of 
AD include transgenic mouse lines expressing familial AD mutations. Popular mouse models 
often focus on modelling Aβ deposition in the brain. Many mouse lines focus on the 
overexpression of the human amyloid precursor protein (APP), which is a key protein leading 
to cleavage and secretion of Aβ (63). Additionally, double and triple transgenic mouse models 
have also been developed, where both APP and PSEN1 mutations are present, further 
increasing amyloid plaque content in the brain (63). Transgenic AD mice present with age-
dependent amyloid deposition in the brain, which include amyloid plaques as well as activated 
microglia and astrocytes. Furthermore, such mice develop cognitive and memory 
impairments. However, no existing model of AD exhibits all features of AD, which includes 
cognitive deficits, amyloid plaques, neurofibrillary tangles, gliosis, synapse loss and 
neurodegeneration. For example, in many AD-mouse models, tau pathology is not observed. 
Neurofibrillary tangles are only seen when human tau is expressed, whilst neuronal loss is 
observed in a few lines (64). For a comprehensive review on mouse models of AD see (65). 
Other dementia models also use genetic manipulations of commonly implicated human 
genetic mutations (as in the case of FTD; discussed later), whereas other models use surgical 
methods to cause a reduction in cerebral blood flow (CBF) as in the case of modelling VaD, 




Table 1 – Models of CVD and CbVD 
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1.15 – Comorbid CVD/CbVD Models 
According to the British Heart Foundation, up to 80% of people with a form of CVD also have 
at least one other comorbidity, with the most common being cerebrovascular disease (42). 
Due to the nature of CVDs affecting the circulatory system, inevitably, there are secondary 
effects that can develop in almost any organ or area – notably to the brain. The human brain 
weighs just 2% of total body weight but receives 20% of cardiac output (5). The brain therefore 
is susceptible to global circulatory changes either originating directly due to cardiac disease, 
or due to atherosclerosis of peripheral and cerebral vessels, leading to many cerebrovascular 
disease (5) (discussed in depth later). As with all CVDs and CbVDs, multiple comorbidities 
present alongside these conditions creating a more complex aetiological and 
pathophysiological nature. One of the most common comorbidities associated with CVDs and 
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CbVDs is hypertension, in addition to diabetes mellitus, obesity and infection. The other, and 
perhaps more important non-modifiable factor, is that of advanced age. Typically, younger 
rodents have been used for stroke research, for example, whereas older animals would be 
more appropriate, combined with one or two more comorbidities to better replicate the human 
conditions. It is for this reason many promising stroke therapies that have worked in traditional 
models have failed to translate effectively in clinical settings (74).  
 
Investigators are now starting to consider preclinical models with co-morbidities. As discussed 
earlier, MCAO is a common model of (acute) stroke and this ‘mechanical’ model was applied 
to atherosclerotic APOE-/- mice by Ayata et al (discussed earlier) to test perfusion deficit 
differences between controls and ApoE-/- mice fed a high-fat diet (14) (Table 2). MCAO 
abruptly reduced regional CBF, however, the perfusion reduction was more severe in the area 
of the affected penumbra of ApoE-/- mice compared to controls, leading to significantly larger 
infarct volumes in ApoE-/- mice (14). Thus, this study highlights the susceptibility of worsened 
stroke outcomes in patients with atherosclerosis. By combining an atherosclerosis model 
(ApoE-/-) with an acute stroke model (MCAO), a comorbid mouse model was created providing 
novel and comprehensive insights into cerebrovascular dysfunction in stroke with underlying 
CVD.  
 
As mentioned previously, hypertension is also major risk factor for dementia, stroke and CVD 
and is, perhaps, the most modifiable too, and easy to induce in pre-clinical models. This has 
been modelled using a spontaneously hypertensive rat (SHR) model, normotensive at birth 
but which gradually develops hypertension due to overactive renin-angiotensin systems by 
6m of age (75) (Table 2). These animals when fed with a high-salt diet rapidly increased their 
blood pressure to above 240mmHg making a stroke-prone SHR (spSHR), with cortical strokes 
and SVD (75). This model remains the best stroke model for lacunar stroke due to the 
development of SVD, although the model itself is often very unpredictable. Another study 
combined the spSHR rat model with the mutated familial-Alzheimer’s disease (fAD) 
APPswe/PS1ΔE9 transgene resulting in a comorbid fAD-spSHR mixed dementia rat model 
(76) (Table 2). The level of phosphorylated-tau was substantially higher in fAD-spSHR rats 
compared to spSHR, fAD rats alone. This corresponded to an increased microglial cell number 
and soma size (reactive states), increased astrogliosis and increased expression of 
aquaporin-4. Furthermore, there was evidence of SVD such as increased collagen IV and 
PECAM1/CD31 expression in cerebral vessels. Interestingly, the number of amyloid plaques 
was reduced in the fAD-spSHR rat compared to fAD alone (76). Neuronal damage was much 
higher in the fAD-spSHR rats with increased caspase-cleaved actin levels as well as loss of 
myelin and reduced calbindin staining in neurons, in addition to the loss of mitochondrial 
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complex I & II (76). This truly mixed comorbid rat model is one of the very few and limited 
models to combine multiple diseases alongside successfully recapitulating features of the 
human conditions. Such models will be important in driving future pre-clinical research into 
understanding the complex pathophysiology of comorbid disease and serving as excellent 
stable models for therapeutics research.  
 
Other interesting murine comorbid models include diabetes-accelerated atherosclerosis 
models in which ApoE-/- or LDLR-/- mice are given streptozotocin; STZ (a pancreatic beta-cell 
cytotoxin) to induce type-1 diabetes mellitus in (77-79) (Table 2). In the diabetic ApoE-/- mouse 
model, there was an acceleration of large vessel atherosclerosis of the aortic sinus and carotid 
arteries with the presence of foam cells and increased oxidised-LDL uptake without further 
increases in plasma lipid levels, as seen in diabetic CVD patients (79). This also explains why 
many diabetic individuals have a higher risk of developing CHD. This however, was not the 
case in diabetic LDLR-/- mice despite elevated hyperglycaemia and enhanced advanced 
glycation end-product (AGE) in arterial walls of these mice including the presence of elevated 
serum IgG’s against AGE epitopes (77). Thus, these two diabetic atherosclerotic models 
display differences in the effect of hyperglycaemia on atherogenesis and may in part reflect 
the severity of the atherosclerotic model i.e. more aggressive ApoE-/- mediated atherogenesis 
is exacerbated by higher hyperglycaemia whereas milder LDLR-/- mediated atherogenesis is 
not hugely affected by milder hyperglycaemia. In the ApoE-/- diabetic model, 200mg/kg STZ 
was used compared to 160mg/kg for LDLR-/- mice, again reflecting the severity of diabetes 
induction. As will be discussed later in more detail, metabolic syndrome comprising of 
hypertension, hyperglycaemia, diabetes mellitus and obesity are all linked to a substantially 
increased risk of developing dementia, thus models combining diabetes and atherosclerosis 
may better reflect the human condition, and more research needs to be done on the 
neuropathological, behavioural (cognitive) and neurovascular function in these models.  
 
Other non-murine models include rabbit atherosclerotic models (high-fat diet induced) 
alongside a chronic antigen-induced arthritis (AIA) by injection of ovalbumin with vessel injury 
in the study of the effect of arthritis (inflammation) on atherosclerosis (80) (Table 2). Compared 
to controls, atherosclerosis alone or AIA alone, the new comorbid model showed much higher 
levels of inflammation marked by substantially higher IL-6, CRP, COX2 & PGE2. Although the 
intima-media thickness of both atherosclerotic rabbits and comorbid rabbits remained the 
same, the mixed model had a higher level of infiltrating macrophages in their lesions. 
Furthermore, only 27% of rabbits fed a high-fat diet displayed significant aortic lesions 
whereas 60% of comorbid atherosclerotic and AIA rabbits had aortic lesions (80). This study 
shows how arthritis can exacerbate atherosclerosis by added inflammation and metabolic 
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pathways. It has relevance to humans since midlife rheumatoid arthritis increases the risk of 
developing cognitive impairment and dementia in patients within 2 decades (81), perhaps by 
increasing vascular pathology as modelled in the above study. Modelling disease in rabbits 
could therefore serve to be an important model to test therapeutics for patients that have both 
diseases. 
 
Table 2 – Comorbid CVD/CbVD Models 
Model Description Phenotype Age 
Ranges 
Advantages Limitations References 
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It is clear that there are many overlapping risk factors and interactions between several 
cardiovascular, metabolic and neurological processes that lead to the synergistic interactions 
between CVD, CbvD and dementia (summarised in Figure 1.8). For example, diabetes and 
arthritis can exacerbate atherogenesis, CHD and dementia. As atherosclerosis is implicated 
in CHD, CbVD, VaD and AD, having metabolic or inflammatory disorders can greatly influence 
the onset and progression of dementia and therefore, models addressing such comorbidities 






















Figure 1.8 - CVD, CbVD and Dementia Overlap. Hyperlipidaemia is the primary cause of 
atherosclerosis (ApoE-/-, LDLR-/-, mPCSK9 models), which in the heart can lead to coronary artery 
occlusion (CHD) (ApoE-/-/LDLR-/-;PDZK1-/-/SRB1-/- models) and by affecting both extracranial and 
intracranial arteries can lead to reduced global or regional CBF. This can lead to ischaemia within 
the brain and cause stroke (MCAO, embolism and spSHR models), alongside other CbVDs – one 
of which is VaD (BCAS model). Metabolic disorders such as diabetes mellitus (STZ models) and 
obesity, in addition to systemic inflammatory disorders such as arthritis can also greatly influence 
cerebrovascular dysfunction as well as exacerbating or contributing to AD (fAD models). The 
common mechanisms implicated in dementia onset as a result of CVD/CbVD are global or regional 
oligemia (reduced CBF) leading to hypoxia and ischemia, neuroinflammation, SVD and 
subsequent BBB breakdown. Mismatch between neuronal metabolic expenditure and 
energy/oxygen provision (breakdown of neurovascular coupling) can lead to dementia. Specific 
risk factors such as APOE4-allele coupled with pre-existing CVD and metabolic disorders can 
exacerbate beta-amyloid and tau accumulation leading to AD. Inevitably, as we age, the 
coexistence of two or more diseases leads to synergistic interactions between different 
pathological mechanisms contributing to complications or exacerbation of disease. (Adapted from 








1.16 – Conclusions and Future Directions 
The use of preclinical models in the study of human diseases is an invaluable method to 
understand the pathobiological mechanisms underlying different disease processes. Genetic 
manipulation, surgical techniques and chemical exposure have allowed us to interrogate 
different aspects of disease at the molecular, cellular, tissue, organ and systemic levels. Whilst 
models of disease tend to generally focus on one aspect e.g. genetic knockouts, and have 
hugely improved our understanding of disease, these models inherently lack the true 
complexity associated with human disease – which tends to be multifactorial and involves the 
coexistence of many multimorbidities. Thus, the generation of comorbid models combining 
two or more diseases may more accurately reflect the human condition, help us understand 
the synergy and interactions between different conditions, as well as developing novel 
therapeutics that have previously failed using conventional pure models. Thus, future research 
involving comorbid models is essential if therapeutics are to pass clinical trials, especially with 
respect to dementia – which, as of yet, has no curative or preventative treatment. Models 
incorporating fAD/fFTD mutations, for example, in combination with CVD, or T2DM to better 
reflect human comorbidity, may be more appropriate if therapies are to succeed.   
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The manuscript section that I authored ends here. The following sections are not part of 
the above paper, but form part of the rest of chapter 1. In brief, the next section describes the 
background on the neuroimaging, the genesis of my PhD project including the knowledge 
gaps that existed when I began my project, my hypotheses and project aims.  
1.18 – 2D-Optical Imaging Spectroscopy Background 
2D-optical imaging spectroscopy (2D-OIS) is a technique that allows measurements in the 
changes in total haemoglobin (HbT); akin to cerebral blood volume (CBV) changes, in addition 
to blood oxygenation (Kennerley et al., 2005, Kennerley et al., 2009, Kennerley et al., 2012). 
Compared to fMRI, 2D-OIS has a higher spatial and temporal resolution in the investigation of 
cerebral haemodynamics and the BOLD response. A more detailed overview of the 
methodology (biophysics) and experimental paradigm is given in section 2.2.3. 
 
In previous work (Kennerley et al., 2012), baseline oxygen saturation values of 50% were used 
(based on rats breathing air), however, mice breathing oxygen were approximated to have a 
baseline oxygen saturation of 70%, and varying this value in the different physiological ranges 
between 40-70% had little effect on the BOLD signal magnitude (Kennerley et al., 2012). In 
our most recent publication (Sharp et al., 2019), varying the HbT baseline micromolar value 
(from 60-120µM) results in different peak HbT values if comparing micromolar changes, 
however, if presented as a fractional change (or % change), then the fractional change is 
identical as it is scaled by itself and is not different. Throughout the imaging protocol, I will be 
measuring changes in baseline volume and saturation in the animals when switching from 
breathing 100% oxygen to air. Moreover, even if estimates of volume and saturation were 
wrong (which is not likely the case), the fractional change in HbT response would be 
unaffected.  
 
With respect to the total haemoglobin concentration in the superficial areas of the cortex (the 
area being imaged by 2D-OIS), the value of 100µM was determined as:  
 





The profile of blood volume fractionation (vf) can be converted into baseline haemoglobin 
concentration (HbT0) in brain tissue by where Hct is the fraction of the haematocrit (0.46), Rc/l	
is the ratio of cerebral tissue to large vessels (0.69; based on Wyatt et al, 1990), [Hb]RBC	is the 
concentration of haemoglobin in red blood cells (340g/l) and MmHb is the molecular mass of 
haemoglobin (64,450g/M) (Kennerley et al., 2009). Thus, the haemoglobin concentration 
value of 100µM is used throughout.  
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In other previous work (Kennerley et al., 2005), direct comparisons of MRI measurements of 
CBV changes with concurrent 2D-OIS measurements of HbT changes were found to be 
identical in the superficial layers of the cortex assuming a constant haematocrit level, thus 
CBV and HbT changes can be used interchangeably and the profile of normalised 

















Changes in CBV (determined by 2D-OIS) and CBF (determined by LDF) follow a scaling 
relationship CBV=CBFa, with the mean alpha being 0.38+/-0.06 (Kennerley et al., 2005), 
based on Grubb et al 1974. In Jones et al, the alpha value was found to be 0.29 for stimulation 
and 0.31 for hypercapnia (Jones et al., 2001). Thus, the relationship between CBF-CBV is 
similar regardless of how a change in flow is achieved. As illustrated in Jones et al, the time 
series for flow and volume changes from stimulation onset to peak are very similar; although 
there is a slight 0.2s lag between volume and flow that is only detectable due to a high temporal 
resolution of the data collection (Jones et al., 2001). Post-peak, whilst flow returns to 
baselines, volume changes remain elevated for a little while before returning to baseline 
slower. Using CBF measurements (from LDF), HbT and HbR can be used to calculate CMRO2. 
However, since I will not be measuring CBF, I will not be able to calculate CMRO2. 
 
The spectrographic analysis is based upon the path length scaling algorithm (PLSA) described 
in detail elsewhere (Mayhew et al., 1999). The 4 wavelength image data set (discussed in 
section 2.2.3) is analysed against the known absorption coefficients for HbR and HbO in 
addition to parametrising Monte Carlo Simulations (MCS) of light transport through a 
homogenous tissue model with the baseline volume and blood oxygen saturation values 
(derived from Kennerley et al., 2009). The MCS tracks photon transport by incorporating an 
array of different parameters such as absorption, remittance, scattering in the tissue and 
undisturbed propagation to provide an approximation of the path length through with the 
photon has travelled (Kennerley et., 2012). The computed data is entered into a lookup table 
which uses a modified Beer-Lambert law which relates light attenuation to the path length, 
absorption coefficients and concentrations of the specific chromophores to determine changes 
and produce 2D-maps of HbO, HbR and HbT concentration as a mean across all stimulations 
within a given experiment. For this algorithm to work, values for baseline concentrations and 
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saturation have to be inputted. For this, the haemoglobin concentration was inputted as 100µM 
and oxygen saturation was 70% (as discussed earlier). As reported in (Jones et al., 2001), the 
results of the analysis are qualitatively the same over a range of haemoglobin concentrations 
(50-200µM).  
 
To summarise, changes in neuronal activity produce changes in the relative concentrations of 
HbO and HbR chromophores, and OIS exploits the differences in absorption by HbO and HbR 
as a function of wavelength (λ). The Beer-Lambert law states that the attenuation of light 
(A(λ)) is linearly related to the concentrations (ci) of the absorbers in the medium by:  
 
 𝐴(𝜆) = 𝐿	∑-𝜀-(𝜆)𝑐- 
 
where ɛi(λ) is the specific extinction coefficient of the ith absorbent. However, in brain tissue, 
this linear relationship is no longer accurate as the path length within a scattering medium 
(brain tissue) is longer than that of non-scattering media, thus the likelihood of the photon 
being absorbed is increased. Therefore, the relationship between (A(λ)) and ci becomes non-
linear and dependent on the properties of the medium. Consequently, the OIS algorithm uses 
a differential path length Ld(λ) which relates changes in attenuation (ΔA) to changes in the 
concentrations of absorbents (Δc): 
 
 ∆𝐴(𝜆) = 𝐿𝑑	(𝜆)	∑𝑖𝜀𝑖(𝜆)∆𝑐𝑖 
 
The differential path length defined is related to the mean and partial path lengths. Changes 
in neuronal activity alter the concentrations of HbO and HbR. The path length is dependent 
only on the absorption coefficient µa(λ)∝(ɛHbO(λ)HbO	 +	 ɛHbR(λ)HbR) and the reduced 
scattering coefficient µ′s(λ) of the tissue. Once the path length is estimated, changes in HbT 
and oxygen saturation (Y) due to evoked changes in neural activity are calculated as follows: 
 
∆𝐴(𝜆) = 𝐿𝑑		(𝜆)	(𝜀𝐻𝑏𝑂	(𝜆)	∆𝐻𝑏𝑂+ 	𝜀𝐻𝑏𝑅	(𝜆)	∆𝐻𝑏𝑅 
 












A more detailed discussion about the spectroscopy algorithms and assumptions are detailed 
in Kennerley et al., 2009, and validated using fMRI in Kennerley et al., 2012.  
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1.19 – Work Leading to my PhD Project 
In 2015, the lab published a paper outlining an anaesthetised mouse surgical and imaging 
preparation method that was optimised for the best neurovascular responses to sensory 
stimulations, that had similar profiles to an awake preparation (Sharp et al., 2015). The 
surgically implanted chronic imaging window allowed longitudinal imaging up to 3-6 months. 
The anaesthetic regimen was optimised to combine midazolam and fentanyl-fluanisone in 
sterile water in a 1:1:2 ratio injected into the mouse i.p. Furthermore, all imaging and 
experiments began at least 1-hour post anaesthetic induction to allow neurovascular 
responses to return to normal after an initial ‘inverted response’ (Sharp et al., 2015). Using 
this novel chronic preparation, the lab investigated neurovascular coupling in the J20-
hAPP(Sw,Ind) mouse model of AD between the ages of 9-12m (Sharp et al., 2019), and published 
these data in a paper that I co-authored. I will summarise this briefly. Based on the literature 
investigating neurovascular function in this mouse model, which suggested impaired 
neurovascular responses, we sought to validate these findings accordingly using our new 
method. Contrary to expectation, we found no significant differences in terms of stimulus-
evoked haemodynamic and neural responses in the J20-mouse compared to WT controls 
when imaging was performed using the novel chronic setup (Sharp et al., 2019). We only saw 
significantly perturbed responses in acute imaging sessions where the skull was drilled, and 
an electrode inserted to record neural responses simultaneously, thus leading to the 
hypothesis that electrode insertion causes cortical spreading depression to occur in all animals. 
Thus, that study highlights the importance of methodology and animal preparation methods in 
the study of neurovascular coupling. Chapter 3 aims to follow up on the findings of Sharp et 
al, 2019 with the same approach but at an earlier time point. A more detailed analysis of this 
is made in the discussion section of chapter 3 (Shabir et al., 2020) and the mechanisms 
underlying this presented and discussed in chapter 4.  
 
In 2015, the University of Sheffield took a strategic decision to fund 3 PhD students as part of 
the (then) new Neuroimaging in Cardiovascular Disease (NICAD) network – a collaboration of 
neuroscientists & cardiovascular scientists across the Faculty of Medicine and Faculty of 
Science. Human imaging analysis in diabetes (Dounavi/Wilkinson/Martin), zebrafish models 
of hyperglycaemia (Chhabria/Chico/Howarth) and mouse models of dementia 
(Shabir/Berwick/Francis) were the three projects, the latter which I applied to and was awarded 
the studentship for (in 2017). The NICAD mouse project aimed to investigate neurovascular 
function and interactions between neurological disease and cardiovascular disease – an 
increasingly popular and important research area at the nexus of neuroscience and 
cardiovascular science. With respect to models of atherosclerosis, a novel virally inducible 
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method (rAAV8-mPCSK9) (Bjorklund et al., 2014) – mentioned earlier in chapter 1, and 
discussed in detail in chapter 4 – was used to investigate neurovascular function.  
 
The gaps in knowledge prior to my PhD are summarised below: 
• Reliability of surgical and imaging preparations in models of AD 
• Neurovascular function in a novel model of atherosclerosis (PCSK9) 
• The lack of comorbid models to better reflect human disease  
1.20 – Hypothesis 
The central hypothesis is that neurovascular coupling is impaired in the Alzheimer’s, 
atherosclerosis and comorbid models of human disease. There will be increased 
neuropathology in the mixed comorbid model. Furthermore, based on previous observations, 
electrode insertion into the brain causes cortical spreading depression to occur in all animals 
that impairs evoked-haemodynamic responses. These findings will provide an insight into any 
potential biomarkers, novel disease mechanisms and therapeutic targets or strategies that 
could lead to clinical therapies in the future.  
1.21 – Aims  
The overall aims of this thesis were to investigate neurovascular function in pre-clinical mouse 
models of human disease. In order to achieve this, a combination of pre-clinical neuroimaging 
techniques and electrophysiology were performed to investigate neurovascular coupling, 
functionally. Furthermore, post-mortem cellular and molecular studies were used to validate 
in vivo findings to provide a more comprehensive overview of changes to neurovascular 
function. Specific aims of the different studies were: 
1. To investigate neurovascular coupling in young 6-9m old J20-hAPP(Sw,Ind) mouse 
model of Alzheimer’s disease (AD) compared to healthy wild-type (WT) controls using 
2D-optical imaging spectroscopy (2D-OIS) and neural electrophysiology (Chapter 3).  
2. To investigate neurovascular coupling in mid-age 9-12m old rAAV8-mPCSK9-D377Y 
mouse model of atherosclerosis compared to WT controls using 2D-OIS and neural 
electrophysiology. To further investigate the cellular expression of cells of the 
neurovascular unit (NVU) by performing immunohistochemistry (IHC) on fixed post-
mortem tissue, as well as markers of neuroinflammation by performing qRT-PCR on 
snap-frozen brains (Chapter 4).   
3. To induce atherosclerosis in the J20-hAPP mouse model of AD (AAV-mPCSK9 
injection) to form a novel comorbid mixed model of disease, and to characterise 

















































2.1 – Materials 
2.1.1 – Commercial Kits & Reagents  
Description Details Company 
Tris-Buffered Saline (TBS) 85g NaCl, 60.5g Tris-base in 10L 
d.H2O 
NA 
Trisodium Citrate (TSC) 3g TSC in 1L d.H2O pH6.5 Fisher Scientific 
Ethylenediaminetetra acetic 
acid (EDTA) 
0.372g in 1L d.H2O pH8  
VectaStain ABC 
Immunohistochemistry Kits 
Mouse, Goat & Rabbit Kits: 
Blocking solution – 3 drops normal 
serum in 10ml TBS. Secondary – 3 
drops biotinylated IgG secondary 
antibody in 10ml TBS. ABC reagent – 
2 drops Avidin (A), 2 drops biotinylated 
HRP (B) in 10ml TBS 
Vector 
Laboratories, US 
DAB Substrate Kit 3.3’-diaminobenzidine (DAB) substrate 
kit SK-4100: 2 drops buffer, 2 drops 
H2O2 & 4 drops DAB in 5ml d.H2O 
Vector 
Laboratories, US 
3% Hydrogen Peroxide 
(H2O2) 
12ml H2O2 in 388ml methanol VWR Chemicals 




2.1.2 – Diets 
Description Details Company/Stock 
Western Diet 21% fat, 0.15% cholesterol, 
0.03% cholate, 0.296% 
sodium 
#829100 
Special Diet Services (SDS)-
Witham, UK  
 
2.1.3 – Viruses 
Description Details Company/Stock 
AAV-Virus for 
Atherosclerosis Induction 
6.1x1012 virus molecules/ml 
rAAV8-mPCSK9-D377Y 
dialysed w/350mM NaCl & 
5% D-Sorbitol in PBS 
Lot#AV8541 University of 
North Carolina (UNC) GTC 




2.1.4 – Antibodies & Immunohistochemistry Conditions 
Description Details Company/Stock 
Antibody for Astrocytes  Rabbit anti-GFAP (glial fibrillary acidic 
protein) 1:500 (microwave antigen retrieval 
pH6.5 TSC) – 2 minutes with DAB  
Dako Z0334 
Antibody for Microglia Goat anti-Iba1 (allograft inflammatory factor 
1) 1:250 (microwave antigen retrieval pH6.5 
TSC) – 2.5 minutes with DAB  
Abcam ab5076  
Antibody for Neurons Rabbit anti-NeuN (neuronal nuclei) 1:3000 
(microwave pH9 EDTA) – 2.5 minutes with 
DAB 
Abcam ab177487  
Antibody for Pericytes Goat anti-PDGFRb (Platelet-derived growth 
factor receptor beta) 1:250 (microwave pH9 
EDTA) – 2 minutes with DAB 
R&D Systems 
AF1042-SP  
Antibody for Amyloid 
Plaques 
Mouse anti-Beta-Amyloid 1:100 (microwave 
pH6.5 TSC) – 5.5 minutes with DAB 
Dako M0872  
 
2.1.5 – RNA Extraction 
Description Details Company 
RNA Extraction Kit  Direct-Zol RNA MiniPrep Kit Zymo Research (US) 
TRI Reagent Trizol Zymo Research (US) 
 
2.1.6 – PCR and Primers 
Description Details Company 
cDNA Synthesis Kit UltraScript 2.0 cDNA Synthesis Kit BioSystems 
qPCR Mix Luna qRT-PCR Master Mix BioLabs 
qRT-PCR Primer for 
beta-actin (ACTB) 
Primer (fwd) 1 5’-GCGAGCACAGCTTCTTTG-
3’ 





qRT-PCR Primer for 
interleukin-1-beta 
(IL1b) 
Primer 1 (fwd) 5’-
GCAAGTGTCTGAAGCAGCTAT-3’ 
Primer 2 (rev) 5’-
GTCCGTCAACTTCAAAGAACAG-3’ 






qRT-PCR Primer for 
tumour necrosis 
factor-alpha (TNFa) 
Primer 1 (fwd) 5’-
AGACCCTCACACTCAGATCA-3’ 






qRT-PCR Primer for 
nitric oxide 
synthase-1 (NOS1) 
Primer 1 (fwd) 5’-
TCAACTACATCTGTAACCACGTC-3 






qRT-PCR Primer for 
nitric oxide 
synthase-3 (NOS3) 
Primer 1 (fwd) 5’-
CTTGAGGATGTGGCTGTGT-3’ 
Primer 2 (rev) 5’-
TGGTCCACTATGGTCACTTTG-3’ 





2.1.7 – Laboratory Equipment 
Description Details Company 
Nikon Microscope Nikon Eclipse Ni (Brightfield) with 
DS-Ri1 camera 
Nikon 
Centrifuge  1-15PK Centrifuge Sigma 
Thermal Cycler (Incubator) PTC-200 Peltier Thermal Cycler MJ Research 
qRT-PCR CFX384 Real-Time System with 
C1000 Touch Thermal Cycler 
Bio-Rad 
 
2.1.8 – Software 
Description Details Company 
Nikon microscope capture and 
editing software 
NIS-elements Nikon 
MATLAB for 2D-OIS and 
electrophysiology analysis 
MATLAB R2019a MathWorks  
GraphPad for Bar graphs and 
statistics   




2.1.9 – Statement of Ethics 
All animal procedures were performed with approval from the UK Home Office in accordance 
to the guidelines and regulations of the Animal (Scientific Procedures) Act 1986 and were 
approved by the University of Sheffield ethical review and licensing committee. This work was 
licenced to PPL: 70/8547/M (J Berwick) and PIL: I4CEF849C (O Shabir), under University of 
Sheffield ISP: JB-13 (all moderate severity procedures).  
 
2.1.10 – Animals 
 
 
Figure 2.1 – Mouse Models Used.  
 
Mice were housed with littermates in a 12hr dark/light cycle at a temperature of 23OC, with 
food and water supplied ad-libitum. Western diet pellets were replaced twice a week to prevent 
them from drying out.  
 
Description Details Company 
Wild-Type (WT) Mice Male C57BL/6J 
Normal Rodent Chow 
Charles River 
Mouse Model of Alzheimer’s 
Disease (AD) 
Male J20 B6.(PDGFB-hAPP(Sw,Ind) 
Normal Rodent Chow 
JAX 
Mouse Model of 
Atherosclerosis (ATH) 




Mixed Comorbid Mouse 
Model of AD & ATH 
Male J20 B6.(PDGFB-hAPP(Sw,Ind) 





2.2 – In Vivo Neuroimaging 
2.2.1 – Experimental Overview 
In order to investigate neurovascular coupling in vivo, a combination of haemodynamic 
imaging with 2D-optical imaging spectroscopy (2D-OIS) and neural multichannel 
electrophysiology was used. To allow access and visualisation of cortical vasculature, surgery 
was performed to chronically implant a thinned cranial window, and mice were recovered for 
a minimum of 2 weeks. All chronic imaging sessions (with the skull intact) were performed 3 
weeks post-surgery, and a final terminal acute experimental session was performed 1 week 
after chronic sessions where the skull was drilled, and a multichannel electrode was inserted 












Figure 2.2 - Experimental Plan/Paradigms.  
A – Thinned cranial window surgery was performed on all mice which were then given 3 weeks to 
recover. 1 initial chronic imaging session was performed 3 weeks post-surgery with the skull intact. 1 
week later, a final acute imaging (terminal) session was performed with an electrode inserted into the 
brain. After terminal experiments, mice were sacrificed for tissue.  
B – Each imaging session performed had the same set of experiments with the same timings (post 
anaesthesia/drilling) and within each experiment. The first stimulation began at least 1-hour post-
anaesthesia. All experiments took around 3 hours to complete. The Shabir Paradigm (illustrated) was 
used in Chapters 4 & 5. The Sharp Paradigm: 1) 2s-O2, 2) 2s-O2, 3) >Air, 4) 2s-Air, 5) 16s-Air, 6) >O2, 
7) 16s-O2 & 8) CO2) for Chapter 3.  
C – Each 2s-whisker stimulation (5Hz/5V) had baselines of 10s and a post-stimulus period of 13s. 2s-
stimulations consisted of 30 trials.  
D– Each 16s-whisker stimulation (5Hz/5V) had baselines of 10s and a post-stimulus period of 44s. 16s-






2.2.2 – Thinned Cranial Window Surgery 
Mice were anaesthetised with 7ml/kg i.p. injection of fentanyl-fluanisone (Hypnorm, 
Vetapharm Ltd, Leeds, UK), midazolam (Hypnovel, Roche Ltd, Welwyn Garden City, UK), 
diluted in sterile water in a 1:1:2 by volume ratio for surgery induction, and subsequently 
maintained in surgical anaesthesia by the inhalation of 0.5-0.8% isoflurane in 100% oxygen 
(flow rate of 1L/min). Core body temperature was maintained at 36.5-37.0OC using a 
homoeothermic blanket (Harvard Apparatus, Cambridge, UK) through rectal temperature 
monitoring. Eyes were protected from drying out by the application of an ophthalmic ointment; 
Viscotears® (Novartis, Surrey, UK). Mice were placed in a stereotaxic frame (Kopf 
Instruments, Tujunga, US) ensuring the head was stable before the scalp was excised using 
surgical scissors (Figure 2.3-I). After exposing the skull, bone overlying the right 
somatosensory cortex was thinned to translucency using a dental drill to form a thinned cranial 
optical window (measuring ~3mm2) (Figure 2.3-II). A thin layer of clear cyanoacrylate glue 
was applied over the cranial window to reduce specularities and to reinforce the surface of the 
window. A circular wall of dental cement (Super Bond C&B, Sun Medical, Shiga, Japan) was 
made around the perimeter of the window to which a metal head-plate was fixed to allow 
chronic imaging over several weeks (Figure 2.3-III). Mice were given a saline injection (s.c. 
250μl) to re-hydrate and placed into an incubator at 29OC until the resumption of normal awake 
behaviour, as well as being continually monitored for signs of pain and abnormal behaviour. 
All mice were given 3 weeks to rest and recover before the first imaging session was 
performed, in addition to allowing time for any bruising and inflammation to subside. 
 
Figure 2.3 – Thinned Cranial Window Surgery.  
I – Mice were anaesthetised, scalp was shaved, and mice placed in a stereotaxic frame before scalp 
was excised. 
II – The skull overlying the right somatosensory cortex was thinned to translucency and a thin layer of 
acrylate was applied to reinforce the window and remove specularities.  
III – Dental cement was applied to the periphery of the window to form a chamber to which a metal 




2.2.3 – 2D-Optical Imaging Spectroscopy (2D-OIS) 
2D-OIS measures changes in cortical haemodynamics by estimating changes in total 
haemoglobin (HbT), oxyhaemoglobin (HbO) and deoxyhaemoglobin (HbR) concentrations as 
described previously38. For the experimental session, mice were anaesthetised (as described 
above) and placed into a stereotaxic frame with heads fixed using attached headplates. 
Anaesthesia was maintained using low-levels of isoflurane (0.3-0.6%) (Figure 2.4). For 
imaging, the right somatosensory cortex was illuminated using 4 different wavelengths of light 
appropriate to the absorption profiles of the differing haemoglobin states; see Figure 2.5 below: 
(495nm ± 31, 559nm ± 16, 575nm ± 14 & 586nm ± 9) using a Lambda DG-4 high-speed 
galvanometer (Sutter Instrument Company, US). A Dalsa 1M60 CCD camera with a frame 
rate of 32Hz operating in a 4x4 binning mode acquired images at 184x184 pixels; giving a 
pixel resolution of 75x75µm, was used to capture the re-emitted light from the cortical surface. 
 
Figure 2.4 – 2D-OIS Imaging Setup. Adapted from (Lee et al., 2020); Figure authored by me. 
 
 
Figure 2.5 – 2D-OIS Wavelength and Absorption Co-Efficient for HbO & HbR. Figure Adapted from 
(Saka et al., 2010). Oxy-Hb (HbO) & Deoxy-Hb (HbR) summate for HbT.  
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All spatial images recorded from the re-emitted light underwent spectral analysis based on the 
path length scaling algorithm (PLSA) as described previously (Berwick et al., 2005, Mayhew 
et al., 1999), which uses a modified Beer-Lambert law with a path-length correction factor 
converting detected attenuation from the re-emitted light with a predicted absorption value. 
Relative HbT, HbR and HbO concentration estimates were generated from baseline values in 
which the concentration of haemoglobin in the tissue was assumed to be 100µM and O2 
saturation to be 70%. The spectral analysis produced 2D-images of micromolar changes in 
volume of HbT, HbO & HbR over each stimulation period. Analysis was performed using 
MATLAB (MathWorks). An automated region of interest (ROI) was selected using the 
stimulation data from spatial maps generated using 2D-OIS. The threshold for a pixel to be 
included within the ROI was set at 1.5xSTD, therefore the automated ROI for each session 
per animal represents the area of the cortex with the largest haemodynamic response, as 
determined by the HbT. For each experiment, the response across all pixels within the ROI 
was averaged and used to generate a time-series of the haemodynamic response against 
time for HbT, HbO & HbR.  
 
2.2.4 – Neural Multichannel Electrode Electrophysiology 
In order to assess neurovascular function in its entirety, both haemodynamic and neural 
measures were obtained. Simultaneous measures of neural activity alongside 2D-OIS were 
performed in a final acute imaging session 1-week after the 1st imaging. A small burr-hole was 
drilled through the skull overlying the barrel cortex (as defined by the biggest HbT changes 
from 2D-OIS imaging) and a 16-channel microelectrode (100µm spacing, 1.5-2.7MW 
impedance, site area 177µm2) (NeuroNexus Technologies, USA) was inserted into the whisker 
barrel cortex to a depth of ~1500µm. The microelectrode was connected to a TDT preamplifier 
and a TDT data acquisition device (Medusa BioAmp/RZ5, TDT, USA). All data collected was 
sampled at 24kHz and downsampled to 6kHz for analysis of multi-unit activity (MUA) and 
local-field potentials (LFPs). Multi-unit analysis (MUA) was performed on the data. All channels 
were depth aligned to ensure twelve electrodes covered the depth of the cortex in each animal. 
The data was filtered above 300Hz to remove all low frequency components and then split 
into 100ms temporal bins. Within each bin any data crossing a threshold of 1.5SD above the 
mean baseline was counted and the results presented in the form of spikes per 100ms of data, 




2.3 – Cellular Studies 
2.3.1 – Tissue Harvest & Perfusion  
After terminal acute experiments, mice were given an overdose of pentobarbital (0.13ml per 
mouse via i/p injection) and after the loss of the pedal reflex, were transcardially perfused. 
Briefly, the ribcage was cut and removed from the chest, a butterfly-clip needle attached to a 
syringe of 5ml warm saline (0.9%) was inserted into the bottom of the left-ventricle of the heart 
followed by snipping of the right-atrium/vena cava allowing blood to be gently expelled from 
the body. Post-perfusion, mice were decapitated, and the brains were manually dissected from 
the skull. Once the brains were isolated, the brains were cut into 2 hemispheres with the right 
hemisphere being placed in 4%v/v formalin for fixation, and the left hemispheres snap-frozen 
in isopentane at -20OC for 2 minutes before being stored at -80OC. The formalin-fixed 
hemispheres were then subsequently embedded in paraffin-wax and stored at room 
temperature.  
 
2.3.2 – Immunohistochemistry (IHC) 
Right hemispheres that were formalin-fixed paraffin-embedded (FFPE) underwent standard 
dewaxing and antigen retrieval steps (as described in 2.1.4) before immunohistochemistry 
was performed according to the avidin-biotin complex (ABC) staining method (2.1.1). Briefly, 
sections deparaffinated in xylene (10min) and rehydrated through increasing gradients of 
ethanol to water (2min each) before being placed in 3% peroxide/methanol for 20min. 
Following this step, sections underwent the necessary antigen retrieval steps (described in 
2.1.4) before sections were blocked for 30min. Primary antibodies (described in 2.1.4) were 
applied for the necessary timings and temperatures before being washed and secondary 
biotinylated antibodies applied for 1hr. After washing, ABC reagent was applied for 30min, 
followed by washing and the application of DAB for the necessary timings. All sections were 
then counterstained using haematoxylin (30sec) followed by Scott’s water for 10sec. Finally, 
all slides were dehydrated to absolute ethanol through increasing ethanol gradients (2min 
each), then xylene (2min) before being mounted with coverslips using DPX.  
 
2.3.3 – Imaging and Analysis 
All sections were imaged using a brightfield setting on a Nikon Eclipse Ni-microscope attached 
to a DS-Ri1 camera. 5 random and non-overlapping regions within the hippocampus and 
cortex were taken for each condition and animal (20x magnification). Computer software 
(ANALYsis^D) was used to quantify % area coverage of staining of each image. All 
experimentation, imaging and analysis was performed blinded. Mean % coverage (out of 5 
sections per animal per antibody) was calculated for hippocampus and cortex respectively.  
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2.4 – Genetic Studies 
2.4.1 – RNA Extraction 
Left hemispheres from the snap-frozen brains (described above in 2.3.2) had cerebellums 
excised off using a scalpel. The remaining cerebrums of each brain were placed in tubes along 
with 300µl of TRI-reagent™ and RNA extraction was performed as per the manufacturer’s 
guidelines (Direct-Zol™ RNA MiniPrep Kit; Zymo Research, US). Briefly, brain samples were 
homogenised and centrifuged (10,000g; 50sec) before 250µl abs. ethanol was added to the 
supernatant in a fresh tube. The supernatant was transferred to an IIC-filtered column tube 
and this was centrifuged (10,000g; 50sec). Next, 400µl RNA Pre-Wash (Direct-Zol™) was 
added to the column and the contents centrifuged again (10,000g; 50sec) with this step being 
repeated twice. After centrifugation, 700µl of RNA-wash buffer was added to the column and 
centrifuged (10,000g; 120sec) before finally eluting the RNA into a 1.5ml Eppendorf tube 
applying 25µl nuclease-free water to the column and then centrifuging (10,000g; 50sec). The 
quality of the extracted RNA was determined using a NanoDrop™ ND-100 spectrophotometer 
by adding 1µl of the eluted RNA from each sample.  
 
2.4.2 – cDNA Synthesis 
cDNA synthesis from the extracted RNA was performed as to the manufacturer’s guidelines 
using the UltraScript™ 2.0 cDNA Synthesis Kit (BioSystems®). Briefly, master mixes were 
made up for each RNA sample by adding 4µl of 5x cDNA Synthesis Mix, 1µl UltraScript™ 2.0 
and a minimum of 3.5µg RNA by adding the respective volume of nuclease-free water, with 
ratios of RNA to water being calculated from minimum [RNA] being 47ng/µl. Samples were 
mixed and spun-down briefly before being incubated at 53OC (PTC-200) for 30min for reverse 
transcription, and finally at 95OC for 10min to denature before being stored at -20OC.  
 
2.4.3 – Real-Time Quantitative Polymerase Chain Reaction (qRT-PCR) 
qRT-PCR was performed using PrimeTime™ qPCR assay tubes according the 
manufacturer’s guidelines (IDT, US). Briefly, primers for IL1b, TNFa, NOS1 & NOS3 (including 
ACTB as a housekeeping gene for normalisation) were resuspended in 100µl IDTE buffer to 
produce a 20x stock solution. Primer sequences are described in 2.1.6. A master mix for each 
gene was made up by adding 13µl of primer, 52µl Luna® qPCR Master Mix (SYBR Green) 
(BioLabs™) and 52µl nuclease-free water from which 9µl of the primer/qPCR mix was added 
to 1µl cDNA for each sample. 4µl of the sample mix was then pipetted in duplicates in a 384-
well plate, covered and centrifuged (1760g; 60sec) before placing in a C1000 Touch Thermal 
Cycler attached to a CFX384 Real-Time System (BioRad) incubated at 95OC for 3min, before 
48 cycles (95OC; 10sec, 60OC; 30sec).  
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2.5 – Analysis and Statistics 
To compare haemodynamic & neural responses, analysis was performed using Graphpad 
Prism v8 and SPSS v25. Statistical comparisons were made on HbT, HbO, HbR & MUA values 
using two-way repeated measures ANOVAs as well as 2-tailed unpaired t-tests. P-values 
<0.05 were considered statistically significant. For chapter 5, SPSS v25 was used to perform 
statistical analyses. Shapiro-Wilks test was used to check for normality and Levene’s test was 
used to assess equality of variances. 2-way mixed design ANOVA, 1-way ANOVA or Kruskal-
Wallis tests were used, as appropriate. The Shapiro-Wilks test suggested that, for chronic 
experiments, peak values of HbT and HbO are normally distributed, however, HbR values are 
significantly non-normal. 2-way mixed design was used to compare peak values for HbT, HbO 
& HbR (although HbR failed the S-W test for normality, an ANOVA was used as they were 
considered fairly robust against small deviations from normality). Dunnett’s (two-sided) 
multiple comparisons test was used to compare disease models to WT, and for HbR, Games-
Howell multiples comparisons were used. 
 
For immunohistochemistry, analysis was performed using GraphPad Prism v8. All data sets 
were found to be normally distributed after performing a Shapiro-Wilk normality test (p=>0.05 
for all conditions and animals). Due to the data being normally distributed in all cases, 
statistical analyses were performed using single t-tests (between WT vs disease for each 
condition) and two-way ANOVAs (with post-hoc Dunnett’s multiple comparisons).  
 
For the qRT-PCR data, all the Ct values were inputted into a Microsoft Excel spreadsheet and 
the data was analysed according to the well-established ‘delta-delta-Ct’ method by 
normalisation of all Ct values to ACTB for each gene in each mouse sample. All the data was 
found to be normally distributed using the Shapiro-Wilk test, and all WT vs disease 
comparisons were performed using multiple t-tests and two-way ANOVAs (with post-hoc 
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3.2 – Abstract 
Early impairments to neurovascular coupling have been proposed to be a key pathogenic 
factor in the onset and progression of Alzheimer’s disease (AD). Studies have shown impaired 
neurovascular function in several mouse models of AD, including the J20-hAPP mouse. In this 
study, we aimed to investigate early neurovascular changes using wild-type (WT) controls and 
J20-hAPP mice at 6 months of age, by measuring cerebral haemodynamics and neural activity 
to physiological sensory stimulations. A thinned cranial window was prepared to allow access 
to cortical vasculature and imaged using 2D-optical imaging spectroscopy (2D-OIS). After 
chronic imaging sessions where the skull was intact, a terminal acute imaging session was 
performed where an electrode was inserted into the brain to record simultaneous neural 
activity. We found that cerebral haemodynamic changes were significantly enhanced in J20-
hAPP mice compared with controls in response to physiological stimulations, potentially due 
to the significantly higher neural activity (hyperexcitability) seen in the J20-hAPP mice. Thus, 
neurovascular coupling remained preserved under a chronic imaging preparation. Further, 
under hyperoxia, the baseline blood volume and saturation of all vascular compartments in 
the brains of J20-hAPP mice were substantially enhanced compared to WT controls, but this 
effect disappeared under normoxic conditions. This study highlights novel findings not 
previously seen in the J20-hAPP mouse model, and may point towards a potential therapeutic 
strategy.  
 
3.3 – Introduction 
Alzheimer’s disease (AD) is the most prevalent form of dementia worldwide and is 
characterised by a progressive decline in cognition. AD is pathologically characterised by the 
presence of extracellular amyloid beta (Aβ) plaques and intracellular neurofibrillary tangles 
composed of hyperphosphorylated-tau, which are associated with the progressive 
neurodegeneration and synaptic dysfunction seen in AD1. At present there are limited disease 
modifying or curative treatments for AD and studying disease mechanisms in human subjects 
is difficult. Therefore, pre-clinical models of AD; mainly mouse models, have been generated 
to study AD mechanisms in vivo. Whilst numerous mouse models of AD exist, they do not fully 
recapitulate the human disease in its entirety2,3. However, these mouse models can effectively 
model specific aspects of AD pathology, such as amyloid plaque deposition and toxicity where 
smaller oligomers (8-24-mers) have been shown to be more toxic than larger matured fibrils4.  
The J20-hAPP mouse model of AD over-expresses human amyloid precursor protein (hAPP) 
with the Swedish (K670N and M671L) and the Indiana (V7171F) familial mutations5. These 
mice produce more Aβ1-42 and plaques begin to readily form in the hippocampus from around 
5-6 months of age5,6. The J20-hAPP mouse model displays significant neuroinflammation 
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characterised by gliosis of both astrocytes and microglia6. They also display significant long-
term memory impairment6. 
 
The brain is extremely metabolically demanding, and the neurophysiological process of 
neurovascular coupling ensures that neurons receive an efficient and adequate blood supply 
to match the metabolic demands that neurons exert. The neurovascular degeneration 
hypothesis; as proposed by Zlokovic7,8, suggests that neurovascular breakdown is an 
important step in the pathogenesis of cerebrovascular and neurodegenerative disease, 
especially in AD. Evidence suggests that vascular dysregulation is the earliest feature of late-
onset AD, preceding Aβ deposition, metabolism and structural deficits9. Therefore, studying 
neurovascular coupling and neurovascular degeneration is important to identify early 
biomarkers or treatment strategies. Using a chronic mouse preparation, previous research 
from our laboratory found no significant neurovascular deficits in the J20-hAPP mouse 
between 9-12m age10, despite neuroinflammation and memory deficits6. This is contrary to 
what other laboratories have shown with the J20-mouse at the same age11–13. Such deficits 
have only been reported in acute experimental preparation sessions where the measurement 
of neurovascular function is performed on the same day as surgery, and not in chronic 
sessions where the effects of surgery have been mitigated. Based on these observations, we 
hypothesised that neurovascular function will not be altered in 6m old J20-hAPP mice using a 
chronic imaging preparation. The aim of the study therefore was to investigate neurovascular 
function at an earlier stage (around 6m) in the J20-hAPP mouse model to investigate whether 
there were neuronal or vascular abnormalities at an earlier disease stage when amyloid-
plaques start to form, or whether they would remain intact as seen in 9-12m old J20-hAPP 
mice.  
 
3.4 – Results 
3.4.1 – Enhanced Blood Volume (HbT) Responses in J20-hAPP Mice 
Imaging of the cortex through a thinned cranial window using 2D-OIS allows estimation of 
cortical haemodynamics in terms of relative changes of HbT (total haemoglobin, blood volume), 
HbR (deoxyhaemoglobin) & HbO (oxyhaemoglobin) concentration (Figure 3.1). Mechanical 
whisker stimulations at 5Hz evoke a haemodynamic response within the branches of the 
middle cerebral artery (MCA) and the immediately surrounding regions from which an active 
region of interest (ROI) can be determined (Figure 3.1B). From the ROI, an average time-
series of the haemodynamics can be produced showing percentage changes of HbT, HbR & 





Figure 3.1 - Representative 2D-OIS haemodynamic data from an AD mouse to a 2s-
mechanical whisker stimulation. Top: chronic imaging sessions. Bottom: Acute imaging 
sessions with electrode. A) Raw grayscale image of thinned cranial window overlaid with the active 
region of interest (ROI; red) as defined from B. B) Spatial map of HbT activation across a 
stimulation trial with colour-bar representing the % change of HbT from baseline. C) Vessel map 
showing arteries and veins within the window and active ROI. D) Time-series profiles of the 
haemodynamic data showing increases to HbT & HbO and a decrease (washout) in HbR. Dotted 



















A week after chronic imaging sessions (in which the skull remains intact), a small burr-hole 
was drilled through the skull in the centre of the barrel cortex; determined from 2D-OIS data 
on a previous chronic imaging session, and a micro-electrode was inserted through the brain 
as a terminal experiment (Figure 3.1, bottom row). Using the chronic thinned cranial window 
preparation (as shown in Figure 3.1-top) and imaging through an intact skull 2 weeks after 
surgery, the first question addressed was whether stimulation-evoked haemodynamic 
responses were different in J20-hAPP mice compared to WT controls. We found that 
stimulation-evoked HbT (blood volume) responses were significantly higher (on average by a 
+2% change in absolute values) in J20-AD mice compared to WT controls under both 100% 
O2 (hyperoxia) and 21% O2 (normoxia) conditions (2-way repeated-measures ANOVA of peak 
response: F=11.6, p=0.001) (Figure 3.2). HbO peak responses were also significantly 
increased (2-way repeated measures ANOVA: F=8.42, p=0.005). The washout of HbR was 
always significantly smaller in both WT and J20-AD mice in normoxic conditions (2-way 
repeated measures ANOVA: F=5.96, p=0.01), though not significantly more impaired in J20-
hAPP mice compared to WTs (F=0.95, p=0.34). Irrespective of gas condition, HbT and HbO 
were always substantially higher in J20-hAPP mice compared to WTs in all experiments 
(Figure 3.2).  
 
As part of the experimental paradigm, a test of global vascular reactivity was performed at the 
end of the experiment using 10% hypercapnia (Figure 3.6). We found no significant 
differences between WT and J20-hAPP mice (HbT: 2-tailed unpaired t-test p=0.53) suggesting 
that vessels in WT and J20-hAPP mice are able to dilate maximally to the same extent. In 6 
WT and 5 J20-hAPP mice, acute imaging sessions were performed where an electrode was 
inserted into the brain one week after chronic imaging sessions. In these sessions, there were 
no significant differences in the haemodynamic responses between WT and J20-hAPP mice: 







Figure 3.2 – Mean stimulation-evoked haemodynamic responses in WT and J20-hAPP mice. 
WT (n=8) [left column] and J20-hAPP (n=9) [right column] with graphs showing mean % changes 
in the peak values of HbT, HbR & HbO. Error bars ±SEM. A) 2s stimulation in 100% oxygen: WT-
HbT 4.48±0.4, J20-HbT 6.7±1.09, WT-HbO 6.64±0.58, J20-HbO 9.06±1.57, WT-HbR -3.82±1.12, 
J20-HbR -3.99±1.09. B) 2s stimulation in 21% oxygen: WT-HbT 5.3±0.47, J20-HbT 7.38±0.8, WT-
HbO 8.04±0.6, J20-HbO 11.04±1.25, WT-HbR -3.19±0.34, J20-HbR -1.62±0.4. C) 16s stimulation 
in 100% oxygen: WT-HbT 6.62±0.4, J20-HbT 8.09±1.04, WT-HbO 9.44±0.52, J20-HbO 
11.04±1.55, WT-HbR -4.92±0.65, J20-HbR -4.15±1.15. D) 16s stimulation in 21% oxygen WT-HbT 
6.44±0.49, J20-HbT 8.36±0.68, WT-HbO 9.64±0.68, J20-HbO 12.22±0.99, WT-HbR -2.06±0.42, 
J20-HbR -1.18±0.48. Dotted vertical lines indicate start and end time of whisker stimulation.  
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3.4.2 – Neural Activity is Substantially Higher in J20-hAPP Mice 
Next, we investigated whether the J20-hAPP mice had altered neural activity early in the 
disease course. We inserted a multichannel microelectrode into the centre of the barrel cortex 
(Figure 1-bottom row) and recorded neural data simultaneously with 2D-OIS. We found that 
stimulation-evoked multi-unit activity (MUA) was significantly higher in J20-hAPP mice 
compared to WT mice across all stimulation durations and gas conditions (2-way repeated 
measures ANOVA: F=8.82, p=0.005) (Figure 3.3). The enhanced neural activity was 
indicative of neural hyperexcitability in J20-hAPP mice. MUA responses were averaged from 







Figure 3.3 – Multi-Unit Activity (MUA) Data. A) MUA activity (fractional changes of number of 
spikes/100ms) along depth of the microelectrode and time (stimulation periods) for 2s-stimulation 
in 100% oxygen. Cortical regions are at the depth of channels 3-8 (biggest responses in MUA).  
B) Time-series of mean total responses of MUA (fractional changes in spikes/100ms) ±SEM. i) 2s-
stimulation in 100% oxygen: WT-MUA 547.52±98.7 spikes/100ms, J20-MUA 2260.78±710.8 
spikes/100ms. ii) 2s-stimulation in 21% oxygen: WT-MUA 676.1±143.35 spikes/100ms, J20-MUA 
2318.16±932.9 spikes/100ms. iii) 16s-stimulation in 100% oxygen: WT-MUA 4722.73±914.8 
spikes/100ms, J20-MUA 14,158.4±4753.2 spikes/100ms. iv) 16s-stimulation in 21% oxygen: WT-





3.4.3 – Baseline Blood Volume is Substantially Higher in J20-hAPP Mice under 
Hyperoxia 
As part of the experimental protocol, baseline haemodynamics during transition experiments 
(from 100% oxygen to 21% oxygen/air and vice versa) were recorded and quantified. We 
found that the baseline blood volume (HbT) was significantly enhanced in J20-hAPP mice 
under hyperoxic conditions (2-tailed unpaired t-test p=0.0002), but not in WT mice (Figure 
3.4B). Upon transition from 100% oxygen to air (21% oxygen), there was a substantial 
decrease in HbT in J20-AD mice (-6.2% change on average) characterised by the enhanced 










Figure 3.4 – Average gas transitions between hyperoxic and normoxic conditions in WT and 
J20-hAPP mice. A) Time-series of gas transition experiments: top; transition from 100% oxygen 
to 21% oxygen & bottom; transition from 21% oxygen to 100% oxygen. B) Time-series of HbT at 
baseline at 100% oxygen and during gas transition to 21% oxygen with % change in HbT: WT-
HbT 0.5%±1.8%STD, J20-HbT 6.2%%±3%STD. Error bars ±SEM. (C) Representative spatial map 
showing the differences in HbT across all vascular compartments in a J20-hAPP mouse (bottom), 









3.4.4 – Amyloid-Plaques Begin to Form in the Hippocampus of 6m J20-hAPP Mice 
Amyloid plaques are a key pathological hallmark of AD and begin to form in the hippocampus 
in the J20-hAPP AD mouse at around 6m of age6. The progression of plaque pathology and 
subsequent inflammatory changes have been well characterised in the J20-hAPP mouse6. We 
confirmed that in our cohort, by the age of 6m, the hippocampus has numerous medium sized 
plaques (Figure 3.5) with fewer and smaller diffuse ones forming within the deeper cortex, but 
none within the upper layers of the cortex.  
 
 
Figure 3.5 – Representative hippocampal sections. A) WT mice do not develop any amyloid 
plaques. B) In the J20-hAPP mouse, diffuse plaques can be found predominantly forming in the 
dentate gyrus of the hippocampus by 6m, with one or two developing in the deep cortex, but not 


















3.5 – Discussion 
The present study aimed to investigate neurovascular function in the J20-hAPP mouse model 
of AD to establish whether there were any haemodynamic and neural differences at am early 
time point (6 months) compared to WT mice. Stimulation-evoked cerebral haemodynamics 
responses (blood volume and HbO) were significantly enhanced in J20-hAPP mice as 
measured in a stable chronic cranial window preparation (Figure 3.2). This consistent and 
remarkable finding was irrespective of stimulation duration (2s/16s) or gas condition 
(hyperoxia/normoxia). The washout of HbR was always smaller in J20-hAPP mice, but much 
smaller under normoxia. These responses were consistent across all experimental setups and 
the timing of experiments post-anaesthesia. These findings are contrary to the majority of the 
published literature with respect to neurovascular function in the J20-hAPP mouse11–13 which 
all reveal diminished haemodynamic responses in terms of HbT (blood volume) in the J20-
hAPP mouse at a similar age. However, one study has previously reported augmented 
haemodynamics in the APP/PS1 double transgenic model14. In that study, a multi-modal 
approach was used to investigate cerebral haemodynamics in response to electrical 
stimulation of the hind-paw. Laser-Doppler flowmetry, multi-photon laser scanning microscopy 
and intrinsic optical imaging (similar to 2D-OIS) all confirmed enhanced HbT in 7m APP/PS1 
mice and not earlier than 5m, similar to our data from the J20-hAPP mice around 6m of age. 
However, Kim and colleagues did not measure neural activity and speculated that the 
enhanced haemodynamic responses could be attributed to either increased neuronal activity 
or increased vascular reactivity. Our data along with others investigating neural activity confirm 
that there is neuronal hyperexcitability around 6m of age in the J20-hAPP mouse, but that 
there is no difference in vascular reactivity between WT controls and J20-hAPP mice as 
demonstrated by the response to hypercapnia. Previous research from our laboratory has 
shown no significant differences in either haemodynamics or neural activity between 9-12m in 
the same J20-mouse model unless an electrode is inserted into the brain10. Using exactly the 
same approach, we present here novel findings of hyperexcitability and enhanced evoked 
haemodynamic responses at an earlier age, around 6m, in the J20-mouse model of AD. 
Combined, these studies suggest that these effects are only seen at an earlier age point and 
are, therefore, time-dependent.  
 
A major finding from this study was that under normobaric hyperoxia, the baseline blood 
volume and saturation across the entire cortex was substantially higher in J20-hAPP mice 
compared to control mice, and this effect disappeared upon transitioning to normoxia, where 
J20-hAPP mice displayed a significant decrease in HbT to match the baseline of WT controls 
(Figure 3.4). This enhanced blood volume could be seen across all vascular compartments 
across the observable cortical regions. This oxygen-specific effect on cerebral 
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haemodynamics was only observed in the J20-hAPP mice and was not a feature of WT mice 
and did not seem to affect stimulation-evoked haemodynamics in terms of HbT volume. In 
early stages of AD, soluble Aβ fragments can be cleared from the brain through paravascular 
pathways in the brain, including the glymphatic system15 and the intramural periarterial 
drainage system16. It may be possible that naturally increasing cerebral blood flow could 
potentially enhance the clearance of soluble Aβ in the early stages of AD onset, though this 
would require further work to establish if true. Since our data show that normobaric hyperoxia 
can elevate baseline blood volume across the cortex in young J20-hAPP mice, this 
mechanism may provide a potential disease prevention strategy enhancing the clearance of 
Aβ before plaques begin to form, as well as reducing the formation and concentration of Aβ 
oligomers. As we can visualise plaques from around the age these J20-hAPP mice, these 
observations could be related to early Aβ deposition. In terms of corroboration and 
translatability of these findings, it has previously been demonstrated that hyperbaric oxygen 
therapy reduces neuroinflammation in the 3xTg AD mouse model17.  
 
Another finding from this study was that the J20-hAPP mice were hyperexcitable, as indicated 
by the enhanced MUA evoked by whisker stimulation (Figure 3.3) consistent with other 
studies showing neural hyperexcitability in the J20 mouse18. The cause of hyperexcitability in 
J20-hAPP mice, and indeed some AD patients, may be due to neurophysiological 
abnormalities caused by the presence of Aβ19–22, or by aberrant APP processing resulting in 
different intracellular domain fragments23–25. Unprovoked seizures can occur in 10-22% of AD 
patients26, especially myoclonic seizures, which are specifically due to the hyperexcitability of 
the cortex. For unknown reasons, the prevalence of seizures in AD-patients, including the 
myoclonic type, are more frequent in younger AD-patients, especially that of early-onset AD27. 
This hyperexcitability at a young age is also reflected in our data from the J20-hAPP mouse. 
Furthermore, another study showed a higher incidence of epileptiform-like discharges in the 
APP/PS1 mouse model compared to controls which were correlated to the number of Aβ 
plaques between 4-9m of age28. The hyperexcitability and epileptic activity of the J20-hAPP 
mice dissipates by the age of 8m23. Therefore, the hyperexcitability seen in the J20-hAPP 
mouse, APP/PS1 mice and younger AD-patients may be related to the brains initial reaction 
to the emerging presence of Aβ oligomers, or that of aberrant APP processing. Whisker 
deflection in APP/PS1 mice also resulted in much higher neural responses in the cortex, also 
supporting our findings29. In our study, the observed enhanced neural activity couples well 
with the enhanced haemodynamic responses, suggesting that neurovascular coupling in the 




In J20-hAPP mice, amyloid plaques begin to form around 6m of age within the dentate gyrus 
of the hippocampus as well as in some areas of the neocortex30. These mice do not exhibit 
any neurofibrillary tangles of hyperphosphorylated tau at any stage of their life. Neuronal loss 
within CA1 as well as synaptic loss begins around 3m of age within the hippocampus, 
significant neuroinflammation from 6m1,6, with cognitive impairment starting around 4m where 
J20-hAPP mice display spatial memory deficits as measured by the radial arm maze1. In 
human patients with AD, memory deficits come secondary to Aβ deposition9, although 
important pathological hallmarks such as neuroinflammation and hippocampal sclerosis are 
present early on during early mild cognitive impairment (EMCI), in addition to tau pathology. 
Thus the 6m time point of the J20-hAPP mouse could be considered as an equivalent of EMCI 
in humans; characterised by some memory deficits, structural and functional alterations within 
the brain including Aβ deposits, neuronal & synaptic loss in hippocampus as well as 
neuroinflammation, though with the notable exception of any tau pathology as well as 
displaying cognitive impairments before significant Aβ deposition.  
 
In our acute experimental sessions, the intactness of NVC was masked by the technical 
procedure used and a mismatch between neural activity and haemodynamic response was 
recorded (Figure 3.7). As described in our previous research using the J20-hAPP mouse 
between 9-12m of age10, insertion of an electrode into the mouse brain can cause cortical 
spreading depression (CSD) to occur across the cortex31. CSD is characterised by prolonged 
vasoconstriction that can persist for some time (in some cases over an hour) and this generally 
dampens haemodynamic responses and overall cerebral blood flow across a wide area of the 
cerebral cortex32. During this time, neural activity often recovers quickly, however the recovery 
rate of haemodynamics varies and there is a considerable lag33. As such, despite the 
enhanced MUA seen in our J20-hAPP mice to stimulations, the haemodynamics measured 
are comparable to WT controls due to CSD. Although cerebral haemodynamics recover in 
both WT and J20-hAPP mice, the rate of recovery between these varies, and J20-hAPP mice 
take longer as previously demonstrated10. By the end of the experimental period (16s-
stimulaton 100% O2), HbT increases in J20-hAPP mice to match that of WT controls (Figure 
3.7 bottom). Our data, along with our previous research, highlight the major impact that acute 
imaging sessions have on neurovascular studies. Future experiments could combine 2D-OIS 
with non-invasive optical neural readouts (such as genetically encoded calcium indicators 
(GECIs) e.g. GCaMP in neurons, although these have their own technical and physiological 
considerations, discussed in depth elsewhere34. 
 
A limitation of the study was that animals were lightly anaesthetised throughout. While it is 
increasingly argued that all neurovascular studies should be performed using awake animals35 
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due to the effects of anaesthesia on neurovascular function, previous research from our 
laboratory has determined an optimal anaesthetic regimen that has minimal effect on 
cerebrovascular function and reactivity36. Performing experiments at 1-hour post induction of 
anaesthesia, and maintaining sedation via low levels of isoflurane (<0.5%), is comparable to 
awake imaging in terms of haemodynamic responses and profiles to whisker stimulation36. 
Use of such an anaesthetic regime avoids the multiple confounds associated with behavioural 
state (arousal, locomotion, stress, grooming etc.), which are present in the awake animal. A 
second limitation is that our estimates of blood volume and saturation may be inaccurate 
especially for the J20-hAPP mouse. Our recent study10 using older age groups of mice 
discussed this issue in detail, which showed that regardless of the baseline blood volume 
estimation used, our percentage change was scaled by it (i.e. always the same change). 
Therefore the observation in this paper that blood volume is increased in the J20-hAPP mice 
under oxygen compared to air is robust. A third limitation was that blood flow measurements 
were not quantified and therefore we were unable to assess perfusion in the brain as a whole. 
Most other studies however indicate chronic hypoperfusion in patients and the J20-hAPP 
mouse37.  
 
In conclusion, using a stable chronic imaging preparation, we have shown that, at early time 
points, the J20-hAPP mouse model of AD exhibits enhanced haemodynamics in the brain 
marked by an increased blood volume response to sensory stimulations compared to WT 
controls. The likely cause of such increased blood volume responses in young J20-AD mice 
is neural hyperexcitability, suggesting that neurovascular function is preserved in these mice. 
A key finding from this study was that under normobaric hyperoxia, baseline blood saturation 
and volume is enhanced in all vascular compartments in the brain of J20-AD mice. This effect 
did not present under normoxia, with transition from hyperoxia to normoxia resulting in a large 
decrease of HbT/blood volume in J20-hAPP, but not WT mice. The enhancement of blood 
volume in normobaric hyperoxia may provide a time-dependent therapeutic strategy by driving 
enhanced paravascular clearance pathways in the brain. Future work should investigate the 
effect of regular normobaric hyperoxia on the levels of beta-amyloid in the J20-hAPP mouse.  
 
3.6 – Materials & Methods 
3.6.1 – Animals 
All animal procedures were performed with approval from the UK Home Office in accordance 
to the guidelines and regulations of the Animal (Scientific Procedures) Act 1986, as well as 
being approved by the University of Sheffield ethical review and licensing committee. 6m old 
male wild-type (WT) C57BL/6J mice (n=8) and male heterozygous transgenic J20-hAPP 
B6.Cg-Zbtb20Tg(PDGFB-APPSwInd)20Lms/2Mmjax) (MMRRC Stock No: 34836-JAX | J20) 
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mice (n=9) were used. All mice were housed with littermates in a 12hr dark/light cycle at a 
temperature of 23C, with food and water supplied ad-libitum.  
 
3.6.2 – Chronic Thinned Cranial Window Preparation 
Mice were anaesthetised with 7ml/kg i.p. injection of fentanyl-fluanisone (Hypnorm, 
Vetapharm Ltd, UK), midazolam (Hypnovel, Roche Ltd, UK), diluted in sterile water in a 1:1:2 
by volume ratio for surgery induction, and maintained in a surgical anaesthetic plane by 
inhalation of 0.5-0.8% isoflurane. Core body temperature was maintained at 36.5-37.0C 
through rectal temperature monitoring. Mice were placed in a stereotaxic frame (Kopf 
Instruments, US) and the scalp was excised. The bone overlying the right somatosensory 
cortex was thinned to translucency forming a thinned cranial optical window (measuring 
~9mm2). A thin layer of clear cyanoacrylate glue was applied over the cranial window to reduce 
specularities and to reinforce the window. Dental cement (Super Bond C&B, Sun Medical, 
Japan) was applied around the window to which a metal head-plate was chronically attached. 
WT mice were 5.85 months ±3.5 days at surgery, and J20 mice were 5.47 months ±5.4 days 
at surgery. All mice were given 2 weeks to recover before the first imaging session was 
performed.  
 
3.6.3 – 2D-Optical Imaging Spectroscopy (2D-OIS) 
2D-OIS measures changes in cortical haemodynamics by estimating changes in total 
haemoglobin (HbT), oxyhaemoglobin (HbO) and deoxyhaemoglobin (HbR) concentrations as 
described previously38. For the experimental session, mice were anaesthetised (as described 
above) and placed into a stereotaxic frame with heads fixed using attached headplates. 
Anaesthesia was maintained using low-levels of isoflurane (0.3-0.6%). For imaging, the right 
somatosensory cortex was illuminated using 4 different wavelengths of light appropriate to the 
absorption profiles of the differing haemoglobin states (495nm ± 31, 559nm ± 16, 575nm ± 14 
& 587nm ± 9) using a Lambda DG-4 high-speed galvanometer (Sutter Instrument Company, 
US). A Dalsa 1M60 CCD camera with a frame rate of 32Hz operating in a 4x4 binning mode 
acquired images at 184x184 pixels; giving a pixel resolution of 75x75µm, was used to capture 
the re-emitted light from the cortical surface. 
All spatial images recorded from the re-emitted light underwent spectral analysis based on the 
path length scaling algorithm (PLSA) as described previously38,39, which uses a modified Beer-
Lambert law with a path-length correction factor converting detected attenuation from the re-
emitted light with a predicted absorption value. Relative HbT, HbR and HbO concentration 
estimates were generated from baseline values in which the concentration of haemoglobin in 
the tissue was assumed to be 100µM and O2 saturation to be 70%. The spectral analysis 
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produced 2D-images of micromolar changes in volume of HbT, HbO & HbR over each 
stimulation period.  
 
3.6.4 – Stimulation Paradigm & Experimental Overview 
A mechanical whisker stimulation paradigm was used. Whiskers were mechanically deflected 
for a 2s duration and a 16s duration at 5Hz using a plastic T-shaped stimulator which caused 
a 1cm deflection of the left-whisker pad in the rostro-caudal direction. Each individual 
experiment consisted of 30 stimulation trials (for 2s) or 15 stimulation trials (for 16s) from which 
a mean trial was generated after spectral analysis of 2D-OIS (as described previously). 
Stimulations were performed in 100% O2 (normobaric hyperoxia), a gas transition to medical 
air (normobaric normoxia; 21% O2) as well as an additional 10% CO2-hypercapnia test of 
vascular reactivity. The same set of experiments with the same timings were performed on all 
mice on all experimental days. 2-weeks post-surgery the 1st imaging session was performed 
with 2D-OIS alone (a chronic session as imaging was through an intact skull). 1-week after 
the 1st imaging session a 2nd terminal imaging session was performed in combination with 
neural electrophysiology.  
 
3.6.5 – Neural Electrophysiology 
In order to assess neurovascular function in its entirety, both haemodynamic and neural 
measures were obtained. Simultaneous measures of neural activity alongside 2D-OIS were 
performed in a final acute imaging session 1-week after the 1st imaging. A small burr-hole was 
drilled through the skull overlying the barrel cortex (as defined by the biggest HbT changes 
from 2D-OIS imaging) and a 16-channel microelectrode (100µm spacing, 1.5-2.7MW 
impedance, site area 177µm2) (NeuroNexus Technologies, USA) was inserted into the whisker 
barrel cortex to a depth of ~1500µm. The microelectrode was connected to a TDT preamplifier 
and a TDT data acquisition device (Medusa BioAmp/RZ5, TDT, USA). All data collected was 
sampled at 24kHz and downsampled to 6kHz for analysis of multi-unit activity (MUA) and 
local-field potentials (LFPs).   
 
3.6.6 – Region Analysis 
Analysis was performed using MATLAB (MathWorks). An automated region of interest (ROI) 
was selected using the stimulation data from spatial maps generated using 2D-OIS. The 
threshold for a pixel to be included within the ROI was set at 1.5xSTD, therefore the automated 
ROI for each session per animal represents the area of the cortex with the largest 
haemodynamic response, as determined by the HbT. For each experiment, the response 
across all pixels within the ROI was averaged and used to generate a time-series of the 
haemodynamic response against time for HbT, HbO & HbR.  
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3.6.7 – Statistical Analysis 
Statistical analyses were performed using GraphPad Prism v8. To compare haemodynamic & 
neural responses, statistical comparisons were made on HbT, HbO, HbR & MUA values using 
two-way repeated measures ANOVAs as well as 2-tailed unpaired t-tests. P-values <0.05 
were considered statistically significant. All the data are presented as mean values ± standard 
error of mean (SEM), unless otherwise stated.  
 
3.6.8 – Immunohistochemistry 
At the end of terminal experiments, mice were euthanized with an overdose of pentobarbital 
(100mg/kg, Euthatal, Merial Animal Health Ltd) and transcardially perfused with 0.9% saline 
followed by 4% ice-cold paraformaldehyde (0.1M, pH7.4). Brains were dissected and 
embedded in paraffin wax. 5µm coronal sections were obtained using a cryostat. 
Immunohistochemistry was performed using an avidin-biotin complex (ABC) method (as 
described previously6). Briefly, sections were deparaffinised, rehydrated and quenched of 
endogenous peroxidase activity in 0.3% H2O2/methanol solution. Following antigen retrieval 
(pressure cooker at 20psi at 120C for 45s (pH6.5)) sections underwent additional pre-
treatment in 70% formic acid. Sections were incubated with 1.5% normal serum followed by 
incubation with the primary antibody (biotinylated anti-Aβ – 1:100, BioLegend, USA) for 1 hour. 
Horseradish peroxidase avidin-biotin complex (Vectastain Elite Kit, Vector Laboratories, UK) 
was used to visualise antibody binding along with 3,3-diaminobenzidine tetrahydrochloride 
(DAB) (Vector Laboratories, UK). All sections were counterstained with haematoxylin, 
dehydrated and mounted in DPX. Sections were imaged using a Nikon Eclipse Ni-U 
microscope attached to a Nikon DS-Ri1 camera.  
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3.11 – Supplemental Data 
 
Figure 3.6(S) – 10% Hypercapnia Responses. Chronic data for WT (n=8) and J20-hAPP (n=9) 
hypercapnia responses showed no significant differences between groups. Hypercapnia was 




Figure 3.7(S) – Haemodynamic Responses During Acute Imaging Session (with Electrode 
Inserted). There are no significant differences in HbT between WT (n=6) and J20-hAPP (n=5). 
HbT/blood volume recovers in both groups as a result of time post-electrode insertion. Washout 














Chapter 4 – Neurovascular Function in Experimental Models of 
Atherosclerosis (PCSK9), Alzheimer’s Disease (J20-hAPP) and a Novel Mixed 
Comorbid Model (J20-PCSK9) 
 
This chapter is a paper submitted to a mid-tier journal and is currently available as a preprint 
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4.2 – Abstract 
Neurovascular coupling is a critical brain mechanism whereby changes to blood flow 
accompany localised neural activity. The breakdown of neurovascular coupling is linked to the 
development and progression of several neurological conditions including dementia. However, 
experimental data commonly arise from preclinical models in young mice with one disease 
only. In this study, we examined cortical haemodynamics in preparations that modelled 
common co-existing conditions namely Alzheimer’s disease (J20-AD) combined with 
atherosclerosis (PCSK9-ATH) between 9-12m of age. We report novel findings with 
atherosclerosis where neurovascular decline is characterised by significantly reduced blood 
volume (HbT), levels of oxyhaemoglobin (HbO) & deoxyhaemoglobin (HbR), in addition to 
global neuroinflammation. In the comorbid mixed model (J20-PCSK9-MIX), we report a highly 
significant increase (3x fold) in hippocampal amyloid-beta plaques, without any further 
alterations to neurovascular function. There were no significant changes in evoked neural 
activity in any of the disease models, suggesting a breakdown of neurovascular coupling in 
PCSK9-ATH mice with inadequate oxygen delivery. A key finding was that cortical spreading 
depression (CSD) due to electrode insertion into the brain was worse in the diseased animals 
and led to a prolonged period of hypoxia and potentially ischaemia. The inflammatory 
environment in the brain was also perturbed, with interleukin-1 beta raised up to 2-fold and 
tumour necrosis factor raised up to 7-fold in brain tissues from these mice. Taken together, 
these findings suggest that systemic atherosclerosis can be detrimental to neurovascular 
health and that having cardiovascular comorbidities can exacerbate pre-existing Alzheimer’s-
related amyloid-plaques.  
 
4.3 – Significance Statement 
 The development of therapies for dementia is one of the biggest scientific priorities as many 
amyloid-targeting treatments have failed clinical trials in the past, and to date, we have no 
disease modifying therapies. Understanding the different disease mechanisms involved in the 
onset of dementia is important if therapies are to succeed. Evidence has pointed to vascular 
dysfunction as a key potential mechanism involved in dementia onset and many preclinical 
studies have highlighted the role of impaired neurovascular coupling in such models. In this 
study we report novel findings with respect to neurovascular dysfunction in disease models, 
as well as describing how brain state plays a role in worsened outcomes of brain injury and 
migraine in the context of dementia onset.  
 
4.4 – Key Words 
Neurovascular coupling, atherosclerosis, Alzheimer’s disease, CSD, comorbid  
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4.6 – Introduction 
Neurovascular coupling (NVC) is the neurophysiological process that ensures active regions 
of the brain receive an increased local cerebral blood flow (CBF) to match the metabolic 
demands neuronal activity exerts. Cell types including neurons, astrocytes, endothelial cells, 
vascular smooth muscle cells, and pericytes are involved in the facilitation of NVC during 
which local blood vessels dilate (1). The vasodilation of cerebral arterioles causes an influx of 
oxygenated blood (HbO) coupled to a decrease in deoxyhaemoglobin (HbR), that is the source 
of the blood-oxygen-level-dependent (BOLD) fMRI signal (2, 3). The breakdown of NVC is 
thought to be an important and early pathogenic mechanism in the onset and progression of 
a range of neurological conditions (4).  
 
Alzheimer’s disease (AD) is the most common form of dementia worldwide, with the vast 
majority of cases being sporadic and occurring 65 years and over. Population based studies 
have shown that AD and vascular pathologies commonly coexist in the brains of elderly 
individuals (5-8). A major cardiovascular pathology that affects as many as up to 60% of all 
individuals after the age of 55 is atherosclerosis. Atherosclerosis is the progressive thickening, 
hardening and narrowing of major arteries, including those that supply the brain, such as the 
carotids (9). Intracranial atherosclerosis does not occur until much later in life, around 75 years 
and above. As such, Alzheimer’s disease that begins around the 8th decade of life is usually 
present with other comorbidities such as atherosclerosis (10). There is also evidence that, not 
only do these often exist as comorbidities, but they may interact pathogenically with vascular 
disease and neurovascular unit changes contributing to AD (11, 12). To date, there are very 
limited models of comorbidity with respect to preclinical studies, and instead models have 
been very specific and ‘pure’, and not reflective of the clinical pathology in humans. 
Atherosclerosis is known to be a major risk factor for the development of dementia. The 
progressive atheromatous plaque build-up within cerebral arteries that supply the cortex over 
time can lead to stenosis producing insufficient oxygen delivery to the brain parenchyma, 
potentially resulting in neuronal death and symptoms of dementia (1). Indeed, the vascular 
cognitive impairment (VCI) which precedes the onset of dementia may be attributed to a 
variety of different vascular pathologies affecting either systemic or intracranial vasculature 
(both large or small vessels) (13). Due to the complexity of atherosclerosis and dementia 
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pathogenesis, understanding the mechanisms of their mutual interactions is necessary if 
efforts to develop therapeutics to prevent VCI and vascular dementia, which currently has no 
disease-modifying cure, are to succeed. 
 
In the present study, we aimed to investigate neurovascular function in mid-aged (9-12m old) 
mice where atherosclerosis was a comorbidity. We used a novel model of atherosclerosis that 
utilises a single adeno-associated virus (AAV) i.v. injection of a gain of function mutation 
(D377Y) to proprotein convertase subtilisin/kexin type 9 (rAAV8-mPCSK9-D377Y), combined 
with a high-fat Western diet to induce atherosclerosis in most adult mouse strains (14, 15). 
This leads to the constitutively active inhibition of the LDL-receptor preventing cholesterol 
internalisation and degradation by hepatocytes, leading to hypercholesterolaemia to occur and 
the development of robust atherosclerotic lesions within 6-8 weeks (14). Furthermore, in order 
to address the effect atherosclerosis could have on mild Alzheimer’s pathology, we combined 
the atherosclerosis with the mild J20-hAPP mouse model of familial Alzheimer’s disease (fAD) 
to create a mixed comorbid mouse model (J20-PCSK9-MIX). The J20-hAPP mouse model of 
fAD over-expresses human amyloid precursor protein (hAPP) with the Swedish (K670N and 
M671L) and the Indiana (V7171F) familial mutations (16), which begin to develop amyloid-
beta (Aβ) plaques around 5-6 months of age, and show signs of cognitive impairments from 4 
months (17). We hypothesised that atherosclerosis would exacerbate Alzheimer’s disease 
pathology in the brain and that neurovascular function would be further worsened compared 
to AD or ATH models alone. We have previously reported no significant alterations to evoked-
haemodynamics in the J20-AD model of the same age (9-12m); however, under acute imaging 
sessions where an electrode was inserted into the brain, we found significantly perturbed 
haemodynamics (18). We hypothesised that electrode insertion causes cortical spreading 
depression (CSD). Based on recent data linking migraine with aura with cardiovascular 
disease (19), we hypothesised that experimental CSD might be heightened in all disease 
models. We report that experimentally induced atherosclerosis in the J20-AD model increased 
the number of Aβ plaques by 300%. Furthermore, experimental CSD is more severe in all 
diseased groups compared to WT controls. 
 
4.7 – Results 
4.7.1 – 2D-Optical Imaging Spectroscopy (2D-OIS) Measures Brain Cortical 
Haemodynamics Through a Thinned Cranial Window 
We performed chronic imaging of the brain cortex 3-weeks post-surgery, where the thinned 
cranial window remained intact (Figure 4.1A/B), as described previously (18, 20). We 
deployed a range of stimulations (2s & 16s mechanical whisker stimulations) with the mouse 
breathing both 100% oxygen (hyperoxia) and 21% oxygen (normoxia), in addition to recording 
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transitions between conditions and performing a 10% hypercapnia test to test the maximum 
dilation of vessels. Each experimental day consisted of the same set of experiments with 
consistent timings to ensure reliability across all animal groups. First, a 2s-whisker stimulation 
(5Hz) with the mouse breathing 100% oxygen; hyperoxia, consisting of 30 trials, second, a 
16s-whisker stimulation consisting of 15 trials. Animals were then transitioned from hyperoxia 
to 21% oxygen; normoxia, and the baseline haemodynamic changes were recorded. The 
same set of stimulations were deployed under normoxia (2s & 16s stimulations), before 
transitioning back to hyperoxia for a final 10% hypercapnia test. Using these stimulations, 
activation maps of blood volume; total haemoglobin (HbT), can be generated (Figure 4.1C). 
Mice were allowed to recover and after 1-week, a final acute imaging session was performed. 
In this setup, a small burr-hole was drilled through the thinned skull overlying the active region 
of interest (ROI) as determined from the chronic imaging sessions (Figure 4.1D), and a 
multichannel electrode was inserted into the brain (Figure 4.1E) to record neural activity 
simultaneously. We then imaged and recorded the baseline haemodynamics for a 35-minute 
period to observe the effect electrode insertion, before commencing the first stimulation. This 








Figure 4.1 – Experimental Setup and Data Derivation. A) Raw image of representative thinned 
cranial windows for WT, J20-AD, PCKS9-ATH AND J20-PCSK9-MIX mice (chronic imaging 
session). B) Vessel map outlining the major arteries and veins within the thinned cranial window. 
C) HbT spatial activation map showing fractional changes in HbT in response to a 16s-whisker 
stimulation. D) Automated computer-generated region of interest (ROI) determined from the HbT 
activation response in C from which time-series for HbT, HbO & HbR are generated. E) Raw image 
of the same animals in terminal acute imaging sessions with multichannel electrodes inserted into 












4.7.2 – Chronic Haemodynamic Responses in the Brain are Reduced in PCSK9-ATH 
Mice.  
Cortical haemodynamics were imaged through a thinned cranial window to determine whether 
evoked cortical haemodynamics were different between 9-12m old wild-type (WT), 
atherosclerotic (PCSK9-ATH), Alzheimer’s (J20-AD) & mixed (J20-PCSK9-MIX) mouse 
models (Figure 4.2). Across all stimulations and conditions, ATH-PCSK9 mice displayed a 
significant reduction of evoked blood volume responses (HbT; peak value) compared to WT 
controls. J20-AD mice and J20-PCSK9-MIX mice did not exhibit a significant change in HbT 
across all stimulation conditions compared to WT mice. Evoked HbT responses; although 
initially are smaller in J20-PCSK9-MIX mice, recovered to match that of J20-AD mice later in 
the experimental protocol under normoxia (Figure 4.2D). Levels of oxyhaemoglobin (HbO) 
were significantly reduced in PCSK9-ATH mice but showed a reduced trend in J20-PCSK9-
MIX mice too. The washout of deoxyhaemoglobin (HbR) was significantly reduced in PCSK9-
ATH mice compared to WT, but also showed a reduced trend across all diseased groups 
across all conditions compared to WT mice. All mice displayed stable and robust 
haemodynamic responses across the experimental protocol (Figure 4.7). Finally, vascular 
reactivity as determined by the response to 10% hypercapnia was not significantly different 




Figure 4.2 – Fractional Changes in Chronic Stimulus-Evoked (Peak) Haemodynamic 
Responses. A) 2s-stimulation in 100% oxygen. B) 16-stimulation in 100% oxygen. C) 2s-
stimulation in 21% oxygen. D) 16s-stimulation in 21% oxygen. All animals aged 9-12m: WT (n=6), 
J20-AD (n=9), PCSK9-ATH (n=8), J20-PCSK9-MIX (n=6). HbT: There was no significant overall 
effect of disease F(3,25)=2.83, p=0.059. However, Dunnett’s (two-sided) multiple comparisons test 
revealed there was a significant difference between WT and ATH (p=0.023). As expected, there 
was a significant effect of experiment, F(1.65,41.14)=13.64, p<0.001. There was also no significant 
interaction effect between experiment and disease, F(4.94,41.14)=1.50, p=0.211. HbO: There was 
a significant overall effect of disease F(3,25)=4.84, p=0.009. Dunnett’s (two-sided) multiple 
comparisons test revealed there was a significant difference between WT and ATH (p= 0.002). 
There was a significant effect of experiment, F(1.47,36.72)=15.348, p<0.001. There was no 
significant interaction effect between experiment and disease, F(4.41,36.72)=1.64 ,p=0.181. HbR: 
There was a significant overall effect of disease F(3,25)=4.86, p=0.008. Games-Howell multiple 
comparisons reveal HbR peak is significantly different for WT vs ATH (p=0.040). There was a 
significant effect of experiment, F(1.69,42.28)=17.33, p<0.001. There was a significant interaction 
between experiment and disease interaction: F(5.07, 42.28)=3.19, p=0.015. All error bars (lightly 
shaded) are ±SEM. Vertical dotted lines indicate start and end of stimulations. 
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4.7.3 – CSD is Worse in Diseased Animals and Impacts Haemodynamic Recovery to 
Baseline 
1-week after recovery from the chronic imaging protocol, an acute imaging experiment was 
performed wherein a small-burr hole was drilled into the skull overlying the active region 
(determined from HbT responses from chronic experiments) and a microelectrode was 
inserted into the brain to a depth of 1500-1600µm to obtain neural electrophysiology data in 
combination with the imaging of cortical haemodynamics by 2D-OIS. Electrode insertion into 
the brain resulted in a wave of haemodynamic changes that occurred in all mice (CSD) (Figure 
4.3). In WT mice, electrode insertion led to a small decrease in HbT (vasoconstriction) followed 
by a robust HbT bounce back (vasodilation), immediately followed by a small sustained 
vasoconstriction (reduced HbT) that persisted for some time (Figure 4.3A-top). In J20-AD 
mice, electrode insertion caused a large vasoconstriction to occur which spread across the 
cortex in a strong wave of vasoconstriction that was followed by a very small attempted 
recovery. This was masked by a large sustained and prolonged vasoconstriction of contiguous 
vessels that persisted for some time (Figure 4.3A-bottom). The largest vasoconstriction post-
CSD occurred in J20-AD mice, followed by PCSK9-ATH mice, then J20-PCSK9-MIX mice 
compared to WT controls. The smallest of all CSD occurred in WT mice (Figure 4.3B). A 
prolonged and sustained constriction below baseline persisted in all mice post-CSD, however, 
this effect was recovered to baseline in WT mice during the first stimulation experiment 35 
minutes after the CSD occurred (Figure 4.3B). In all disease mouse models, the constriction 
below baseline was more severe and persisted for a much longer time with a slower 
haemodynamic recovery. Following CSD, stimulation-evoked haemodynamic changes were 
not significantly different in any of the diseased groups overall, although they were initially 




Figure 4.3 – Cortical Spreading Depression (CSD) in WT, diseased and comorbid animals. 
A) Representative montage time-series of WT and J20-AD mice showing HbT changes post-
electrode insertion. Colour bar represents fractional changes in HbT from baseline. B) Left: 
Average CSD haemodynamics profiles for control animals (WT C57BL/6J & nNOS-ChR2) (n=7), 
J20-AD (n=7), PCSK9-ATH (n=5) & J20-PCSK9-MIX (n=6) mice. Right: Averaged changes to HbT 




[cont.] HbT: A 1-way ANOVA showed significant effect of disease for HbT (F(3,21)=9.62, p=0.001. 
Dunnett’s 2-sided multiple comparisons showed that AD vs WT p<0.001, ATH vs WT p=0.012 & 
MIX vs WT p=0.020. HbO: 1-way ANOVA showed significant effect of disease for HbO 
(F(3,21)=8.51, p<0.001. Dunnett’s 2-sided multiple comparisons showed that AD vs WT p<0.001, 
ATH vs WT p=0.01 & MIX vs WT p=0.017. HbR: Kruskal-Wallis test revealed no significant effect 

































4.7.4 – Stimulus-Evoked Neural Activity is Not Significantly Altered in Any Disease 
Groups Compared to WT Mice 
In the final imaging session and after a 35-minute period of recovery post-electrode insertion, 
the first experimental stimulation was performed (2s-stimulation in 100% oxygen) where 
evoked cortical haemodynamics were imaged simultaneously with the recording of neural 
multi-unit activity (MUA). Evoked-MUA response were not significantly different in any of the 
diseased groups compared to WT mice (Figure 4.4), suggesting that the significantly different 
evoked-HbT in PCSK9-ATH mice (observed on chronic imaging sessions) was due to 
neurovascular breakdown. Initially, the MUA was slightly lower for J20-AD, PCSK9-ATH & 
J20-PCSK9-MIX mice compared to WT mice (Figure 4.4A), however, later in the experimental 
session by the last stimulation, there was no observable difference in MUA between any of 
the groups (Figure 4.4D). Thus, this suggests that the neural MUA was initially smaller after 
the CSD had occurred, however, recovered fully with time. The haemodynamic responses in 
the acute experimental session were not significantly different across all stimulations for any 













Figure 4.4 – Evoked Neural Multi-Unit Activity (MUA) Responses. MUA heat maps showing 
fractional changes in MUA along the depth of the cortex (channels 4-8) in response to stimulations 
in WT C57BL/6J (n=6), J20-AD (n=9), PCSK9-ATH (n=7) & J20-PCSK9-MIX (n=6) mice. Overall 
effect of disease on MUA F(3,24)=2.24, p=0.109 (2-way mixed design ANOVA). There was a 
significant effect of experiment, as expected, F(2.26, 54.16)=6.83, p=0.002. There was no 
significant interaction between experiment and disease F(6.77, 54.16)=0.70, p=0.670. All error 
















4.7.5 – Increased Number of Hippocampal Aβ Plaques in J20-PCSK9-MIX Mice. 
Increased Neuroinflammation in J20-AD and PCSK9-ATH Mice 
Immunohistochemistry was performed on J20-AD and J20-PCSJK9-MIX mice to assess 
whether there were any specific differences in AD neuropathology changes. Staining was 
performed for Aβ plaques and these were quantified within the hippocampus and the cortex. 
Aβ plaques were significantly increased by 3-fold in the hippocampi of J20-PCSK9-MIX mice 
compared to J20-AD mice (Figure 4.5A/B). Within the cortex, there was no significant 
difference in Aβ plaques between the 2 groups (Figure S7). Next, neuroinflammation was 
assessed by qRT-PCR for 2 key inflammatory markers: interleukin-1β (IL1β) and tumour 
necrosis factor-α (TNFα) to assess the degree of neuroinflammation present globally within 
the brain. IL1β mRNA was significantly upregulated in J20-AD and PCSK9-ATH mice (Figure 
4.5C). TNFα mRNA was significantly upregulated in PCSK9-ATH mice only (Figure 4.5D). 
J20-PCSK9-MIX mice displayed the lowest inflammatory changes in IL1β & TNFα compared 
















Figure 4.5 – Neuropathology and Neuroinflammation. A) Representative histological coronal 
hippocampal sections for J20-AD and J20-PCSK9-MIX mice stained with anti-Aβ to visualise Aβ 
plaques. B) Increased number of amyloid-beta plaques in the hippocampus of J20-PCSK9-MIX 
mice compared to J20-AD mice (p=0.036; unpaired t-test) (n=4 each). Cortical plaques p=0.3372 
(data not shown). D) qRT-PCR for 1L1β: AD vs WT p=0.011, ATH vs WT p=0.0278, MIX vs WT 
p=0.218 (1-way ANOVA with post-hoc Dunnett’s multiple comparisons test). E) qRT-PCR for TNFα: 
AD vs WT p=0.1197, ATH vs WT p=0.0370, MIX vs WT p=0.1313 with post-hoc Dunnett’s multiple 

















4.8 – Discussion 
The present study investigated neurovascular function in a novel experimental model of ATH 
(PCSK9-ATH) and for the first time, in a comorbid setting whereby ATH was experimentally 
induced in a well characterised model of AD; J20-hAPP(Sw,Ind), to create a mixed comorbid 
model (J20-PCSK9-MIX). These mice were compared to age-matched (9-12m) WT C57BL/6J 
controls, and J20-AD mice. Given that systemic ATH is a major risk factor for dementia, the 
mechanisms underpinning the relationship between ATH, neurovascular decline and 
dementia are still largely unclear. In the study, we utilised a chronic mouse preparation to 
image cortical haemodynamics through an intact skull surface, followed by an acute terminal 
imaging session where the skull was drilled, and the brain penetrated with a multichannel 
electrode. In our experimental paradigm, we deployed a range of stimulations (both short 2s 
and long 16s durations) and different respiratory conditions (hyperoxia & normoxia) to assess 
neurovascular coupling to mechanical whisker stimulations, in addition to measuring neural 
activity within the active region defined from the chronic imaging.  
 
In the first part of the study, we characterised evoked-haemodynamic responses using a 
chronic skull-intact & surgery-recovered mouse preparation. We found that PCSK9-ATH mice 
displayed significantly reduced evoked blood volume (HbT) responses, in addition to reduced 
levels of oxyhaemoglobin (HbO) and notably, an impaired washout of deoxyhaemoglobin 
(HbR) across all stimulations and conditions. The J20-PCSK9-MIX mice did not display a 
significant reduction in HbT, nor in HbO or HbR levels. With respect to J20-AD mice, we did 
not observe any significant alterations to HbT as previously published (18). Another important 
finding from the present study was that 10%-hypercapnia responses were not significantly 
different in any of the mice compared to WT controls (Figure 4.8), thus suggesting that 
vascular reactivity was not impaired in any of the mice, indicating that cerebral arterioles were 
unaffected by atherosclerosis at this time-point (9-12m). Thus, the basis of reduced HbT in 
PCSK9-ATH mice cannot be attributed to intracranial atherosclerosis. Previous work 
examining experimental atherosclerosis in the ApoE-/- model of ATH only showed 
extravascular lipid pools in large ventricle-associated and parenchymal blood vessels (21). 
Other work has found hypercapnia differences in the ApoE-/- model (22), however, this may 
be due to the severity differences in the mouse models where ApoE-/- is more severe 
compared to PCSK9-mice which resemble more closely the milder and more ‘human-like’ 
LDLR-/- model.   
 
In the second part of the study, we obtained neural multi-unit activity (MUA) by inserting a 
multichannel electrode into the active region defined from the chronic imaging experiments. In 
order to do this, we carefully drilled a small burr-hole without penetrating the dura, followed by 
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a gentle insertion of the electrode into the brain whilst simultaneously recording the baseline 
haemodynamics by 2D-OIS. As we showed in our previous reports (18, 20), the technical 
procedure of electrode insertion causes a cortical spreading depression (CSD) to occur in all 
animals. Here, we describe the CSD and its recovery on the different disease groups. CSD 
has two distinct phases: 1) a wave of depolarisation within the grey matter characterised by 
neuronal distortion leading to a large change of the membrane potential whereby neuronal 
activity is silenced (spreading depression) & 2) haemodynamic changes that accompany 
neuronal spreading depolarisation which typically result in a wave of prolonged reduced 
perfusion that persists for some time (23, 24). CSD does not typically occur in healthy brain 
tissue, however, it is a common neurophysiological occurrence in certain pathological 
conditions including migraine, epilepsy, brain injury, hyperthermia, chemically induced 
neurotoxicity, hypoxia & ischaemia (24). In WT mice, the initial constriction wave is small, and 
a robust haemodynamic recovery occurs which allows for neurovascular coupling to occur to 
sustain neurons metabolically. Although WT mice exhibit a slight constriction below baseline, 
levels of HbO and HbR are not greatly affected, thus suggesting that CSD in WT mice does 
not result in severe hypoxia or ischaemia. This is a marked difference to the diseased animals, 
which upon electrode insertion to cause a CSD, exhibit profound vasoconstriction with an 
extremely limited haemodynamic recovery resulting in a prolonged constriction, severe 
reductions to blood volume and HbO & HbR levels indicating profound hypoxia and ischaemia. 
Thus, the haemodynamic response to CSD in diseased mice is severely inappropriate and 
can lead to long lasting devastating effects such as widespread cortical pannecrosis of 
neurons and astrocytes (24). As our data shows, baseline blood volumes do not recover in 
the diseased animals for a much longer period compared to WT animals, with the most 
profound CSD occurring in J20-AD mice, followed by PCSK9-ATH mice. The least severe 
CSD of the disease groups occurs in the J20-PCSK9-MIX animals. This surprising effect may 
be related to the levels of neuroinflammation within the brain (see below).  
 
CSD is a reflection of whole brain state and disease burden effects, such as global 
neuroinflammation and in relation to certain pathologies including migraines or TBI, especially 
in the context of pre-existing disease (24). CSD may be the neuropathological link between 
migraine, stroke, cardiovascular disease and dementia in which cardiovascular risk factors, 
genetics and other lifestyle factors which prime the onset of migraine to occur lead to vascular 
vulnerability within the brain predisposing affected individuals to an increased risk of cerebral 
ischaemia and haemorrhagic stroke (25). There is accumulating evidence to suggest that 
shared genetic and associated clinical features observed in migraine patients are involved in 
the increased vulnerability to cerebral ischaemia, therefore, predisposing affected individuals 
to stroke and white matter lesions associated with dementia (26). The underlying mechanism 
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being CSD; the neurophysiological feature of aura in migraines, whose induction threshold 
can be reduced by genetic mutations and systemic comorbidities that contribute to vascular 
dysfunction and neuroinflammation (26). Indeed, mouse models of cerebral autosomal 
dominant arteriopathy with subcortical infarcts and leukoencephalopathy syndrome 
(CADASIL); a genetic cerebrovascular disease caused by NOTCH3 mutations that has a high 
frequency of migraines with aura, have enhanced CSD linking a dysfunctional neurovascular 
unit with migraine with aura (27). Furthermore, a recent study examined women who suffered 
from migraines with and without aura and found that those that suffered migraines with aura 
had a higher incidence rate of cardiovascular disease compared to women without aura or 
any migraines (19). In addition, another recent study found that migraine history was positively 
associated with an increased risk of developing both all-cause dementia and AD, but not VaD 
(28). Our study, along with the previously discussed studies provide an explanation for these 
recent findings and highlights how systemic disease can prime the brain to allow profound 
CSDs to occur in the context of migraine, and as such, migraine frequency and intensity may 
be related to the onset of neurological disease by later in life including dementia. CSD is not 
limited to migraines, but also suggests that those with cardiovascular disease or genetic 
mutations that suffer a brain injury may also suffer from worse effects due to increased severity 
of CSD, as modelled in our experimental protocol by electrode insertion. CSD may also be an 
effective and robust biomarker to assess brain states as well as testing the efficacy of 
therapies in both preclinical studies and in neurological patients.  
 
Surprisingly, neural MUA data was not significantly altered across any of the stimulations or 
conditions for any of the disease groups compared to WT controls. Although the MUA for J20-
AD, PCSK9-ATH & J20-PCSK9-MIX mice does appear to be smaller in the first stimulation 
(Figure 4.4), it was not significant after post-hoc tests were performed. Furthermore, this effect 
disappears under the normoxia conditions (in 21% oxygen) where there is no longer such an 
indicative difference. The similar MUA across all groups, coupled with impaired HbO & HbR 
levels in PCSK9-ATH mice, and to some extent in the other disease models may indicate that 
neurovascular coupling is inefficient and metabolically compromised. A consistent finding 
irrespective of stimulation and condition was that PCSK9-ATH mice display consistently 
reduced evoked-HbT responses (observed in chronic experiments) compared to WT controls, 
which suggests an advanced level of neurovascular breakdown and inefficiency. Other groups 
have found similarly reduced blood flow in the ApoE-/- model without altered cortical activation, 
however, unlike in the present study, reduced hypercapnia response (22). A recent study 
found decreased tissue oxygenation in the LDLR-/- mouse model of atherosclerosis (29), and 
this is most likely to be the case in the PCSK9 model. This is also the case for the J20-AD and 
J20-PCSK9-MIX mice which also display a trend towards reduced HbR washout which 
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suggests that although neurovascular coupling is still present in these mice, it could be less 
efficient resulting in inadequate oxygen delivery to active neurons. PCSK9-ATH mice on the 
other hand display reduced evoked-HbT to normal levels of cortical activation in addition to 
reduced HbR washout indicating neurovascular breakdown and metabolic inefficiency.  
 
A question that arises is why the J20-PCSK9-MIX mice HbT responses are not more severely 
impaired than J20-AD and PCSK9-ATH? There may be redundancies that occur 
physiologically to compensate for mild hypoxia in the brain, such as the possible angiogenesis 
within the brain. Angiogenesis is known to be triggered in cerebral microvessels in AD in 
response to increased Aβ and neuroinflammation and may initially reflect a compensatory 
mechanism to increase perfusion (30). However, neovascularisation in AD is eventually 
thought to be pathogenic and damaging to the brain due to enhanced endothelial Aβ secretion 
that leads to increased ROS and endothelial damage (30). In addition, the levels of 
neuroinflammation seen in these mice may be due to an altered disease-course and 
examining temporospatial expression may reveal much higher levels of inflammation in this 
mixed model at an earlier time-point. Other markers of inflammation may be upregulated 
compared to those that we assessed, and future studies would incorporate transcriptomic 
approaches to identify other mechanisms or markers. Nevertheless, a key translational finding 
from our study was that J20-PCSK9-MIX mice displayed a significant increase in the number 
of hippocampal plaques, and this confirms other studies that have used APP/PS1 mice (31). 
However, the number of cortical plaques were not significantly increased between J20-AD and 
J20-PCSK9-MIX mice, again confirming findings from the previously discussed study (31). 
Furthermore, other research has found that high-fat diet in APP/PS1 double transgenic mouse 
model of AD is able to increase neuropathological changes as well as worsen behavioural 
abnormalities, however, without any further alterations to CBF (32), as seen in our study. Our 
neurovascular data focuses on the cortex, and we do not see worsened responses in J20-
PCSK9-MIX mice compared to J20-AD (or PCSK9-ATH) mice potentially reflecting the similar 
number of amyloid-plaques in the cortex. It is plausible that neurovascular coupling in the 
hippocampus in J20-PCSK9-MIX may be more perturbed than in J20-AD and PCSK9-ATH, 
however, our imaging system does not allow for us to image the hippocampus in vivo. We can 
also hypothesise that inducing atherosclerosis in a more moderate or severe fAD model such 
as the APP/PS1 or 5xfAD could worsen neurovascular coupling and neuropathological and 
neuroinflammation changes compared to the very mild J20-AD model that we have used. In 
the more extreme setting, neurovascular function may be severely perturbed and 
dysfunctional reflecting the later disease-course in humans, whereas the J20-AD model 




There are several notable limitations with the present study. Firstly, all imaging was performed 
on lightly anaesthetised animals, which is known to compromise neurovascular function (33). 
However, previous research from our laboratory has developed an anaesthetic regimen that 
is comparable to awake imaging in terms of the haemodynamic responses to physiological 
whisker stimulation with little effect on vascular reactivity (34). The benefits of lightly 
anaesthetised preparations over awake preparations is that we can avoid the multiple 
considerations of behavioural state in which the animals may be whisking, grooming as well 
as their arousal and stress states which may be present in awake animals. Furthermore, we 
report the stability and robustness of our imaging preparation in this study. We present the 
average of all the raw stimulation trials from each animal across the whole experimental 
session (Figure 4.7), showing the stability and robustness of our preparation, as well as easily 
identifying any changes. Secondly, our imaging analysis assumes O2 saturation to be 70% 
with a baseline haemoglobin concentration of 100µM. This may be important if the assumed 
baselines are different in the diseased animals compared to WT controls; however, our recent 
study (18) using the same J20-AD mouse model discussed this issue in detail, in which we 
showed that regardless of the baseline blood volume estimation used, our percentage change 
was scaled by it (i.e. always the same change). Therefore, the observations in this paper with 
respect to the different diseased animals are robust. Finally, we only performed qRT-PCR for 
2 inflammatory targets, whereas performing RNA-seq on specific cell types or wider 
transcriptomic studies would allow us to investigate the expression of other inflammatory 
targets and cellular pathways that could be important. In addition, examining levels of 
circulating plasma and CSF cytokines may be useful in examining neuroinflammatory changes 
in these mice.  
 
In conclusion, we report novel findings of impaired neurovascular function in a novel 
experimental model of atherosclerosis (PCSK9-ATH) characterised by reduced stimulus-
evoked blood volume without any significant alterations to evoked neural activity. We induced 
atherosclerosis in a mild fAD model (J20-AD) to create a mixed comorbid model (J20-PCSK9-
ATH) in which we report a significant increase in the number of hippocampal Aβ plaques, 
however, without any significant changes to evoked haemodynamic or neural responses 
compared to WT or J20-AD mice. A key finding from this study was CSD was more severe in 
diseased animals. This may reflect the global inflammatory state of the brain and could also 
serve to be an effective preclinical and human clinical biomarker for baseline state and to 
assess therapies. Future studies should include assessment of other inflammatory markers 
and cellular pathway changes by a genome wide transcriptomics approach from single cell 
populations, as well as from sera and CSF. It would also be prudent to induce atherosclerosis 
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in a more severe fAD model to provide a severity continuum of mixed models that reflect 
clinical presentations of dementia. 
 
4.9 – Materials & Methods 
4.9.1 – Animals 
All animal procedures were performed with approval from the UK Home Office in accordance 
to the guidelines and regulations of the Animal (Scientific Procedures) Act 1986 and were 
approved by the University of Sheffield ethical review and licensing committee. Male C57BL/6J 
mice were injected i.v at 6wks with 6x1012 virus molecules/ml rAAV8-mPCSK9-D377Y 
(Vector Core, Chapel Hill, NC) and fed a Western diet (21% fat, 0.15% cholesterol, 0.03% 
cholate, 0.296% sodium; #829100, Special Diet Services UK) for 8m (PCSK9-ATH). These 
mice were compared to age-matched wild-type C57BL/6J mice (with no AAV injection fed 
normal rodent chow) that were used as controls (WT C57BL/6J). In addition, male 
heterozygous transgenic J20-hAPP B6.Cg-Zbtb20Tg(PDGFB-APPSwInd)20Lms/2Mmjax) 
(MMRRC Stock No: 34836-JAX) mice were used. Atherosclerosis was induced in J20-hAPP 
mice alongside WT mice at 6wks of age combined with a Western diet to create a comorbid 
mixed model (J20-PCSK9-MIX). For the CSD imaging experiments, 4 nNOS-ChR2 mice (M/F, 
16-40 weeks old) were included in the WT group. [nNOS-ChR2 mice: heterozygous nNOS-
CreER (Jax 014541, (35)) x homozygous Ai32 mice (Jax 024109, (36)), given tamoxifen 
(100mg/kg, i.p., 3 injections over 5 days) at 1-2 months old]. All mice were imaged between 
9-12m of age. All mice were housed in a 12hr dark/light cycle at a temperature of 23C, with 
food and water supplied ad-libitum. 
 
4.9.2 – Thinned Cranial Window Surgery 
Mice were anaesthetised with 7ml/kg i.p. injection of fentanyl-fluanisone (Hypnorm, 
Vetapharm Ltd), midazolam (Hypnovel, Roche Ltd) and maintained in a surgical anaesthetic 
plane by inhalation of isoflurane (0.6-0.8% in 1L/min O2). Core body temperature was 
maintained at 37oC through use of a homeothermic blanket (Harvard Apparatus) and rectal 
temperature monitoring. Mice were placed in a stereotaxic frame (Kopf Instruments, US) and 
the bone overlying the right somatosensory cortex was thinned forming a thinned cranial 
optical window. A thin layer of clear cyanoacrylate glue was applied over the cranial window 
to reinforce the window. Dental cement was applied around the window to which a metal head-
plate was chronically attached. All mice were given 3 weeks to recover before the first imaging 
session. 
 
4.9.3 – 2D-Optical Imaging Spectroscopy (2D-OIS) 
2D-OIS measures changes in cortical haemodynamics: total haemoglobin (HbT), 
oxyhaemoglobin (HbO) and deoxyhaemoglobin (HbR) concentrations (37). Mice were lightly 
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sedated and placed into a stereotaxic frame. Sedation was induced as described above and 
maintained using low levels of isoflurane (0.3-0.6%). For imaging, the right somatosensory 
cortex was illuminated using 4 different wavelengths of light appropriate to the absorption 
profiles of the differing haemoglobin states (495nm ± 31, 559nm ± 16, 575nm ± 14 & 587nm 
± 9) using a Lambda DG-4 high-speed galvanometer (Sutter Instrument Company, US). A 
Dalsa 1M60 CCD camera was used to capture the re-emitted light from the cortical surface. 
All spatial images recorded from the re-emitted light underwent spectral analysis based on the 
path length scaling algorithm (PLSA) as described previously (37, 38). which uses a modified 
Beer-Lambert law with a path light correction factor converting detected attenuation from the 
re-emitted light with a predicted absorption value. Relative HbT, HbR and HbO concentration 
estimates were generated from baseline values in which the concentration of haemoglobin in 
the tissue was assumed to be 100µM and O2 saturation to be 70%. For the stimulation 
experiments, whiskers were mechanically deflected for a 2s-duration and a 16s-duration at 
5Hz using a plastic T-shaped stimulator which caused a 1cm deflection of the left-whisker. 
Each individual experiment consisted of 30 stimulation trials (for 2s) and 15 stimulation trials 
(for 16s) of which a mean trial was generated after spectral analysis of 2D-OIS. Stimulations 
were performed with the mouse breathing in 100% O2 or 21% O2, and a gas transition to 
medical air (21% O2) as well as an additional 10% CO2-hypercapnia test of vascular reactivity.   
 
4.9.4 – Neural Electrophysiology 
Simultaneous measures of neural activity alongside 2D-OIS were performed in a final acute 
imaging session 1-week after the 1st imaging session. A small burr-hole was drilled through 
the skull overlying the active region (as defined by the biggest HbT changes from 2D-OIS 
imaging) and a 16-channel microelectrode (100µm spacing, 1.5-2.7MΩ impedance, site area 
177µm2) (NeuroNexus Technologies, USA) was inserted into the whisker barrel cortex to a 
depth of ~1500µm. The microelectrode was connected to a TDT preamplifier and a TDT data 
acquisition device (Medusa BioAmp/RZ5, TDT, USA). Multi-unit analysis (MUA) was 
performed on the data. All channels were depth aligned to ensure we had twelve electrodes 
covering the depth of the cortex in each animal. The data were high passed filtered above 
300Hz to remove all low frequency components and split into 100ms temporal bins. Within 
each bin any data crossing a threshold of 1.5SD above the mean baseline was counted and 
the results presented in the form of fractional changes to MUA. 
 
4.9.5 – Region Analysis 
Analysis was performed using MATLAB (MathWorks). An automated region of interest (ROI) 
was selected using the stimulation data from spatial maps generated using 2D-OIS. The 
threshold for a pixel to be included within the ROI was set at 1.5xSD, therefore the automated 
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ROI for each session per animal represents the area of the cortex with the largest 
haemodynamic response, as determined by the HbT. For each experiment, the response 
across all pixels within the ROI was averaged and used to generate a time-series of the 
haemodynamic response against time. 
 
4.9.6 – Statistical Analysis 
Statistical analyses were performed using SPSS v25 & GraphPad Prism v8. Shapiro-Wilks 
test was used to check for normality and Levene’s test was used to assess equality of 
variances. 2-way mixed design ANOVA, 1-way ANOVA or Kruskal-Wallis tests were used, as 
appropriate. For 1-way ANOVA, if variances were unequal, Welch’s F was reported. Results 
were considered statistically significant if p<0.05. The Shapiro-Wilks test suggested that, for 
chronic experiments, peak values of HbT and HbO are normally distributed, however, HbR 
values are significantly non-normal. 2-way mixed design was used to compare peak values 
for HbT, HbO & HbR (although HbR failed the S-W test for normality, an ANOVA was used as 
they were considered fairly robust against small deviations from normality). Inspection of 
Levene’s test suggested that variances were equal, therefore, Dunnett’s (two-sided) multiple 
comparisons test was used to compare disease models to WT, and for HbR, Games-Howell 
multiples comparisons were used. If the Greenhouse-Geisser estimate of sphericity showed 
deviation from sphericity (chronic experiments: HbT (ε=0.55), HbO (ε = 0.49) & HbR (ε=0.564), 
results are reported with Greenhouse-Geisser correction applied. qRT-PCR data was 
analysed by performing 1-way ANOVAs with Dunnett’s multiple comparisons test used to 
compare disease models to WT. P-values <0.05 were considered statistically significant. All 
the data are presented as mean values ± standard error of mean (SEM). 
 
4.9.7 – Immunohistochemistry 
At the end of terminal experiments, mice were euthanized with an overdose of pentobarbital 
(100mg/kg, Euthatal, Merial Animal Health Ltd) and transcardially perfused with 0.9% saline 
and brains were dissected. One half-hemisphere of the brains were fixed in formalin and 
embedded in paraffin wax, with the other half snap-frozen using isopentane and stored at -
80C. 5µm coronal sections were obtained using a cryostat. Immunohistochemistry was 
performed using an avidin-biotin complex (ABC) method (as described previously (Ameen-Ali 
et al., 2019)). Following slide preparation and antigen retrieval (pressure cooker at 20psi at 
120C for 45s (pH6.5)), sections underwent additional pre-treatment in 70% formic acid. 
Sections were incubated with 1.5% normal serum followed by incubation with the primary 
antibody (biotinylated anti-Aβ – 1:100, BioLegend, USA) for 1 hour. Horseradish peroxidase 
avidin-biotin complex (Vectastain Elite Kit, Vector Laboratories, UK) was used to visualise 
antibody binding along with 3,3-diaminobenzidine tetrahydrochloride (DAB) (Vector 
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Laboratories, UK). All sections were counterstained with haematoxylin, dehydrated and 
mounted in DPX. Sections were imaged using a Nikon Eclipse Ni-U microscope attached to a 
Nikon DS-Ri1 camera. Plaques were identified at x40 magnification and manually counted per 
section.  
 
4.9.8 – qRT-PCR 
Snap-frozen hemispheres were homogenised, and RNA was extracted using Direct-zol RNA 
MiniPrep kit with TRI-reagent as per the manufacturer’s guidelines (Zymo) and RNA quality 
checked using NanoDropTM (ThermoFisher Scientific). cDNA was synthesised from the 
extracted RNA using the UltraScript 2.0 cDNA synthesis kit (PCR BioSystems) according to 
the manufacturer’s guidelines. qRT-PCR was performed using PrimeTime qRT-PCR assay 
primers (IDT) for IL1β & TNFα with ACTB as the reference housekeeping gene. Luna qRT-
PCR Master Mix (NEB) was used with the primers, cDNA and nuclease free water and each 
gene for each sample was duplicated. CFX384 Real-Time System (BioRad) with a C1000 
Touch Thermal Cycler (BioRad) was used to perform qRT-PCR consisting of 40 cycles. Data 
was analysed using the well-established delta-Ct method (Livak and Schmittgen, 2001) by 
normalising against ACTB. 
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4.13 – Supplemental Information: 
 
Figure 4.6(S) – Fractional Changes in Acute Stimulus-Evoked Haemodynamic Responses. 
HbT: There was no significant overall effect of disease F(3,24)=1.69, p=0.196. As expected, there 
was a significant effect of experiment, F(2.16,51.73)=76.72, p<0.001. There was no significant 
interaction effect between experiment and disease, F(6.47,51.73)=1.73, p=0.127. HbO: There was 
no significant overall effect of disease F(3,24)=1.36, p=0.280. There was a significant effect of 
experiment, F(2.02,48.57=62.10, p<0.001. There was no significant interaction effect between 
experiment and disease, F(6.07,48.57)=2.08 , p=0.072. HbR: There was no significant overall 
effect of disease F(3,24)=1.42, p=0.262. As expected, there was a significant effect of experiment, 
F(2.18,52.42)=17.54, p<0.001. There was a significant interaction effect between experiment and 
disease F(6.55, 52.42)=2.54, p=0.028. All error bars (lightly shaded) are ±SEM. Vertical dotted 






Figure 4.7(S) – Concatenated data showing stability and robustness of the mouse imaging 
preparation. Left) Chronic imaging sessions including a 35-minute haemodynamics baseline 
before first stimulation. Right) Acute imaging sessions including CSD plus 35-minute 








Figure 4.8(S) – Chronic & Acute Hypercapnia. Chronic: A 1-way ANOVA showed no significant 
effect of disease for HbT (F(3,12.06)=0.49, p=0.694), HbO (F(3,11.98)=0.44, p=0.732) nor HbR 
(F(3,12.081)=0.98, p =0.436). Acute: A 1-way ANOVA showed no significant effect of disease for 
HbO F(3,12.00)=0.74, p=0.549 but there was a significant effect of disease for HbR 
F(3,11.01)=3.77, p=0.044. Games-Howell multiple comparisons showed that, for HbR, there was 
a significant difference between AD and ATH (p=0.019). Kruskal-Wallis test showed no significant 


























































5.1 – Overview 
Dementia is one of the biggest medical and scientific priorities of our time. There are currently 
approximately 50 million worldwide cases of dementia, with over 9.9 million new cases being 
diagnosed each year; that is one new case every 3 seconds (International, 2020). It is 
estimated that globally, cases will rise to 152 million by 2050 ((ARUK), 2020). Within the UK, 
there are currently nearly a million affected individuals with this estimated to double to 2 million 
by 2050. Harrowingly, the leading cause of death for women in the UK was dementia in 2017, 
and the second leading cause of death for men. Most worryingly, compared to the top 10 
leading causes of death in the UK, dementia is the only one that currently does not have any 
disease modifying treatments or therapies to reverse, cure or slow down its progression. 
Within the UK, 10-15% of all dementia cases are mixed with the most common mixed 
dementia being the combination of AD and VaD, and this prevalence increases in patients 
over 75 years of age. Comorbidities are extremely common in older individuals, with the most 
common comorbidities being cardiovascular disease and cerebrovascular disease (Wolters 
and Ikram, 2019). Thus, understanding the mechanisms connecting cardiovascular, 
cerebrovascular and neurological disease (heart-brain-axis) is essential if therapies are to 
succeed. To date, the vast majority of AD treatments have focused on targeting Aβ or the 
cholinergic system. However, none have succeeded at the clinical level owing to the sheer 
complexity of dementia in older adults, that is so often complicated by the presence of two or 
more comorbidities.  
 
Whilst the amyloid-hypothesis of AD still largely dominates the field and remains the biggest 
target for AD treatments, many amyloid-targeting therapies have previously failed clinical trials, 
and to date, there are still no disease-modifying treatments available. Furthermore, the notion 
that AD is purely a neurodegenerative disease has become increasingly more obsolete, with 
evidence that AD is multifactorial and has a large cerebrovascular element to it. Evidence has 
shown that there may be a crucial early role for vascular dysregulation in late-onset AD (Iturria-
Medina et al., 2016). Vascular dysregulation appears prior to observable increases in Aβ 
deposition, metabolic alterations, structural and behavioural changes that occur between 
healthy individuals and those with EMCI-stage of AD. As described in chapter 1, the need for 
preclinical models to study human disease is necessary to understand the different 
pathomechanisms of disease if effective treatments are to be found. The vast majority of AD 
models have modelled fAD mutations (such as the J20 mouse incorporating hAPPSw,Ind 
familial mutations) and model aspects of Aβ overexpression (Mucke et al., 2000). Whilst many 
of these models replicate aspects of human disease including time-dependent pathological 
and behavioural differences (Ameen-Ali et al., 2019), they remain limited due to their 
incomplete recapitulation of the human condition that tends to be multifactorial and complex. 
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Thus, in order to better replicate the human condition (especially with respect to age-related 
conditions), it is important that we consider the use of models that closely resemble the human 
condition (such as the PCSK9 model over the ApoE-/- model of atherosclerosis) as well as 
creating comorbid models that incorporate 2 or more overlapping conditions that are typically 
seen in older human patients. 
 
In my PhD project, I characterised neurovascular function in 2 different mouse models of 
human disease: J20-hAPP(Sw,Ind) model of fAD, rAAV8-mPCSK9-D377Y model of 
atherosclerosis and created a novel comorbid J20-hAPP(Sw,Ind) + rAAV8-mPCSK9-D377Y 
mixed model of fAD and atherosclerosis. Here, I describe the differential phenotypes of the 3 
different disease models and link them to cellular and molecular changes in brain tissue. 
Moreover, I describe novel findings relating to the PCSK9-model of atherosclerosis and report 
a trebling of Aβ plaques in the novel mixed model. These findings strongly support the 2-hit 
neurovascular degeneration hypothesis proposed by Zlokovic and confirm the notion that 
systemic cardiovascular disease is related to impaired neurovascular function and associated 
with the onset of dementia later in life. Furthermore, the evidence of increased plaques in J20-
PCSK9-MIX mice confirms that atherosclerosis exacerbates pre-existing AD-related 
neuropathology and may accelerate disease-course.  
 
5.2 – Enhanced Evoked-HbT Is Associated with Neural Hyperexcitability in 6m J20-AD 
Mice. Under Hyperoxia, J20-AD Mice Exhibit Enhanced Baseline HbT and Saturation. 
In the first part of the project, I characterised neurovascular function in 6m old J20-AD mice 
using a stable chronic imaging protocol as described previously in our study which used the 
same mice at 9-12m of age (Sharp et al., 2019). Between the ages of 4-8 months, J20-AD 
mice exhibit neural hyperexcitability and up to 15% die due to seizures (Palop et al., 2007). 
This is of a translational interest as many up to 22% of early-onset fAD patients also exhibit 
seizures specifically due to cortical hyperexcitability (Vossel et al., 2013). This is thought to be 
in response to the earliest depositions of Aβ in the brain (Minkeviciene et al., 2009), or as a 
result of aberrant processing of APP (Palop et al., 2007). Whilst I did not observe any seizures 
in these mice, 17% of all my J20-AD mice died unexpectedly presumably due to seizures, and 
many others may have had non-fatal seizures. However, all 6m J20-AD mice exhibited neural 
hyperexcitability compared to matched WT controls, and this was associated with an 
increased evoked-HbT. However, the washout of HbR was impaired, especially under 
normoxic conditions. This HbR observation was also present in older 9-12m J20-AD mice 
(discussed in section 5.7.2), and suggests that from an earlier age, these mice may have some 
degree of neurovascular metabolic inefficiency. This may also be indicative of the earliest form 
of vascular dysregulation as proposed by Itturia-Medina (Iturria-Medina et al., 2016). The main 
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translational finding from this study was that under normobaric hyperoxic conditions, the 
baseline blood volume (HbT) and saturation was significantly higher compared to WT controls, 
and this effect disappeared upon transitioning to normoxia (Figure 3.4). This surprising and 
interesting phenomenon was not present in WT controls, and as reported in our previous paper 
(Sharp et al., 2019), this effect is not present in 9-12m old J20-AD mice. As such, this 
hyperoxic effect is a time-dependent phenomenon that occurs at approximately the age of the 
initial Aβ deposition (5/6m), and last until the hyperexcitable phase fades out by around 8m 
(Palop et al., 2007). This was a serendipitous finding as it was not initially hypothesised. 
However, the finding is consistent and reliable (very significant), and the appropriate 2-tailed 
statistical tests were used in the analysis. This also raises an important discussion with respect 
to hypothesis-driven findings compared to serendipitous findings, and caution must be 
exercised when drawing conclusions from such findings, ensuring that the data is presented 
wholly and not cherry-picked, with the appropriate statistical tests being used.  
 
Waste clearance mechanisms in the brain are directly linked to CBF changes. The glymphatic 
system (identified by Nedergaard) is a waste clearance pathway of the central nervous system 
that is formed by glial cells and perivascular channels that is predominantly active during sleep 
(Rasmussen et al., 2018, Jessen et al., 2015). Para-arterial influx of CSF causes it to enter 
the brain parenchyma which leads to solute exchange between CSF and interstitial fluid (ISF) 
within the parenchyma. This fluid and solute exchange is mediated by arterial pulsation 
(Kiviniemi et al., 2016), and the clearance of waste products and excess extracellular fluid 
(ECF) is achieved by the bulk flow of ISF which is mediated by AQP4 channels on astrocyte 
end-feet, which is then eventually drained out of the brain into cervical lymphatic vessels. 
Glymphatic clearance is impaired as we age and may be related to gliosis that occurs as part 
of healthy ageing. Those with unhealthy ageing including those who are at risk of developing 
AD may suffer worse gliosis and inflammation in the brain further worsening glymphatic 
clearance, coupled with increased Aβ production can lead to amyloid plaque development, 
tau pathological changes and subsequent neurodegeneration (Rasmussen et al., 2018) 
(Figure 5.1). However, it is important to highlight that the glymphatic system is controversial 
as some studies have found no evidence of solute clearance in the parenchyma, but suggest 
a different perivascular mechanism that runs in the opposite direction to paravascular flow 
(Bacyinski et al., 2017). Irrespective of the contradictions in the literature, waste clearance 
from the brain, is an important mechanism by which toxic products including Aβ are cleared 
from the brain. In support of glymphatic clearance; which is thought to be more active during 
sleep, recent studies have shown enhanced CSF-mediated Aβ clearance overnight, and sleep 
disturbances can impede this clearance to pose a higher risk of developing AD due to 
increased Aβ deposition (Shokri-Kojori et al., 2018, Lucey et al., 2018).  
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My findings of enhanced baseline blood volume and saturation across the cortex under 
normobaric hyperoxia in 6m J20-AD mice suggests that an increased CBF at baseline may 
enhance the activity of the glymphatic system to drive an increased clearance (bulk flow) of 
soluble Aβ, therefore, delaying amyloid deposition in the brain and subsequently delaying the 
onset of AD (Figure 5.1). This, however, needs to be investigated in future studies to 
determine whether a) normobaric hyperoxia can enhance glymphatic clearance & b) drive an 
enhanced clearance of Aβ from the brain. My hypothesis is that normobaric hyperoxia will be 
able to do both and delay amyloid deposition in the brain to delay the onset of both 
neuropathological and behavioural changes associated with AD. If these preclinical studies 
are successful in clearing Aβ from the brain from early-stage AD mice, and delay the onset of 
cognitive decline, then this may be a simple but extremely effective preventative therapeutic 
strategy to trial in a subset of prodromal AD patients. Hyperbaric hyperoxia, or hyperbaric 
oxygen therapy, is a commonly used clinical intervention for decompression sickness, 
mountain sickness, as well as in cases of ischaemic stroke and some traumatic brain injuries 
(Xu et al., 2012). Recent evidence has shown that hyperbaric oxygen therapy (HBOT) is able 
to reduce the pathophysiology associated with AD (reduced hypoxia, amyloid burden and tau-
phosphorylation) in the 3xTg model of AD in addition to reducing levels of neuroinflammation 
(IL1β & TNFα as well as reducing astrogliosis and microgliosis) and improving behavioural 
outcomes (Shapira et al., 2018). Whilst this study corroborates clinical uses of hyperbaric 
hyperoxia and shows the efficacy of such a therapy in AD, hyperbaric therapies do come with 
additional risks that are mitigated by normobaric hyperoxia and can be used more routinely by 
clinics and easily at home. Interestingly, hypoxia usually results in vasodilation to compensate 
for lower oxygen saturation, whereas normobaric hyperoxia leads to some degree of 
vasoconstriction in healthy individuals (Johnston et al., 2003), although this effect is minimal 
and not as profound as for hypoxia. However, the intriguing and surprising observation that 
hyperoxia is able to elevate baseline blood volume in the cortex of 6m J20-AD mice seems 
counterintuitive. Thus, the exact mechanism underlying this response is unknown and needs 
to be investigated at the cellular level. Trialling the therapeutic applications of this research as 
well understanding the mechanisms underlying the effect have been submitted as a project 




Figure 5.1 – Schematic Summary of Hyperoxia as a Potential Preventative Treatment for AD. A) Healthy 
cerebral arteries in younger individuals allow for an efficient CBF and glymphatic clearance in the brain efficiently 
clearing toxic products preventing any neurological toxicity to occur. B) Healthy brain ageing is characterised by 
weak disruptions to CBF. Whilst Aβ deposition may occur, it occurs minimally, and plaques do not tend to readily 
develop. Glymphatic clearance, although weakened, is not as drastically reduced in healthy ageing and allows 
much of the soluble Aβ to be cleared from cerebral tissue. C) In the early stages of EOAD/MCI, CBF begins to be 
disrupted, also impacting on the efficiency of glymphatic clearance. Coupled with a pathological increase in Aβ 
production, weaker clearance pathways allow Aβ to slowly accumulate in the brain and blood vessels. D) In AD, 
there is an increased Aβ production and deposition both in the cerebral parenchyma as well as around vessels 
(CAA) which leads to an overall constriction of cerebral vessels reducing CBF. Furthermore, pathological changes 
impair fluid dynamics in the brain (such as altered AQP4 expression). This is coupled to a reduced efficiency of 
glymphatic clearance of Aβ, thus Aβ plaques build up readily to cause neurodegeneration and cognitive decline. 
E) Normobaric hyperoxia elevates baseline CBF and oxygen saturation in prodromal stages of AD thus increasing 
the efficiency of glymphatic clearance which allows excess Aβ to be cleared away from the brain, potentially slowing 
down the development and progression of AD.  
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5.3 – Impaired Neurovascular Function in PCSK9-ATH Mice Characterised by 
Consistently Reduced Evoked-HbT and Potential Neurovascular Breakdown. 
In the second part of the project, I characterised neurovascular function in a novel 
experimental model of atherosclerosis; 9-12m old rAAV8-mPCSK9-D377Y mice fed a 
Western diet using the same stable chronic imaging protocol as described previously. Whilst 
there are several neurovascular studies using the more aggressive ApoE-/- model (Denes et 
al., 2012, Ayata et al., 2013), and the more-human like Ldlr-/- model (Jahrling et al., 2018), to 
the best of my knowledge, no group has previously studied neurovascular coupling in the 
PCSK9 model. Whilst this model is similar to the Ldlr-/- model, the fact that it can be induced 
in any major mouse strain of any genotype at any age is the major advantage of this model, 
and results in robust atherosclerotic plaques forming by 8-9 weeks post-induction (Bjorklund 
et al., 2014, Roche-Molina et al., 2015). Robust atherosclerotic plaques (stained by Oil Red 
O) from a representative PCSK9-ATH mouse can be seen in Figure S1.  
 
My data show that PCSK9-ATH mice consistently displayed reduced evoked-HbT responses 
compared to WT controls, thus confirming my initial hypothesis. This was irrespective of 
stimulation duration (2s/16s) or gaseous composition (hyperoxia/normoxia) and was a 
consistent observation not attributable to any baseline haemodynamic shifts that may have 
occurred (Figure 4.7). Furthermore, the hypercapnia data show no significant differences 
between WT and PCSK9-ATH mice, suggesting that vascular reactivity was intact, and all 
observations were due to neurovascular abnormalities. This may be due to a degree of 
neurovascular breakdown and/or reduced cortical activation. The reduced evoked-HbT 
responses were associated with neurovascular breakdown with the haemodynamic responses 
not being reflective of the overall neural activity. However, as Figure 4.4 shows, there was 
still a trend for reduced evoked-MUA in PCSK9-ATH mice, especially under hyperoxia. The 
evidence suggests that in both cases, there are hints at reduced evoked-MUA, but more 
importantly, the consistently reduced evoked-HbT is indicative of perfusion and saturation 
problem. Figure S1 clearly illustrates the extent of atherosclerotic plaques within the aorta 
and subsequent branches. One can speculate that as these mice age, neurovascular function 
would worsen and that neurons would suffer from widespread pannecrosis. My results show 
that systemic atherosclerosis is detrimental to cerebrovascular health at midlife stages, and 
greatly predispose the brain to ischaemic vulnerabilities later in life.  
 
Histological validation of brain tissue revealed small but significant reduction in cortical 
neurons (Figure S6), and a trend in reduced neurons in chapter 5 when comparing to different 
multiple comparisons, as well as the presence of reactive astrocytes and shorter processes 
on microglial. These reactive states were confirmed to be associated with significant IL1β and 
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TNFα mediated neuroinflammation (determined by qRT-PCR), and taken together, these 
observations may explain the impaired neurovascular responses and cerebrovascular function 
in PCSK9-ATH mice. This is summarised in Figure 5.2 below. PCSK9-ATH mice develop 
hypercholesterolaemia (from 82mg/dL to 820mg/dL within a week post atherosclerosis 
induction (Goettsch et al., 2016). Atherosclerotic plaque lesion size is comparable to Ldlr-/- 
mice including aortic calcification. Both Ldlr-/- and AAV-PCSK9 mice display significantly 
reduced LDLR protein expression in the liver; confirming the role of the g.o.f. D377Y mutation 
to PCSK9 in inhibiting LDLR (Goettsch et al., 2016). Not only do plaques readily develop and 
calcify within 20 weeks, there is also extensive collagen remodelling and macrophage 
infiltration and accumulation that occurs in high-fat diet mice subsequently given AAV-PCSK9. 
In mice, HFD alone is not sufficient to cause atherosclerosis (as it is in humans). I fed a WT 
C57BL/6J mouse Western diet for 12wks and compared its neurovascular responses to a WT 
C57BL/6J counterpart as well as an PCSK9-ATH mouse fed a Western diet for 12wks and 
found no differences in evoked-responses between WT and WT + HFD mice (Figure S2), 
however, the PCSK9-ATH mouse did exhibit reductions to HbT, HbO and HbR. It is important 
to note that whilst these atherosclerotic effects are robust and highly reproducible in C57BL/6J 
mice, there are differences between male and female mice, with atherosclerotic induction 
being significantly weaker and highly inconsistent in female mice (Aimee E Vozenilek, 2019). 
This is also the case with cardiovascular diseases generally being more prevalent in men than 
women clinically. For this reason, all male mice were used in my project to allow for robust 
and highly consistent atherosclerosis induction, given the time constraints and funding 
shortfalls. It is important to use mice of both sexes in future studies in accordance to ARRIVE 
guidelines and to observe any potential sex-specific differences that may be behind the greater 




Figure 5.2 – Proposed Neurovascular Dysfunction Mechanism in Atherosclerosis. A) Healthy 
cerebral arterioles/capillaries have an intact BBB, NVU and very little neuroinflammation allowing for 
efficient NVC. B) In atherosclerosis, there is impaired neurovascular coupling, characterised by 
neuroinflammation, reactive astrogliosis, microgliosis, damaged pericytes, as well as potential BBB 
breakdown, immune cell infiltration and ischaemia. Text in purple indicates hypothesised mechanisms 

















5.4 – Increased Aβ plaques in J20-PCSK9-MIX Mice Without Further Impairments to 
Neurovascular Coupling. 
In the final part of my PhD, I generated a mixed comorbid mouse model of fAD and ATH (J20-
PCSK9-MIX) by injecting rAAV8-mPCSK9-D377Y in J20-hAPP(Sw,Ind) mice. This was 
performed at 6wks of age, and all mice were put on a high-fat Western diet. To the best of my 
knowledge, I am the first to generate a mixed comorbid model of J20-hAPP with 
atherosclerosis and study its neurovascular function. One study has previously induced 
atherosclerosis using the AAV-PCSK9 method in a different fAD mouse model: APP/PS1 
(Grames et al., 2018), but they did not characterise neurovascular function. In my model, 
neurovascular coupling was not significantly impaired compared to WT controls; matching the 
data from J20-AD mice, however, J20-PCSK9-MIX mice did display a trend in reduced HbR 
washouts (Figure 4.2), suggesting a degree of neurovascular metabolic inefficiency with 
inadequate oxygen delivery to neurons.  
 
The biggest translational finding from the J20-PCSK9-mixed comorbid model was that there 
was a trebling of Aβ plaques in the hippocampi compared to J20-AD mice alone (Figure 4.5A). 
As proposed as an initial hypothesis in Figure 1.6 (chapter 1); as well proposed by the 2-hit 
degeneration hypothesis by Zlokovic (Zlokovic, 2005, Zlokovic, 2011), these findings that I 
have reported confirm these assumptions and prove that vascular factors (“hit-1”) exacerbate 
neurological factors (“hit-2”) to accelerate, or worsen neurological outcomes. Although this 
finding was not significant in the cortex (Figure S7-left), there was an upwards trend, and if 
the plaque counts are combined for the whole coronal sections incorporating hippocampi and 
cortices, then the overall increase in plaques is still significant (Figure S7-right). Furthermore, 
the size of each plaque in the J20-PCSK9-MIX mice is much larger than in J20-AD mice alone, 
although this morphological assessment needs to be verified at a higher resolution. This novel 
comorbid mouse model is not an aggressive phenotype compared to the other fAD and 
atherosclerotic models; such as 3xTg fAD (APP/PS1/Tau) or the ApoE-/- model of 
atherosclerosis. I hypothesise that inducing atherosclerosis using the AAV-PCSK9 method in 
APP/PS1, 3xTg, 5xfAD models of AD, or crossbreeding these models with ApoE-/- strains fed 
a Western diet would lead to severe phenotypes, that could equate to aggressive forms of fAD 
that occur earlier in life. However, despite the mild nature of this comorbid mouse model, the 
trebling of plaques in the hippocampus is indicative of an accelerated disease-course, and as 
such proves that comorbid factors; namely atherosclerosis, can worsen pre-existing AD-
related neuropathology. I further hypothesise that this trebling of plaques could worsen 
behavioural outcomes, which would be assessed in future studies. Aβ plaques can wrap 
around cerebral blood vessels; cerebral amyloid angiopathy (CAA), which can lead to impeded 
vasodilatory responses (Figure S9), and this would be worse in such models.  
143 
 
A consistent finding irrespective of stimulation and condition was that PCSK9-ATH mice 
display stability throughout the imaging sessions, and all responses are similar across the 
session. J20-AD and J20-PCSK9-MIX, on the other hand, exhibited a baseline HbT shift 
throughout the imaging session, especially after transitioning to air and after CSD (in a time 
dependent manner) (Figure S4). This highlights the critical importance of methodology in 
determining the true reflection of disease-dependent effects, where timing (post-anaesthesia 
and CSD) and procedure (acute vs chronic) are important considerations for preclinical 
neurovascular studies. It is important to note, on acute imaging sessions haemodynamic 
responses were compromised due to the effect of CSD and were no longer significantly 
different in any of the mice in such circumstances, especially as I began my first stimulations 
after a 35-minute period of recovery post-CSD. This is in contrast to the labs previous work 
(Sharp et al., 2019), in which on acute imaging sessions, there was a significant difference in 
HbT between WT and J20-AD mice as we did not wait the additional time period to allow the 
CSD to recover. However, as presented in chapter 4, I have allowed the effects of CSD to 
somewhat subdue and baselines to partially recover thus the initial stimulation is no longer 
significantly different across any of the groups (Figure 4.6). Using the labs preparation and 
my paradigm, I am able to tease apart the effects of disease but there are added confounds 
such as baseline state of J20-based animals that dependent on anaesthesia and disease. As 
the concatenated data shows (Figure 4.7), any of these observations can be made easily due 
to the attention to such details. I also presented the average of all the raw stimulation trials 
from each animal across the whole experimental session (Figure 4.7), showing the stability 
and robustness of the preparation, as well as easily identifying any changes; such as baseline 
shifts, which are apparent in J20-based animals. A question may arise as to why would J20-
based animals exhibit such a baseline drift at this age? As chapter 3 discusses in detail, 
hyperexcitability is seen in all J20-animals up to around the age of 8/9 months. Since I used 
animals starting at this age group, it may be that the hyperexcitability related oxygen effect 
may still be present in these animals, albeit to a smaller extent, and this may be the cause of 
such a baseline dilation at the start as my paradigm begins using hyperoxia.  
 
During the experimental stage, two J20-PCSK9-MIX mice died due to anaesthetic induction 
and a further mouse had to be humanely euthanised after it became paralysed after 
anaesthesia for surgery. One PCSK9-ATH mouse also died after recovery from surgery. 
Common in all these mice was their excessive weight (Figure S3). None of the WT or J20-AD 
mice died due to anaesthesia. In humans, carrying excessive body weight, fat and increased 
BMI >30 leads to several complications especially with respect to sudden death, pulmonary, 
cardiac and cerebrovascular incidents (Adams and Murphy, 2000). This risk is further 
exacerbated in anaesthetic conditions where the risk of hypoventilation, hypoxaemia, 
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hypercapnia and cardiac failure greatly increases. It may be that these mice suffered from 
such effects causing their deaths. Furthermore, the incidence of stroke causing paralysis is 
also raised post-anaesthesia especially with existing comorbidities (Wong et al., 2000).  
 
5.5 – CSD Is More Severe in Diseased Mice and Relates to Levels of Neuroinflammation. 
As part of the experimental protocol, the final experimental session included an acute imaging 
session where a small burr-hole was drilled into the skull overlying the active region 
(determined from the chronic imaging sessions), and a multichannel microelectrode inserted 
into the brain to record neural activity in combination with haemodynamic activity by 2D-OIS. 
As discussed throughout chapter 3 and chapter 4, whenever an electrode was inserted into 
the brain, the initial stimulation resulted in a much smaller haemodynamic response compared 
to the first stimulation on chronic imaging days. As suggested in a previous paper that I co-
authored (Sharp et al., 2019), the technical process of electrode insertion may cause a CSD 
that leads to the impaired phenotypes observed (a hypothesis that I tested in my PhD project 
and subsequently confirmed). To test this, I recorded the baseline haemodynamics prior to 
and after electrode insertion to assess what changes occurred in the cortex. In all mice, the 
haemodynamic correlate of CSD occurred. This is characterised by a triphasic S-shaped 
change in HbT; an initial decrease (constriction), followed by an increase (dilation), then 
decrease again, that persists for some time in all mice (Figure 4.3). The observed CSD began 
at the site of electrode insertion and spread unidirectionally across the observable cortical 
surface to the opposite end in a wave of this characteristic triphasic change in HbT. However, 
CSD profiles were significantly different in the diseased groups compared to WT mice. 
Compared to WT mice, the initial constriction was more profound in the 3 diseased groups; 
with the strongest constriction in J20-AD mice, and the dilatory bounce back was minimal as 
this phase was quickly succumbed to a prolonged and profound constriction below the 
baseline that persisted for a significantly longer time compared to WT controls. These 
observations may be related to IL1β neuroinflammatory changes (Figure 4.5), where J20-AD 
mice display the most significant upregulation of IL1β mRNA and display the most severe CSD, 
followed by PCSK9-ATH, followed by J20-PCSK9-MIX mice, although this needs to be further 
validated to prove causation. This will be discussed in more detail later (section 5.6). 
 
In the experimental protocol, the insertion of an electrode is akin to a pin-prick model of 
minimal brain damage which causes CSD. However, as this trigger causes CSD, it can also 
be a proxy model for migraine with aura and epilepsy spread. As discussed extensively in 
chapter 5, the frequency of migraines is higher in those with cardiovascular disease (Kurth et 
al., 2020), those at risk of developing AD (Morton et al., 2019), and epilepsy is a more common 
occurrence in EOAD/EMCI (Sherzai et al., 2014). Furthermore, recurrent sports-related 
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injuries (concussions causing TBI) can lead to an increased risk of developing severe 
neurological conditions including Parkinson’s and AD (Henry et al., 2017). The strongest CSDs 
occurred in brains with the highest levels of IL1β (AD and ATH respectively), thus confirming 
previous epidemiological and clinical observations that migraine frequency is associated with 
cardiovascular disease and an increased risk of dementia. My data show that brains with the 
highest levels of global neuroinflammation are primed for a more devastating effect of CSD – 
whether it occurs as a result of migraine, epilepsy or TBI – and lead to prolonged ischaemic 
and potentially hypoxic periods characterised with long period of neurovascular uncoupling 
and metabolic shifts that cause neuronal stress and potentially pannecrosis of both neurons 
and glia. This, over time, would lead to widespread neurodegeneration and lead to the onset 
of dementia. Although the CSD in J20-PCSK9-MIX mice was the least severe of the other 2 
disease groups, it directly relates to the levels of neuroinflammation (i.e. reduced compared 
to J20-AD and PCSK9, but still higher than WT), and as I have suggested that these mice may 
have an altered and accelerated disease-course, it may be that observing CSD at an earlier 
timepoint may reveal more profound changes. Due to prolonged periods of reduced CBF and 
ischaemia, coupled with increased Aβ deposition, I would hypothesise that AD-onset would 
be exacerbated in these mice coupled with more severe behavioural deficits.  
 
5.6 – Cellular & Molecular Mechanisms Underpinning the Observed Phenotypes – 
Potential Therapeutic Implications by Targeting Neuroinflammation? 
Understanding the cellular and molecular basis for the observed phenotypes is essential in 
finding viable and prominent therapeutic targets. In order to assess cellular & molecular 
alterations in the different mouse groups, I dissected the brains from the mice after terminal 
acute imaging experiments and processed one half hemisphere in formalin to use for 
immunohistochemistry, whereas the other half hemisphere was snap-frozen using isopentane 
and stored at -80oC for genetic studies. Firstly, I performed immunohistochemistry for the 
major cell types of the NVU: neurons (NeuN), astrocytes (GFAP), microglia (Iba1) & pericytes 
(PDGFRb). With respect to neuronal counts, there was a small trend towards a reduction in 
the number of cortical neurons in PCSK9-ATH mice compared to WT controls (Figure S6). 
J20-AD mice do not exhibit any significant neuronal loss. J20-PCSK9-ATH mice also display 
reduced cortical neuronal counts which was significant in the cortex (Figure S6), although the 
baseline drift of HbT throughout the imaging protocol confounds the earlier observed 
impairments overall (2s-oxygen; Figure 4.2). These results are indicative of the beginnings 
of potential neuronal decline at this age-group; exacerbated by comorbidity, and longitudinal 
assessments after this age group may reveal enhanced neurodegeneration in all diseased 




All diseased mice showed evidence of reactive astrocytes and alterations to microglial 
morphology, though none exhibited a clear cellular proliferation (Figure S6). Furthermore, all 
3 diseased groups exhibited altered microglial morphologies that may relate to a reactive state. 
Together with astrogliosis and microgliosis, these are indicative of potential nervous system 
damage in all 3 disease mouse groups (especially with reduced neuronal counts in the cortex 
of PCSK9-ATH and J20-PCSK9-MIX mice). Although I do not report a significant increase in 
Iba1+ microglia (i.e. no proliferation at this stage), the presence of shorter processes and 
some ameboid cells is indicative of microglial transitioning in response to neuroinflammation. 
Furthermore, the clustering of active microglia in J20-AD and J20-PCSK9-MIX mice may be 
around Aβ plaques (Figure S6), although this needs to be validated by dual staining in future 
studies. Other studies have shown increased cell number of microglia in the more severe 
ApoE-/- model (Denes et al., 2012). The findings of the PCSK9-ATH model may be more 
reflective of a milder disease-course in both mice and humans. Another interesting observation 
from the histological analysis was a reduction in pericyte coverage in PCSK9-ATH and J20-
PCSK9-MIX mice compared to WT and J20-AD mice (Figure S6), although this effect was 
non-significant after correcting for multiple comparisons. Despite this, this suggests a trend 
towards reduced pericyte numbers in these diseased mice and may be causative in 
microvascular dysfunction associated with small vessel disease and ischaemia in cortical 
tissue. Many other studies have found decreased pericyte coverage and capillary length in the 
ApoE4 model of sporadic AD (Halliday et al., 2016), and show evidence of pericyte-loss 
mediated neurodegeneration (Sagare et al., 2013).  
 
As alluded to in the previous discussion in chapter 4, there may be several reasons why the 
J20-PCSK9-MIX mice displayed lower levels of neuroinflammation compared to J20-AD and 
PCSK9-ATH mice. Firstly, this new phenotype may be reflective of an altered disease-course 
(temporal changes) with an advanced stage phenotype compared to the age-matched pure 
models. Thus, the peak of neuroinflammation may have been at an earlier time-point. It may 
be that increased levels of neuroinflammation (in PCSK9-ATH and J20-AD mice) are 
representative of an initial phase of disease that leads to the profound changes seen in both 
human patients and model organisms, and that over time these significantly higher levels 
begin to resolved by the time-point I investigated (in J20-PCSK9-MIX mice), and other factors 
could be upregulated. Secondly, it is not necessarily the case that 2 distinct inflammatory 
diseases ‘add-up’ their levels of inflammation in a comorbid setting, due to different 
mechanisms involved. Interestingly, neurovascular coupling is impaired in PCSK9-ATH mice 
the most, and this corresponds to these mice having the highest levels of TNFα in the brain, 
however, this also needs to be validated. TNFα may be a crucial cytotoxic chemokine leading 
to neuronal and glial dysfunction in the brain. Astrocytes are able to secrete TNFα induced by 
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circulating cytokines, including IL1β (Chung and Benveniste, 1990), which itself is the key 
inflammatory driver of systemic atherosclerosis (Rader, 2012). Furthermore, a study showing 
the pharmacological inhibition of reactive astrogliosis by withaferin A was able to protect 
against neuronal loss by limiting the production of TNFα (Livne-Bar et al., 2016). The de novo 
production of TNFα by glial cells within the CNS is part of the neuro-inflammatory response in 
the presence of neuropathology (Olmos and Llado, 2014). TNFα can lead to glutamate-
mediated excitotoxicity as well as increased calcium-mediated excitotoxicity within neurons 
thus leading to a progressive neuronal loss within the brain (Olmos and Llado, 2014), as seen 
in my data. Behaviourally, it has been shown that systemic TNFα can produce cognitive 
dysfunction and symptoms of sickness behaviour (Hennessy et al., 2017). Symptoms of 
delirium are also highly exacerbated by the presence of neuroinflammation, importantly due 
to high levels of TNFα within the brain (van Gool et al., 2010). Though I have not performed 
any behavioural tests on these mice, performing cognitive tests may confirm signs of early 
dementia and sickness behaviour in future studies. I also saw a significant increase in IL1β 
levels in the brains of PCSK9-ATH mice. It has been demonstrated that hypoxia is able to 
induce IL1β expression in macrophages, in addition to enhanced secretion of IL1β in the 
presence of cholesterol crystals (Folco et al., 2014). However, it is important to note that my 
findings of neuroinflammation are related to global changes across the brain (whole 
homogenates) rather than being cell-specific, thus the origin of TNFα in my study cannot be 
determined. Future work would investigate the cell specific origins of inflammation in the brain 
of these mice to provide a more comprehensive outlook as to the exact mechanisms 
underlying the observed phenotypes of neuronal loss.  
 
Whilst the CSD haemodynamic changes were significant for PCSK9-ATH mice compared to 
WT (Figure 4.3), the most profound CSD occurred in J20-AD mice, and this may relate to the 
levels of IL1β (Figure 4.5). However, another interesting observation relating to the MUA 
changes immediately post-CSD seemed to be more related to levels of TNFα with the highest 
surge in MUA followed by the strongest silencing of MUA happening in PCSK9-ATH mice 
(Figure S8). The exact physiological relevance of this observation is not immediately apparent; 
however, it is likely that this surge phase (200s) is related to the ‘bounce back’ phase of the 
CSD-haemodynamic recovery (upwards HbT during the triphasic response). The period of 
MUA silencing after this phase is also interesting as it may be reflective of the sustained 
vasoconstriction below baseline that occurs and may be related to neuronal exhaustion due 
to the metabolic mismatch during the initial CSD phase where periods of neurovascular 
uncoupling lead to massive metabolic deficits (i.e. severely reduced perfusion and saturation 
not able to sustain neuronal function) leading to this period of silencing in order to recuperate.  
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Finally, a surprising finding was the upregulation of NOS1 and NOS3 mRNA in J20-AD, 
PCSK9-ATH and J20-PCSK9-MIX mice (Figure S5). NOS1 encodes neuronal nitric oxide 
synthase (nNOS) and NOS3 encodes endothelial NOS (eNOS). qRT-PCR revealed the 
highest upregulation of NOS1 mRNA in J20-AD mice, whilst the highest upregulation of NOS3 
mRNA was in PCSK9-ATH mice. These observations reflect the pathology, AD being 
neurological in origin (nNOS) whereas atherosclerosis is vascular in origin (eNOS). Whilst the 
literature surrounding NOS expression in clinical and preclinical studies is often contradictory 
and inconclusive, my finings of upregulated NOS mRNA may be indicative of two distinct 
possibilities: i) increased functional hyperaemia from lowered baseline by increased NOS (i.e. 
vasodilatory) to compensate for perceived ischaemia, or ii) the production of toxic NO- radicals 
by NOS uncoupling. eNOS, releasing NO, can influence vessel tone and diameter via cGMP 
signalling, however, in excessive amounts, the enzyme can uncouple leading to the production 
of NO and O2- reactive oxygen species (ROS) which subsequently react to form OONO-, a 
major cause of oxidative damage (Huang, 2009). It has been demonstrated that TNFα is able 
to induce both eNOS in HeLa cells (Barsacchi et al., 2003) and iNOS in macrophages under 
experimental inflammatory conditions (Fonseca et al., 2003). Thus, there may be a toxic 
vicious cycle of induction and synergy between TNFα and NOS under pathological conditions 
such as atherosclerosis that can contribute to neuronal death. The enhanced levels of eNOS, 
along with iNOS, may be a compensatory mechanism to sustain baseline vasodilation in the 
presence of diminished cerebral blood flow and hypoxia in the PCSK9-ATH mice, but also 
inadvertently damaging to neurons due to the potential production of ROS and interactions 
with TNFα. Thus, the potentially toxic combination of enhanced glial TNFα as well as eNOS 
may/could be the cause of the neurovascular deficits seen in PCSK9-ATH mice, though this 
would be investigated in future studies to define a mechanism.  
 
Whilst the initial upregulation, seen here, may be related to compensatory mechanisms, it may 
be that over time toxic NO- radical contribute to neurovascular decline. A recent study 
published in Nature found that caveolae within brain arterioles play a key role in regulating 
neurovascular coupling (Chow et al., 2020). Caveolae are membrane invaginations found 
within cells (to allow transcytosis) and tissues (including arterioles), and are formed by 
caveolin-1, encoded by Cav1. In their study, Cav1-/- mice displayed impaired caveolae, and 
subsequently exhibited impaired haemodynamic responses; both arteriolar diameter changes 
and capillary blood flow, to whisker stimulation compared to controls (Chow et al., 2020). Cav1 
interacts with eNOS, and NOS3-/- mice display similar levels of evoked-arteriolar dilation and 
capillary blood flow compared to Cav1-/- mice, but NOS3-/-/Cav1-/- mice exhibit completely 
ablated evoked-responses, suggesting both mediate their effects independently. Thus, this 
study highlights not only novel mechanisms of NVC but also the importance of assessing 
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redundant mechanisms that may allow for continued physiological processes to occur. 
Furthermore, the recent identification of NO-containing endothelial notches in zebrafish, called 
Kugelns (identified by Elizabeth Kugler & Tim Chico here at the University of Sheffield) (Kugler 
et al., 2019), which may also play a role in endothelial function and NO signalling is of great 
interest, however, these need to be identified in mammals to understand their function in 
health and disease models. As discussed in chapter 4, the interactions between TNFα and 
eNOS can cause a vicious cycle of detrimental effects, thus targeting neuroinflammation may 
allow for the resumption of normal NOS function.  
 
5.7 – Conclusion 
In conclusion, I have found key neurovascular, neuropathological and neuroinflammatory 
changes in 3 different mouse models of human disease: J20-AD (hAPPSw,Ind), PCSK9-ATH 
(rAAV8-mPCSK9-D377Y) and a novel comorbid J20-PCSK9-MIX model.  
 
The 4 key translational findings from my PhD are summarised below: 
1. Normobaric hyperoxia can elevate baseline blood volume and oxygen saturation 
in the brain in young 6m J20-AD mice. Increasing baseline blood volume, flow and 
saturation may enhance the glymphatic clearance of Aβ from the brain. This effect 
could also be used clinically to elevate baseline blood flow and saturation in 
prodromal/early-onset AD patients to increase glymphatic mediated Aβ clearance.  
2. Systemic atherosclerosis leads to reduced evoked-haemodynamic responses in 
the cortex characterised by impairments to neurovascular coupling and neurovascular 
inefficiency. These findings are associated with elevated cerebral neuroinflammation: 
IL-1β and TNFα, and therapeutically antagonising these may reverse these 
phenotypes and work as effective treatments in patients with cardiovascular disease.  
3. Cortical spreading depression (CSD) is more severe in diseased animals and 
relates to global neuroinflammation levels. Furthermore, this is highly related to 
increased migraine and seizure frequency. In addition, CSD could be an effective 
clinical biomarker in the assessment of brain-state in determining cerebral 
vulnerabilities in the potential development of dementia and may also be an effective 
assessment of therapeutic interventions in preclinical neurovascular studies.  
4. Systemic atherosclerosis exacerbates pre-existing AD-related neuropathology, 
especially Aβ plaques in the brain, and lead to an accelerated disease-course. Treating 
and managing midlife cardiovascular diseases is of vital importance for cerebral health 
later in life. This needs to be implemented as an urgent public health policy in countries 




Recently, a new form of dementia, limbic-predominant age-related TDP-43 encephalopathy 
(LATE), was identified that may actually account for up to a third of all presumed AD-diagnoses 
over the age of 85 (Nelson et al., 2019). This may also be a reason as to why so many AD-
related drugs that initially were successful preclinically (modelled in fAD animals) did not 
succeed clinical trials of larger and older AD clinical cohorts. Preclinical research, therefore, 
is absolutely vital in elucidating mechanisms of disease and pathophysiological processes, as 
well as in the development of novel and effective treatments. Recently, aducanumab; a 
monoclonal antibody against Aβ developed by Biogen (currently in Phase III trials), was sent 
for FDA approval for use in prodromal stages of AD to inhibit Aβ deposition after evidence 
emerged of successful Aβ reduction with some clinical benefits with as much as up to 23% 
reduction in the rate of cognitive decline (Schneider, 2020). This was not a definitive clinical 
treatment in a parallel clinical trial. Whilst both of these new discoveries have been the two 
single most important advancements in the field of AD research, there still remain no definitive 
disease modifying or curative treatment. The findings from my PhD suggest novel findings 
with respect to prodromal AD and midlife atherosclerosis and mixed pathology, which need to 
be considered if new therapies are to succeed clinically. Namely, normobaric hyperoxia could 
work similar to aducanumab in terms of reducing early-Aβ, and that the targeting of 
neuroinflammation early in life may be critical in stabilising neurovascular, neuropathological 
and subsequent clinical decline associated with VaD, AD and mixed dementia. Furthermore, 
and importantly, the presence of one comorbidity can greatly exacerbate neuropathology at 
the same age, thus therapies aiming to reduce Aβ; such as aducanumab, may not be as 
effective in comorbid patients due to the higher levels of overall Aβ. This is why it is absolutely 
crucial to investigate comorbid models to better reflect the clinical presentation, and if any 
novel therapy is able to target the enhanced effects of comorbidity that is present in large 
proportions of patients.  
 
5.7 – Future Directions 
The findings from my PhD have several translational implications and testing them in 
preclinical settings are needed before implementing such strategies in clinical trials. Firstly, 
trialling normobaric hyperoxia in J20-AD and related fAD-models to assess i) the effectiveness 
of the therapy on Aβ clearance & ii) assess behavioural outcomes by performing simple 
cognitive tests to determine the effectiveness of this simple approach. Finally, iii) to understand 
the mechanisms by which normobaric hyperoxia leads to enhanced baseline CBF in 
prodromal AD mice. This proposal has been submitted to Alzheimer’s Society as a project 
grant by JB. Secondly, the findings of IL1β and TNFα mRNA upregulation in disease mice 
suggests that neuroinflammation may be one of the major causative factors in neurovascular 
decline and targeting these with antagonists: Anakinra (IL1) and Infliximab (TNFα), may 
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improve neurovascular function, neuropathological and behavioural outcomes. Both of these 
proposals have been submitted as a project grant (to BHF for IL1 by SEF; which was awarded 
in August 2020 to start in October 2020 as me as the post-doc) and a postdoctoral fellowship 
application (to ARUK & AlzSoc for TNFα by OS). These applications will seek to investigate 
the cellular & molecular mechanisms underlying the observed phenotypes, and to confirm 
some of the previously mentioned associations e.g. links to IL1β and TNFα inflammation, 
assessment of BBB damage and immune system involvement in the brain. Furthermore, 
performing behavioural studies will be important in assessing both the extent of cognitive 
decline in these models, but also to test the effect of the anti-inflammatory treatments (and 
oxygen therapy). The implications of my research findings have exciting and potentially 
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Figure S1 – Oil Red O Staining of Atherosclerotic Aorta. Dissected aorta from an atherosclerotic 
mouse was stained for fatty (lipid) deposits using Oil Red O to reveal the extent of aortic atherosclerosis. 
Deposits can be found bilaterally primarily in aortic arch, including the branches of the common carotids 
















Figure S2 – 2s-Stimulation for WT, WT + HFD and AAV-PCSK9 Mice. 2s-duration evoked 
haemodynamic response for WT + Normal Diet (ND) (n=1), WT + High-Fat Western Diet (HFD) (n=1) & AAV8-
mPCSK9/ATH (n=1). There is no difference in evoked HbT, HbO and HbR between WT and WT + HFD. ATH mice 
displays reduced HbT, HbO and HbR compared to both. This suggests that in mice, HFD alone (chronic) does not 


















Figure S3 – Mouse Body Weights. Individual and mean body weights (g) of all mouse groups (used 
in chapter 6) showing. No overall significant difference between any of the groups. All HFD mice were 
given no more than 5g/day/mouse worth of pellets to prevent overeating and obesity. The trend for ATH 
and half of the MIX mice is increased weight, whereas for almost all AD and 2 MIX mice is decreased 
weight. The average weight of a C57BL/6J is 36g at this age group (dotted horizontal line). Error bars 



























Figure S4 – Bar Graph of Mean HbT for Mouse Groups Across all Stimulations. WT and ATH mice 
display consistent responses across the experimental period whereas AD and MIX mice exhibit and 
upwards drift in baseline and evoked responses by the end of the experimental protocol. Where MIX 
mice display significant HbT differences compared to WT in the first stimulation, they do not by the end 








      
 
Figure S5 – NOS1 and NOS3 qRT-PCR. Left) NOS1 (nNOS) mRNA is significantly upregulated in AD 
mice compared to WT (p=0.0048), ATH p=0.056(ns, but close to significance) (1-way ANOVA with post-
hoc Dunnett’s multiple comparisons test). Right) NOS3 (eNOS) mRNA is significantly upregulated in 
AD mice (p=0.0368) and ATH mice (p=0.012) compared to WT (1-way ANOVA with post-hoc Dunnett’s 
multiple comparisons test). Error bars ±SEM.  















































Figure S6 – Qualitative & Quantitative Histological Analysis (Cortical). Neurons (NeuN) MIX 
p=0.0424(*) (1-way ANOVA post-hoc Dunnett’s test), astrocytes (GFAP), microglia (Iba1), pericytes 
(PDGFRb). N=4 each. Reduction in astrocytes in MIX may be related to neuronal and glial loss. Scale 
bar 200µm. Error bars ±SEM. Experiments jointly performed by Ben Pendry under my training and 
supervision for his MSc in Translational Neuropathology.  
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Figure S7 – Aβ Plaques. Left) Cortical Aβ plaques p=0.3372(ns). Right) Total Aβ plaques 

















































Figure S8 – CSD Haemodynamic and MUA Profiles. Left) CSD haemodynamic changes upon 
electrode insertion in WT, J20-AD, PCSK9-ATH & J20-PCSK9-MIX mice. Middle) CSD MUA changes 
immediately after electrode insertion (200s) characterised by an initial surge (strongest being in PCSK9-
ATH mice), followed by MUA silencing in PCSK9-ATH and J20-PCSK9-MIX mice. Right) Timeseries 
























Figure S9 – Cerebral Amyloid Angiopathy in 15m J20-AD Mouse. I) 2s-stimulation evoked HbT 
response over zoomed in branch of MCA showing an irregular vasodilatory response characterised by 
a full dilation ‘blob’ juxtaposed to adjacent areas of less dilation. II) MCA region visualised by methoxy-




Table S1 – RNA Concentration and Quality (NanoDrop).  
All RNA was of good usable quality and quantity and all concentrations made up to 700ng/µl (to 
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